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Description
[0001] The present invention relates to polynucleotides from Cochliobolus heterostrophus C5, Cyanothece sp.
CCY0110, Mycocentrospora acerina and Hyaloperonospora parasitica, which code for desaturases and which can be
employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors,
host cells and transgenic nonhuman organisms which comprise the polynucleotides according to the invention, and to
the polypeptides encoded by the polynucleotides. The invention furthermore relates to antibodies against the polypeptides
according to the invention. Finally, the invention also relates to production processes for the polyunsaturated fatty acids
and for oil, lipid and fatty acid compositions and to their use as drugs, cosmetics, foodstuffs, feedstuffs, preferably fish
food, or food supplements.
[0002] Fatty acids and triacylglycerides have a multiplicity of applications in the food industry, in animal nutrition, in
cosmetics and in the pharmacological sector. Depending on whether they are free saturated or unsaturated fatty acids
or else triacylglycerides with an elevated content of saturated or unsaturated fatty acids, they are suitable for very different
applications. Polyunsaturated fatty acids such as linoleic acid and linolenic acid are essential for mammals, since they
cannot be produced by the latter themselves. Polyunsaturated ω3-fatty acids and ω6-fatty acids are therefore an important
constituent in animal and human nutrition.
[0003] Polyunsaturated long-chain ω3-fatty acids such as eicosapentaenoic acid (= EPA, C20:5Δ5,8,11,14,17) or do-
cosahexaenoic acid (= DHA, C22:6Δ4,7,10,13,16,19) are important components in human nutrition owing to their various
roles in health aspects, including the development of the child brain, the functionality of the eyes, the synthesis of
hormones and other signal substances, and the prevention of cardiovascular disorders, cancer and diabetes (Poulos,
A Lipids 30:1-14, 1995; Horrocks, LA and Yeo YK Pharmacol Res 40:211-225, 1999). This is why there is a demand for
the production of polyunsaturated long-chain fatty acids.
[0004] ω3-fatty acids, which are preferentially found in fish oils, to the food is particularly important. Thus, for example,
polyunsaturated fatty acids such as docosahexaenoic acid (= DHA, C22:6Δ4,7,10,13,16,19) or eicosapentaenoic acid (=
EPA, C20:5Δ5,8,11,14,17) are added to infant formula to improve the nutritional value. The unsaturated fatty acid DHA is
said to have a positive effect on the development and maintenance of brain functions.
[0005] Hereinbelow, polyunsaturated fatty acids are referred to as PUFA, PUFAs, LCPUFA or LCPUFAs (polyunsat-
urated fatty acids, PUFA, long-chain polyunsaturated fatty acids, LCPUFA).
[0006] The various fatty acids and triglycerides are mainly obtained from microorganisms such as Mortierella and
Schizochytrium or from oil-producing plants such as soybean, oilseed rape, algae such as Crypthecodinium or Phaeo-
dactylum and other organisms, where they are obtained, as a rule, in the form of their triacylglycerides (= triglycerides
= triglycerols). However, they can also be obtained from animals, such as, for example, fish. The free fatty acids are
advantageously prepared by hydrolysis. Very long-chain polyunsaturated fatty acids such as DHA, EPA, arachidonic
acid (= ARA, C20:4Δ5,8,11,14), dihomo-γ-linolenic acid (C20:3Δ8,11,14) or docosapentaenoic acid (DPA, C22:5Δ7,10,13,16,19)
are not synthesized in oil crops such as oilseed rape, soybean, sunflower or safflower. Conventional natural sources of
these fatty acids are fish such as herring, salmon, sardine, redfish, eel, carp, trout, halibut, mackerel, zander or tuna, or
algae.
[0007] Depending on the intended use, oils with saturated or unsaturated fatty acids are preferred. In human nutrition,
for example, lipids with unsaturated fatty acids, specifically polyunsaturated fatty acids, are preferred. The polyunsatu-
rated ω3-fatty acids are said to have a positive effect on the cholesterol level in the blood and thus on the possibility of
preventing heart disease. The risk of heart disease, a stroke or hypertension can be reduced markedly by adding these
ω3-fatty acids to food. Also, ω3-fatty acids have a positive effect on inflammatory, specifically on chronically inflammatory,
processes in association with immunological diseases such as rheumatoid arthritis. They are therefore added to food-
stuffs, specifically to dietetic foodstuffs, or are employed in medicaments. ω6-Fatty acids such as arachidonic acid tend
to have a negative effect on these disorders in connection with these rheumatic diseases on account of our usual dietary
intake.
[0008] w3- and ω6-fatty acids are precursors of tissue hormones, known as eicosanoids, such as the prostaglandins,
which are derived from dihomo-γ-linolenic acid, arachidonic acid and eicosapentaenoic acid, and of the thromboxanes
and leukotrienes, which are derived from arachidonic acid and eicosapentaenoic acid. Eicosanoids which are formed
from ω6-fatty acids (known as the PG2 series) generally promote inflammatory reactions, while eicosanoids from ω3-
fatty acids (known as the PG3 series) have little or no proinflammatory effect.
[0009] Owing to their positive characteristics, there has been no lack of attempts in the past to make available genes
which are involved in the synthesis of fatty acids or triglycerides for the production of oils in various organisms with a
modified content of unsaturated fatty acids. Thus, WO 91/13972 and its US equivalent describe a Δ9-desaturase. WO
93/11245 claims a Δ15-desaturase and WO 94/11516 a Δ12-desaturase. Further desaturases are described, for example,
in EP-A-0 550 162, WO 94/18337, WO 97/30582, WO 97/21340, WO 95/18222, EP-A-0 794 250, Stukey et al., J. Biol.
Chem., 265, 1990: 20144-20149, Wada et al., Nature 347, 1990: 200-203 or Huang et al., Lipids 34, 1999: 649-659.
However, the biochemical characterization of the various desaturases has been insufficient to date since the enzymes,
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being membrane-bound proteins, present great difficulty in their isolation and characterization (McKeon et al., Methods
in Enzymol. 71, 1981: 12141-12147, Wang et al., Plant Physiol. Biochem., 26, 1988: 777-792). As a rule, membrane-
bound desaturases are characterized by being introduced into a suitable organism which is subsequently analyzed for
enzyme activity by analyzing the starting materials and the products. Δ6-Desaturases are described in WO 93/06712,
US 5,614,393, WO 96/21022, WO 00/21557 and WO 99/27111. Their application for production in transgenic organisms
is described, for example, in WO 98/46763, WO 98/46764 and WO 98/46765. In this context, the expression of various
desaturases and the formation of polyunsaturated fatty acids is also described and claimed; see, for example, WO
99/64616 or WO 98/46776. As regards the expression efficacy of desaturases and its effect on the formation of polyun-
saturated fatty acids, it must be noted that the expression of a single desaturase as described to date has only resulted
in low contents of unsaturated fatty acids/lipids such as, for example, γ-linolenic acid and stearidonic acid. Moreover, a
mixture of ω3-and ω6-fatty acids was obtained, as a rule.
[0010] Especially suitable microorganisms for the production of PUFAs are microalgae such as Phaeodactylum tri-
cornutum, Porphiridium species, Thraustochytrium species, Schizochytrium species or Crypthecodinium species, ciliates
such as Stylonychia or Colpidium, fungae such as Mortierella, Entomophthora or Mucor and/or mosses such as Phys-
comitrella, preferably Physcomitrella patens, Ceratodon and Marchantia (R. Vazhappilly & F. Chen (1998) Botanica
Marina 41: 553-558; K. Totani & K. Oba (1987) Lipids 22: 1060-1062; M. Akimoto et al. (1998) Appl. Biochemistry and
Biotechnology 73: 269-278). Strain selection has resulted in the development of a number of mutant strains of the
microorganisms in question which produce a series of desirable compounds including PUFAs. However, the mutation
and selection of strains with an improved production of a particular molecule such as the polyunsaturated fatty acids is
a time-consuming and difficult process. This is why recombinant methods as described above are preferred whenever
possible. However, only limited amounts of the desired polyunsaturated fatty acids such as DPA, EPA or ARA can be
produced with the aid of the abovementioned microorganisms. Moreover, depending on the microorganism used, these
are generally generated as fatty acid mixtures of, for example, EPA, DPA and ARA.
[0011] A variety of synthetic pathways is being discussed for the synthesis of arachidonic acid, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA). Thus, EPA or DHA are produced in marine bacteria such as Vibrio sp. or
Shewanella sp. via the polyketide pathway (Yu, R. et al. Lipids 35:1061-1064, 2000; Takeyama, H. et al. Microbiology
143:2725-2731, 1997).
[0012] An alternative strategy is the alternating activity of desaturases and elongases (Zank, T.K. et al. Plant Journal
31:255-268, 2002; Sakuradani, E. et al. Gene 238:445-453, 1999). A modification of the pathway described in Zank et
al. and in Sakuradani et al. via Δ6-desaturase, Δ6-elongase, Δ5-desaturases, Δ5-elongase and Δ4-desaturases is the
Sprecher synthesis pathway (Sprecher 2000, Biochim. Biophys. Acta 1486:219-231) in mammals. Instead of the Δ4-
desaturation, a further elongation step is effected here to give C24, followed by a further Δ6-desaturation, and finally β-
oxidation to give the C22 chain length. What is known as the Sprecher synthesis pathway is, however, not suitable for
the production in plants and microorganisms since the regulatory mechanisms are not yet known.
[0013] Depending on their desaturation pattern, the polyunsaturated fatty acids can be divided into two large classes,
viz. w6- or ω3-fatty acids, which differ with regard to their metabolic and functional activities. The starting material for
the ω6-metabolic pathway is the fatty acid linoleic acid (18:2Δ9,12), while the ω3-pathway proceeds via linolenic acid (18:
3Δ9,12,15). Linolenic acid is formed by the activity of a Δ15-desaturase (Tocher et al. 1998, Prog. Lipid Res. 37, 73-117;
Domergue et al. 2002, Eur. J. Biochem. 269, 4105-4113).
[0014] Mammals, and thus also humans, have no corresponding desaturase activity (Δ12- and Δ15-desaturase) and
must take up these fatty acids (essential fatty acids) via food. Starting with these precursors, the physiologically important
polyunsaturated fatty acids arachidonic acid (= ARA, 20:4Δ5,8,11,14), an ω6-fatty acid, and the two ω3-fatty acids eicos-
apentaenoic acid (= EPA, 20:5Δ5,8,11,14,17) and docosahexaenoic acid (DHA, 22:6Δ4,7,10,13,17,19) are synthesized via the
sequence of desaturase and elongase reactions. The application of ω3-fatty acids shows the therapeutic activity described
above in the treatment of cardiovascular diseases (Shimikawa 2001, World Rev. Nutr. Diet. 88, 100-108), inflammations
(Calder 2002, Proc. Nutr. Soc. 61, 345-358) and arthritis (Cleland and James 2000, J. Rheumatol. 27, 2305-2307).
[0015] Higher plants comprise polyunsaturated fatty acids such as linoleic acid (C18:2) and linolenic acid (C18:3).
ARA, EPA and DHA are not found at all in the seed oil of higher plants, or only in miniscule amounts (E. Ucciani: Nouveau
Dictionnaire des Huiles Végétales [New Dictionary of Vegetable Oils]. Technique & Documentation - Lavoisier, 1995.
ISBN: 2-7430-0009-0). However, the production of LCPUFAs in higher plants (preferably in oil crops such as oilseed
rape, linseed, sunflower and soybeans) would be advantageous since large amounts of high-quality LCPUFAs for the
food industry, animal nutrition and pharmaceutical purposes might be obtained economically. A potential route is via
recombinant methods, where genes which code for enzymes of the biosynthesis of LCPUFAs are introduced and ex-
pressed into oil crops. These genes code for, for example, Δ6-desaturases, Δ6-elongases, Δ5-desaturases or Δ4-de-
saturases. These genes can advantageously be isolated from microorganisms and lower plants which produce LCPUFAs
and incorporate them in the membranes or triacylglycerides. Thus, it has already been possible to isolate Δ6-desaturase
genes from the moss Physcomitrella patens and Δ6-elongase genes from P. patens and from the nematode C. elegans.
(Zank, T.K. et al. Plant Journal 31:255-268, 2002, Beaudoin et al. Biochem Soc Trans 28 :661-663, 2000).
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[0016] The first transgenic plants which comprise and express genes coding for LCPUFA biosynthesis enzymes and
which produce LCPUFAs were described for example, in DE-A-102 19 203 (process for the production of polyunsaturated
fatty acids in plants). However, these plants produce LCPUFAs in amounts which require further optimization for process-
ing the oils which are present in the plants.
[0017] To ensure the enrichment of food and of feed with these Polyunsaturated fatty acids, there is therefore a great
need for means and measures for a simple, inexpensive process for the production of these polyunsaturated fatty acids,
specifically in eukaryotic systems.
[0018] The object on which the present invention is based is the provision of such means and measures. This object
is achieved by the embodiments which are described in the patent claims and hereinbelow.
[0019] The present invention thus relates to a polynucleotide comprising a nucleic acid sequence selected from the
group consisting of:
(a) nucleic acid sequence as shown in any of SEQ ID No. 1, 2, 8, 9, 15, 16, 50 or 51;
(b) nucleic acid sequence which codes for a polypeptide which features an amino acid sequence as shown in any
of SEQ ID No. 3, 10, 17 or 52;
(c) nucleic acid sequence which has at least 70% identity to one of the nucleic acid sequences of (a) or (b), and
which codes for a polypeptide with a desaturase activity; and
(d) nucleic acid sequence for a fragment of a nucleic acid of (a), (b) or (c), wherein the fragment codes for a
polypeptide with a desaturase activity.
[0020] The class of the ω6-fatty acids is based on the ω6-fatty acid linoleic acid (18:2Δ9,12), while the class of the ω3-
fatty acids is based on the (3-fatty acid linolenic acid (18:3(9,12,15); see Figure 1. These two fatty acids are the substrates
for the synthesis of long-chain (6- and (3-PUFAs, respectively. The increase of the content in these fatty acids according
to the genes which are introduced leads to an increase of the content in long-chain-PUFAs.
[0021] The present invention provides polynucleotide sequences which lead to an increase of the substrates 18:2
(9,12 and 18:3(9,12,15, respectively. There have been identified polynucleotide sequences which code for enzymes
with (12-desaturase activity, with (12- and (15-desaturase activity, with (15-desaturase activity or with (3-desaturase
activity.
[0022] According to the invention, the term "polynucleotide" refers to polynucleotides which comprise nucleic acid
sequences which code for polypeptides with desaturase activity. The desaturase activities are preferably required for
the biosynthesis of lipids or fatty acids. Especially preferably, they take the form of the following desaturase activities:
Δ12-desaturase, Δ15-desaturase, Δ12- and Δ15-desaturase or omega-3-desaturase activity. The desaturases are pref-
erably involved in the synthesis of polyunsaturated fatty acids (PUFAs) and especially preferably in the synthesis of
long-chain PUFAs (LCPUFAs). Suitable detection systems for these desaturase activities are described in the examples
or in WO 2005/083053. The desaturase activities according to the invention especially preferably have substrate spe-
cificities and/or conversion rates which are comparable to those of the respective homologous desaturase enzymes
from Pythium irregulare, Ostreococcus tauri, Phytophtora sojae or Phytophtora infestans. The specific polynucleotides
according to the invention, i.e. the polynucleotides with a nucleic acid sequence as shown in SEQ ID No.: 1, 2, 8, 9, 15,
16, 50 or 51 have been obtained from Cochliobolus heterostrophus C5, Cyanothece sp. CCY0110, Polaromonas sp.
JS666, Prochlorococcus marinus str. MIT 9313, Synechococcus sp. PCC 7335, Mycocentrospora acerina or Hyaloper-
onospora parasitica.
[0023] In particular, the nucleic acid sequences according to SEQ ID No. 1 and 2 originate from Cochliobolus heter-
ostrophus C5, the nucleic acid sequences according to SEQ ID No. 8 and 9 from Cyanothece sp. CCY0110, the nucleic
acid sequences according to SEQ ID No. 15 and 16 from Mycocentrospora acerina and the nucleic acid sequences
according to SEQ ID No. 50 and 51 from Hyaloperonospora parasitica. SEQ ID No. 1, 8 and 50 are genomic sequences,
SEQ ID No. 15 is an mRNA transcript, while SEQ ID No. 2, 9, 16 and 51 are coding sequences (cds). SEQ ID No. 3,
10, 17 and 52 show the corresponding amino acid sequences.
[0024] Thus, polynucleotides according to the invention are especially preferred:
Polynucleotides which code for a polypeptide with Δ15-desaturase activity and which comprise (i) a nucleic acid
sequence as shown in SEQ ID No. 1 or 2, (ii) a nucleic acid sequence which codes for a polypeptide as shown in
SEQ ID No. 3, (iii) a nucleic acid sequence which has at least 70% identity to one of the nucleic acid sequences of
(i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), where the fragment codes
for a polypeptide with a Δ15-desaturase activity.
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[0025] Polynucleotides which code for a polypeptide with Δ15-desaturase activity and which comprise (i) a nucleic
acid sequence as shown in SEQ ID No. 8 or 9, (ii) a nucleic acid sequence which codes for a polypeptide as shown in
SEQ ID No. 10, (iii) a nucleic acid sequence which has at least 70% identity to one of the nucleic acid sequences of (i)
or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), where the fragment codes for a
polypeptide with a Δ15-desaturase activity.
[0026] Polynucleotides which code for a polypeptide with Δ12-desaturase activity and which comprise (i) a nucleic
acid sequence as shown in SEQ ID No. 15 or 16, (ii) a nucleic acid sequence which codes for a polypeptide as shown
in SEQ ID No. 17, (iii) a nucleic acid sequence which has at least 70% identity to one of the nucleic acid sequences of
(i) or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), where the fragment codes for
a polypeptide with a Δ12-desaturase activity.
[0027] Polynucleotides which code for a polypeptide with ω3-desaturase activity and which comprise (i) a nucleic acid
sequence as shown in SEQ ID No. 50 or 51, (ii) a nucleic acid sequence which codes for a polypeptide as shown in
SEQ ID No. 52, (iii) a nucleic acid sequence which has at least 70% identity to one of the nucleic acid sequences of (i)
or (ii), or (iv) a nucleic acid sequence for a fragment of a nucleic acid of (i), (ii) or (iii), where the fragment codes for a
polypeptide with a ω3-desaturase activity.
[0028] The term "delta-12-desaturase (or Δ-12-desaturases or d-12-desaturase or d12-Des or d12Des)" or "delta-12-
desaturase (or Δ-12-desaturases or d-12-desaturase or d12-Des or d12Des) activity" as used in the present context
refers to an enzyme with the enzymatic function for dehydrogenating C18-fatty acids which are already dehydrogenated
on the C atom 9-10. Here, the C atoms C12 and C13 are dehydrogenated in each case one hydrogen atom, giving rise
to a double bond between these two C atoms.
[0029] The term "delta-15-desaturase (or Δ-15-desaturase or d-15-desaturase or d15-Des or d15Des)" or "delta-15-
desaturase (or Δ-15-desaturases or d-15-desaturase or d15-Des or d15Des) activity" as used in the present context
refers to an enzyme with the enzymatic function for dehydrogenating C18- and/or C20-fatty acids which are dehydro-
genated on the C atoms 6-7, 8-9, 9-10, 12-13 and/or 13-14. Here, the C atoms C15-16 and/or C17-18 are dehydrogenated
in each case one hydrogen atom, giving rise to a double bond between the two C atoms.
[0030] The term "delta-12- and delta-15-desaturase (or Δ-12- and Δ-15-desaturase or as written hereinabove)" or
"delta-12- and delta-15-desaturase (or Δ-12- and Δ-15-desaturase or as written hereinabove) activity" as used in the
present context refers to an enzyme with the enzymatic function for dehydrogenating C18- and/or C20-fatty acids which
are dehydrogenated on the C atoms 6-7, 8-9, 9-10 and/or 13-14. Here, the C atoms C12-13 and C15-16 and/or C17-18
are dehydrogenated in each case one hydrogen atom, giving rise to a double bond between the two C atoms.
[0031] The term "omega-3-desaturase (or (3-desaturase or (3-Des or (3Des or omega3 Des or o3Des) " or "omega-
3-desaturase (or (3-desaturase or (3-Des or (3Des or omega3 Des or o3Des) activity" as used in the present context
refers to an enzyme with the enzymatic function for the dehydrogenation of C18-, C20- and/or C22-fatty acids which are
dehydrogenated on the C atoms 4-5, 5-6, 6-7, 8-9, 9-10, 13-14 and/or 16-17. Here, the C atoms C15-16 and/or C17-18
and/or C19-20 are dehydrogenated by in each case one hydrogen atom, giving rise to a double bond between the two
C atoms.
[0032] Desaturases according to the invention especially preferably feature, in succession, the desaturase motif 1
"GX10HX3HX13GX9PX3WX3H" (SEQ ID No. 46), the desaturase motif 2 "PX14(H/Q)H " (SEQ ID No. 47) and either
the desaturase motif 3 "HX2HHX5PXY" (SEQ ID No. 48) or the desaturase motif 4 "HX2HHX6PXY" (SEQ ID No. 49),
where X stands for any amino acid. Whether it is a Δ12-, Δ15- or omega3-desaturase can be deduced from the amino
acid at the variable position 16 of the desaturase motif 2 (H or Q): Q = glutamine is indicative of putative Δ12-desaturases,
H = histidine is indicative of Δ15- or omega3-desaturases.
[0033] In this context, the polynucleotide sequences or the peptide sequences according to the invention preferably
originate from the abovementioned organisms.
[0034] It is clear that, in the light of the degeneracy of the genetic code, the abovementioned specific sequences can
also be modified, where the modified polynucleotides still code for polypeptides with an amino acid sequence as shown
in any of SEQ ID No. 3, 10, 17 or 52 and which have the abovementioned desaturase activities.
[0035] The term "polynucleotide" also comprises variants of the abovementioned specific polynucleotides. These may
take the form of homologous, orthologous or paralogous sequences. Such variants comprise nucleic acid sequences
which feature at least one base substitution, one base addition or one base deletion, it being intended that the variants
still code for a polypeptide with the abovementioned biological activity of the respective starting sequence. Variants
comprise polynucleotides which are capable of hybridization with the abovementioned polynucleotides, preferably under
stringent conditions. Especially preferred stringent conditions are known to the skilled worker and can be found in Current
Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred example of stringent hybridization
conditions are hybridizations in 6 x sodium chloride/sodium citrate (= SSC) at approximately 45°C, preferably 50°C,
55°C, 60°C and most preferably at 62°C, followed by one or more wash steps in 0.1 x SSC, 0.1 % SDS at 50 to 65°C,
preferably 55 to 65°C even more preferably at 60 to 65°C. The skilled worker knows that these hybridization conditions
differ as a function of the type of nucleic acid and, for example when organic solvents are present, with regard to the
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temperature and the buffer concentration. Under "standard hybridization conditions", the temperature differs as a function
of the type of nucleic acid between 42°C and 58°C in aqueous buffer with a concentration of from 0.1 to 5 x SSC (pH
7.2). If organic solvent is present in the abovementioned-buffer, for example 50% formamide, the temperature under
standard conditions is approximately 42°C. The hybridization conditions for DNA:DNA hybrids are preferably for example
0.1 x SSC and 20°C to 45°C, preferably between 30°C and 45°C. The hybridization conditions for DNA:RNA hybrids
are preferably for example 0.1 x SSC and 30°C to 55°C, preferably between 45°C and 55°C. The abovementioned
hybridization temperatures are determined for example for a nucleic acid of approximately 100 bp (= base pairs) in length
and a G + C content of 50% in the absence of formamide. The skilled worker knows how to determine the hybridization
conditions required with the aid of textbooks, such as the one mentioned hereinabove, or from the following textbooks:
Sambrook et al., "Molecular Cloning", Cold Spring Harbor Laboratory, 1989; Hames and Higgins (eds.) 1985, "Nucleic
Acids Hybridization: A Practical Approach", IRL Press at Oxford University Press, Oxford; Brown (ed.) 1991, "Essential
Molecular Biology: A Practical Approach", IRL Press at Oxford University Press, Oxford. As an alternative, variants of
the specific polynucleotides according to the invention may also be provided by polymerase chain reaction (PCR)-based
methods. To this end, it is possible first to derive primers from conserved sequences (for example sequences which
code for functional domains in the polypeptide). Conserved sequences can be determined by sequence comparisons
with polynucleotides which code for polypeptides with a similar activity. The template used may be DNA or cDNA from
bacteria, fungi, plants or animals. DNA fragments obtained by PCR can be used for screening suitable genomic libraries
or cDNA libraries in order to - if required - isolate the complete open reading frame of the polynucleotide and to determine
it by sequencing. Preferred variants comprise polynucleotides which comprise a nucleic acid sequence with at least
50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at
least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91
%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% (or
a different percentage than mentioned herein) identity with one of the abovementioned specific nucleic acid sequences
and codes for a polypeptide with the respective biological activity. Equally preferably comprised are polynucleotides
which comprise nucleic acid sequences which code for a polypeptide with an amino acid sequence with at least 50%,
at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least
83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at
least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% (or a different
percentage than mentioned herein) identity with one of the abovementioned specific amino acid sequences and where
the polypeptide has the respective biological activity of the starting sequence.
[0036] The percentage of identical nucleotides or amino acids preferably relates to a sequence segment of at least
50% of the sequences to be compared, and especially preferably over the entire length of the sequences to be compared.
A multiplicity of programs which implement algorithms for such comparisons are described in the prior art and commercially
available. In particular, reference may be made to the algorithms of Needleman and Wunsch or Smith and Waterman,
which give particularly reliable results. These algorithms can preferably be implemented by the following programs:
PileUp (J. Mol. Evolution., 25, 351-360, 1987, Higgins 1989, CABIOS, 5: 151-153), Gap and BestFit (Needleman and
Wunsch (J. Mol. Biol. 48; 443-453 (1970) and Smith and Waterman (Adv. Appl. Math. 2; 482-489(1981))), as part of the
GCG software (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711, 1991). For the purposes
of the present invention, it is especially preferred to determine the percentage (%) of the sequence identity with the GAP
program over the entire sequence, with the following set parameters: Gap Weight: 50, Length Weight: 3, Average Match:
10.000 and Average Mismatch: 0.000.
[0037] A polynucleotide which only comprises a fragment of the abovementioned nucleic acid sequences is also a
polynucleotide according to the invention. Here, it is intended that the fragment codes for a polypeptide which features
the biological activity of the starting sequence, or of the polypeptide which the latter codes for. Polypeptides which are
encoded by such polynucleotides therefore comprise, or consist of, domains of the abovementioned specific polypeptides
(starting polypeptides) which confer the biological activity. A fragment for the purposes of the invention preferably com-
prises at least 50, at least 100, at least 250 or at least 500 consecutive nucleotides of the abovementioned specific
sequences or codes for an amino acid sequence comprising at least 20, at least 30, at least 50, at least 80, at least 100
or at least 150 consecutive amino acids of one of the abovementioned specific amino acid sequences, and confers
biological activity, preferably desaturase activity, as described above.
[0038] The polynucleotide variants according to the invention preferably feature at least 10%, at least 20%, at least
30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the respective biological
activity of the polypeptide which is encoded by the starting sequence. That is to say the polypeptides which are encoded
by the polynucleotides according to the invention can participate in the metabolism of compounds required for the
synthesis of fatty acids, fatty acid esters such as diacylglycerides and/or triacylglycerides in an organism, preferably in
a plant or plant cell, or can participate in the transport of molecules across membranes, which means C18-, C20- or
C22-carbon chains in the fatty acid molecule with double bonds at at least two, advantageously three, four, five or six
positions.
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[0039] The polynucleotides according to the invention either comprise the abovementioned specific nucleic acid se-
quences or consist of them. That is to say, that the polynucleotides according to the invention may, in principle, also
comprise further nucleotides. These may preferably be 3’- or 5’-untranslated regions of the genomic nucleic acid se-
quence. They preferably consist of at least 100, 200 or 500 nucleotides at the 5’ terminus and of at least 20, 50 or 100
nucleotides at the 3’ terminus of the coding region. Further polynucleotides which comprise additional nucleic acid
sequences are those which code for fusion proteins. Such fusion proteins can code for further polypeptides or polypeptide
portions, in addition to the abovementioned polypeptides. The additional polypeptide or polypeptide portion may take
the form of further enzymes of lipid or fatty acid biosynthesis. Others which are feasible are polypeptides which may act
as expression markers (green, yellow, red, blue fluorescent proteins, alkaline phosphatase and others) or so-called
"tags" as labels or as an aid for purification (for example FLAG tags, 6-histidine tags, MYC tags and others).
[0040] Polynucleotide variants can be isolated from different natural or artificial sources. For example, they can be
generated artificially by in-vitro or in-vivo mutagenesis. Homologs or orthologs of the specific sequences can be obtained
from a wide range of animals, plants and microorganisms. They are preferably obtained from algae. Algae such as
Isochrysis, Euglena or Crypthecodinium, algae/diatoms such as Thalassiosira, Phaeodactylum or Thraustochytrium,
Pythium, mosses such as Physcomitrella, preferably Physcomitrella patens or Ceratodon are preferred, very especially
preferred are the algae of the genus Euglena or the diatoms of the class Oomycota such as the genera Pythium or
Phytophtora or fungi such as Postia placenta or Microdochium nivale, or from the division Zygomycota from the genera
Rhizopus, Aspergillus, Thraustochytrium, Phytophthora, Entomophthora, Mucor or Mortierella. The polynucleotides can
also be obtained from plants, preferably from the family Selaginellaceae, such as Selaginella moellendorffii, or from
higher plants such as Primulaceae such as Aleuritia, Calendula stellata, Osteospermum spinescens or Osteospermum
hyoseroides, bacteria such as Shewanella, cyanobacteria such as Synechococcus, yeasts or animals such as nema-
todes, for example Caenorhabditis, molluses, insects or fish. The polynucleotide variants are also preferably derived
from an animal from the order vertebrates. Especially preferably, the polynucleotides are derived from the class Verte-
brata; Euteleostomi, Actinopterygii; Neopterygii; Teleostei; Euteleostei, Protacanthopterygii, Salmoniformes; Salmonidae
or Oncorhynchus and, very especially preferably, from the order Salmoniformes such as the family Salmonidae, such
as the genus Salmo, for example from the genera and species Oncorhynchus mykiss, Trutta trutta or Salmo trutta fario.
Here, the polynucleotides according to the invention can be isolated by means of standard techniques of molecular
biology and of the sequence information provided herein. Also, it is possible, with the aid of comparative algorithms, to
identify for example a homologous sequence or homologous, conserved sequence regions at the DNA or amino acid
level. These can be employed as hybridization probe and standard hybridization techniques (such as, for example, those
described in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd Ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) for isolating further nucleic acid sequences which are
useful in the process. Moreover, it is possible to isolate polynucleotides or fragments thereof by means of polymerase
chain reaction (PCR), where oligonucleotide primers which are based on this sequence or parts thereof are employed
(for example, a nucleic acid molecule comprising the complete sequence or part thereof can be isolated by polymerase
chain reaction using oligonucleotide primers which have been generated on the basis of this same sequence). For
example, it is possible to isolate mRNA from cells (for example by the guanidinium thiocyanate extractive method by
Chirgwin et al. (1979) Biochemistry 18:5294-5299), and cDNA can be generated by means of reverse transcriptase (for
example Moloney MLV reverse transcriptase, obtainable from Gibco/BRL, Bethesda, MD, or AMV reverse transcriptase,
obtainable from Seikagaku America, Inc., St.Petersburg, FL). Synthetic oligonucleotide primers for the amplification by
means of polymerase chain reaction can be generated on the basis of the polynucleotide and amino acid sequences
shown in the SEQ ID numbers (SEQ ID NR:). A nucleic acid according to the invention can be amplified using cDNA or,
alternatively, genomic DNA as the template and suitable oligonucleotide primers, following standard PCR amplification
techniques. The nucleic acid amplified thus can be cloned into a suitable vector and characterized by means of DNA
sequence analysis. Oligonucleotides which correspond to a desaturase nucleotide sequence can be generated by
standard synthetic methods, for example using an automatic DNA synthesizer.
[0041] The polynucleotides according to the invention can either be provided in the form of isolated polynucleotides
(i.e. isolated from their natural origin, for example the genomic locus) or else in genetically modified form (i.e. the
polynucleotides may also be present at their natural genetic locus, but, in such a case, must be genetically modified).
An isolated polynucleotide preferably comprises less than 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleic acid
sequence which occurs naturally in its environment. The polynucleotide according to the invention may be present as
a single-stranded or double-stranded nucleic acid molecule and may take the form of genomic DNA, cDNA or RNA.
Preferably, the polynucleotide according to the invention consists of RNA or DNA. The polynucleotides according to the
invention comprise all orientations of the sequences shown in the SEQ ID numbers, i.e. also complementary strands
and reverse, or reverse-complementary, orientations. The term furthermore also comprises chemically modified nucleic
acids, such as the naturally occurring methylated DNA molecules, or artificial nucleic acids, for example biotinylated
nucleic acids.
[0042] The invention also comprises oligonucleotides of at least 15 bp, preferably at least 20 bp, at least 25 bp, at
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least 30 bp, at least 35 bp or at least 50 bp, which are capable of specifically hybridizing under stringent conditions with
one of the abovementioned polynucleotides. The oligonucleotides may consist of DNA or RNA or both. Such oligonu-
cleotides can be employed as primers for the PCR, as expression-inhibitory antisense oligonucleotides, for RNA inter-
ference (RNAi) approaches or for chimeroplastic or genoplastic approaches. RNAi methods are described for example
in Fire et al., Nature (1998) 391:806-811; Fire, Trends Genet. 15, 358-363 (1999); Sharp, RNA interference 2001. Genes
Dev. 15,485-490 (2001); Hammond et al. Nature Rev. Genet. 2, 1110-1119 (2001); Tuschl, Chem. Biochem. 2, 239-245
(2001); Hamilton et al., Science 286, 950-952 (1999); Hammond et al., Nature 404, 293-296 (2000); Zamore et al., Cell
101, 25-33 (2000); Bernstein et al., Nature 409, 363-366 (2001); Elbashir et al., Genes Dev. 15, 188-200 (2001); WO
01/29058; WO 99/32619; or Elbashir et al., 2001 Nature 411: 494-498 and serve for inhibiting gene expression by
degrading the mRNA. Chimeroplastic or genoplastic approaches serve the in-vivo modification (for example the intro-
duction of point mutations) into genes at their endogenous loci. Corresponding methods are disclosed in US5,565,350,
US5,756,325, US5,871,984, US5,731,181, US5,795,972, US6,573,046, US6,211,351, US6,586,184, US6,271,360 and
US6,479,292.
[0043] Advantageously, it has emerged that the polynucleotides according to the invention can be employed particularly
efficiently for the recombinant production of polyunsaturated fatty acids in host cells and in transgenic organisms. In
particular, the polypeptides which are encoded by the polynucleotides according to the invention and which have Δ12-
desaturase, Δ15-desaturase, Δ12- and Δ15-desaturase or omega-3-desaturase activity are capable of converting C18-,
C20- and C22-fatty acids with one, two, three, four or five double bonds and preferably polyunsaturated C18-fatty acids
with one, two or three double bonds such as C18:1(9, C18:2(9,12 or C18:3 (6,9,12, polyunsaturated C20-fatty acids
with three or four double bonds such as C20:3(8,11,14, C20:4(5,8,11,14 or C20: 4(8,11,14,17 or polyunsaturated C22-
fatty acids with four or five double bonds such as C22:4(7,10,13,16 or C22:5(7,10,13,16,19. Especially preferably, the
polynucleotide and amino acid sequences according to the invention lead to an increase in the 18:2(9,12-or 18:3(9,12,15-
fatty acids. Figure 1 shows where these desaturases according to the invention engage in the biosynthesis of long-chain
polyunsaturated fatty acids and/or how they can be used for producing these fatty acids.
[0044] In this context, it is especially preferred to employ the Δ6-desaturase encoded by the polynucleotide sequence
with SEQ ID No. 22 (d6Des(Pir)), the Δ6-elongase encoded by the polynucleotide sequence with SEQ ID No. 31 (d6Elo
(Pp)), the Δ5-desaturase, encoded by the polynucleotide sequence with SEQ ID No. 25 (d5Des(Tc)), the Δ15-elongase
encoded by the polynucleotide sequence with SEQ ID No. 34 (d5Des(Ot)), the Δ14-desaturase encoded by the polynu-
cleotide sequence with SEQ ID No. 37 (d4Des(Tc)), the Δ6-elongase encoded by the polynucleotide sequence with
SEQ ID No. 40 (d6Elo(Tp)); the Δ6-desaturase encoded by the polynucleotide sequences with SEQ ID No. 41 (d6Des
(Tc)) with one or more of the desaturases according to the invention in order to synthesize long-chain polyunsaturated
fatty acids; see in this context W02006/100241. Alternatively, it was also possible to employ a Δ9-elongase and a Δ8-
desaturase instead of the abovementioned Δ6-desaturase and the Δ6-elongase as described in W02004/057001. De-
pending on the fatty acid which is to be prepared, it is possible to coexpress, in the host cells or transgenic organisms
described hereinbelow, or to use in the methods according to the invention, a variety of combinations of the polynucleotides
according to the invention with the abovementioned desaturases or elongases. Especially preferred combinations for
the production of eicosapentaenoic acid are shown in tables 5 and 8 and for docosahexaenoic acid in table 6 hereinbelow.
For example, it is possible to use a Δ12-desaturase, Δ15-desaturase, Δ12- and Δ15-desaturase, or omega-3-desaturase
according to the invention, alone or in a suitable combination (for example a Δ12-desaturase and a Δ15-desaturase),
together with d6Des(Pir) and/or d6Des(Ot), d6Elo(Pp), d5Des(Tc) and ω3Des(Pi) for the production of EPA. Equally, a
Δ12-desaturase, Δ15-desaturase, Δ12- and Δ15-desaturase, or omega-3-desaturase according to the invention, alone
or in a suitable combination, can be used together with d6Des(Pir) and/or d6Des(Ot), d6Elo(Pp), d5Des(Tc), ω3Des(Pi),
d5Elo(Ot), d4Des(Tc) for the production of docosahexaenoic acid.
[0045] Preferably, it is the fatty acids in phospholipids or CoA fatty acid esters which are desaturated, advantageously
in the CoA fatty acid esters. Thus, a simple, inexpensive production of these polyunsaturated fatty acids is possible,
specifically in eukaryotic systems. The unsaturated fatty acids produced by means of the polynucleotides according to
the invention can then be formulated as oil, lipid and fatty acid compositions and can be employed in a suitable manner.
[0046] The present invention furthermore relates to a vector which comprises the polynucleotide according to the
invention.
[0047] The term "vector" refers to a nucleic acid molecule which is capable of transporting another nucleic acid molecule,
such as the polynucleotides according to the invention, to which it is bound. One type of vector is a plasmid, a circular
double-stranded DNA loop into which additional DNA segments can be ligated. A further type of vector is a viral vector,
it being possible for additional DNA segments to be ligated into the viral genome. Certain vectors are capable of auton-
omous replication in a host cell into which they have been introduced (for example bacterial vectors with bacterial
replication origin). Other vectors are advantageously integrated into the genome of a host cell when they are introduced
into the host cell, and thus replicate together with the host genome. Moreover, certain vectors can govern the expression
of genes with which they are in operable linkage. These vectors are referred to in the present context as expression
vectors. Usually, expression vectors which are suitable for DNA recombination techniques take the form of plasmids. In
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the present description, "plasmid" and "vector" can be used exchangeably since the plasmid is the form of vector which
is most frequently used. However, the invention is also intended to comprise other forms of expression vectors, such
as viral vectors, which exert similar functions. Furthermore, the term "vector" is also intended to comprise other vectors
with which the skilled worker is familiar, such as phages, viruses such as SV40, CMV, TMV, transposons, IS elements,
phasmids, phagemids, cosmids, linear or circular DNA, artificial chromosomes. Finally, the term also comprises constructs
for the targeted, i.e. homologous, recombination, or the heterologous insertion of polynucleotides.
[0048] Vectors can be introduced into prokaryotic and eukaryotic cells via conventional transformation or transfection
techniques. The terms "transformation" and "transfection", conjugation and transduction, as used in the present context,
are intended to comprise a multiplicity of methods known in the prior art for the introduction of foreign nucleic acid (for
example DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated
transfection, lipofection, natural competence, chemically mediated transfer, electroporation or particle bombardment.
Suitable methods for the transformation or transfection of host cells, including plant cells, can be found in Sambrook et
al. (Molecular Cloning: A Laboratory Manual., 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY, 1989) and other laboratory textbooks such as Methods in Molecular Biology, 1995, Vol.
44, Agrobacterium protocols, Ed.: Gartland and Davey, Humana Press, Totowa, New Jersey.
[0049] Suitable cloning vectors are generally known to the skilled worker. In particular, they include vectors which can
replicate in microbial systems, that is mainly vectors which ensure efficient cloning in yeasts or fungi and which make
possible the stable transformation of plants. Those which must be mentioned are in particular various binary and cointe-
grated vector systems which are suitable for the T-DNA-mediated transformation. Such vector systems are, as a rule,
characterized in that they comprise at least the vir genes, which are required for the agrobacterium-mediated transfor-
mation, and the T-DNA-bordering sequences (T-DNA border). Preferably, these vector systems also comprise further
cis-regulatory regions such as promoters and terminators and/or selection markers, by means of which suitably trans-
formed organisms can be identified. While in the case of cointegrated vector systems vir genes and T-DNA sequences
are arranged on the same vector, binary systems are based on at least two vectors, one of which bears vir genes, but
no T-DNA, and the other bears T-DNA, but no vir gene. As a result, the last-mentioned vectors are relatively small, easy
to manipulate and to replicate both in E. coli and in Agrobacterium. These binary vectors include vectors from the pBIB-
HYG series, the pPZP series, the pBecks series and the pGreen series. Preferably used according to the invention are
Bin19, pBI101, pBinAR, pGPTV and pCAMBIA. An overview of binary vectors and their use is found in Hellens et al,
Trends in Plant Science (2000) 5, 446-451. The vectors with the inserted polynucleotides according to the invention can
be propagated stably under selective conditions in microorganisms, in particular Escherichia coli and Agrobacterium
tumefaciens, and make possible a transfer of heterologous DNA into plants or microorganisms. The polynucleotides
according to the invention can be introduced into organisms such as microorganisms or plants by means of the cloning
vectors and thus used for transforming plants. Vectors which are suitable for this purpose are published in: Plant Molecular
Biology and Biotechnology (CRC Press, Boca Raton, Florida), chapter 6/7, p. 71-119 (1993); F.F. White, Vectors for
Gene Transfer in Higher Plants; in: Transgenic Plants, vol. 1, Engineering and Utilization, eds.: Kung and R. Wu, Academic
Press, 1993, 15-38; B. Jenes et al., Techniques for Gene Transfer, in: Transgenic Plants, vol. 1, Engineering and
Utilization, eds.: Kung and R. Wu, Academic Press (1993), 128-143; Potrykus, Annu. Rev. Plant Physiol. Plant Molec.
Biol. 42 (1991), 205-225.
[0050] The vector is preferably an expression vector. The polynucleotide is present in the expression vector according
to the invention in operative (i.e. functional) linkage with an expression control sequence. The expression control sequence
together with the polynucleotide and optionally further sequence elements of the vector is also referred to as the expression
cassette. The expression control sequence ensures that, after transformation or transfection into a host cell, the poly-
nucleotide can be expressed. The expression control sequence to be used preferably comprises cis-regulatory elements
such as promoter and/or enhancer nucleic acid sequences, which are recognized by the transcription machinery of the
host cells. The term furthermore comprises other expression control elements, for example polyadenylation signals and
RNA-stabilizing sequences. These regulatory sequences are described for example in Goeddel: Gene Expression Tech-
nology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990) or see: Gruber and Crosby, in: Methods
in Plant Molecular Biology and Biotechnology, CRC Press, Boca Raton, Florida, eds.: Glick and Thompson, chapter 7,
89-108, including the literature cited therein. Expression control sequences comprise those which govern the constitutive
expression of a nucleotide sequence in many types of host cells, and those which govern the direct expression of the
nucleotide sequence only in certain host cells under certain conditions. The skilled worker knows that the design of the
expression vector may depend on factors such as the choice of the host cell to be transformed, the extent of the expression
of the desired protein and the like. The polynucleotides according to the invention may be present in one or more copies
in the expression cassette or in the expression vector according to the invention (for example in the form of several
expression cassettes). Here, the regulatory sequences or factors can preferably have a positive effect on the gene
expression of the introduced genes, as described above, and thereby increase it. Thus, it is possible to enhance the
regulatory elements advantageously at the transcription level by using strong transcription signals such as promoters
and/or "enhancers". Besides, it is also possible to enhance the translation, for example by improving the mRNA stability.
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Further expression control sequences within the meaning of the present invention are translation terminators at the 3’
end of the polynucleotides to be translated. An example which can be used here is the OCS1 terminator. As in the case
of the promoters, a different terminator sequence should be used for each polynucleotide to be expressed.
[0051] Preferred expression control sequences or regulatory sequences are present in promoters such as the cos,
tac, trp, tet, trp-tet, Ipp, lac, lpp-lac, laclq, T7, T5, T3, gal, trc, ara, SP6, λ-PR or λ-PL promoters and are advantageously
employed in Gram-negative bacteria. Further advantageous regulatory sequences are, for example, present in the Gram-
positive promoters amy and SPO2, in the yeast or fungal promoters ADC1, MFα, AC, P-60, CYC1, GAPDH, TEF, rp28,
ADH or in the plant promoters CaMV/35S [Franck et al., Cell 21 (1980) 285-294], PRP1 [Ward et al., Plant. Mol. Biol.
22 (1993)], SSU, OCS, lib4, usp, STLS1, B33, nos or in the ubiquitin or phaseolin promoter. Advantageous in this context
are also inducible promoters, such as the promoters described in EP-A-0 388 186 (benzenesulfonamide-inducible),
Plant J. 2, 1992:397-404 (Gatz et al., tetracycline-inducible), EP-A-0 335 528 (abscisic acid-inducible) or WO 93/21334
(ethanol- or cyclohexenol-inducible). Further suitable plant promoters are the cytosolic FBPase promoter or the ST-LSI
promoter of potato (Stockhaus et al., EMBO J. 8, 1989, 2445), the glycine max phosphoribosyl-pyrophosphate ami-
dotransferase promoter (Genbank Accession No. U87999) or the node-specific promoter described in EP-A-0 249 676.
Especially advantageous promoters are promoters which make possible the expression in tissues which are involved
in the biosynthesis of fatty acids. Very especially advantageous are seed-specific promoters, such as the USP promoter,
but also other promoters such as the LeB4, DC3, phaseolin or napin promoter. Further especially advantageous promoters
are seed-specific promoters which can be used for monocotyledonous or dicotyledonous plants and which are described
in US 5,608,152 (oilseed rape napin promoter), WO 98/45461 (Arobidopsis oleosin promoter), US 5,504,200 (Phaseolus
vulgaris phaseolin promoter), WO 91/13980 (Brassica Bce4 promoter), by Baeumlein et al., Plant J., 2, 2, 1992:233-239
(LeB4 promoter from a legume), these promoters being suitable for dicots. Examples of promoters which are suitable
for monocots are the barley lpt-2 or lpt-1 promoter (WO 95/15389 and WO 95/23230), the barley hordein promoter and
other suitable promoters described in WO 99/16890. In principle, it is possible to use all natural promoters together with
their regulatory sequences, such as those mentioned above, as expression control sequences. It is also possible to use
synthetic promoters, either in addition or alone, in particular when they mediate seed-specific expression, as described,
for example, in WO 99/16890.
[0052] In order to achieve a particularly high PUFA content, especially in transgenic plants, the polynucleotides of the
present invention should preferably be expressed in oil crops in a seed-specific manner. To this end, seed-specific
promoters can be used, or those promoters which are active in the embryo and/or in the endosperm. In principle, seed-
specific promoters can be isolated both from dicotyledonous and from monocotyledonous plants. Advantageous preferred
promoters are listed hereinbelow: USP (= unknown seed protein) and vicilin (Vicia faba) [Bäumlein et al., Mol. Gen
Genet., 1991, 225(3)], napin (oilseed rape) [US 5,608,152], acyl carrier protein (oilseed rape) [US 5,315,001 and WO
92/18634], oleosin (Arabidopsis thaliana) [WO 98/45461 and WO 93/20216], phaseolin (Phaseolus vulgaris) [US
5,504,200], Bce4 [WO 91/13980], legumines B4 (LegB4 promoter) [Bäumlein et al., Plant J., 2,2, 1992], Lpt2 and lpt1
(barley) [WO 95/15389 and WO 95/23230], seed-specific promoters from rice, maize and wheat [WO 99/16890], Amy32b,
Amy 6-6 and aleurain [US 5,677,474], Bce4 (oilseed rape) [US 5,530,149], glycinin (soybean) [EP 571 741], phosphoenol
pyruvate carboxylase (soybean) [JP 06/62870], ADR12-2 (soybean) [WO 98/08962], isocitrate lyase (oilseed rape) [US
5,689,040] or α-amylase (barley) [EP 781 849].
[0053] Plant gene expression can also be facilitated via a chemically inducible promoter (see a review in Gatz 1997,
Annu. Rev. Plant Physiol. Plant Mol. Biol., 48:89-108). Chemically inducible promoters are particularly suitable when it
is desired that gene expression should take place in a time-specific manner. Examples of such promoters are a salicylic
acid-inducible promoter (WO 95/19443), a tetracycline-inducible promoter (Gatz et al. (1992) Plant J. 2, 397-404) and
an ethanol-inducible promoter.
[0054] To ensure stable integration of the various biosynthesis genes into the transgenic plant over a plurality of
generations, each of the polynucleotides according to the invention should be expressed under the control of a separate
promoter, preferably a promoter which differs from the other promoters, since repeating sequence motifs can lead to
instability of the T-DNA, or to recombination events. In this context, the expression cassette is advantageously constructed
in such a way that a promoter is followed by a suitable cleavage site (advantageously in a polylinker) for insertion of the
nucleic acid to be expressed and, if appropriate, a terminator is then positioned behind the polylinker. This sequence is
repeated several times, preferably three, four or five times, so that up to five genes can be combined in one construct
and introduced into the transgenic plant in order to be expressed. Advantageously, the sequence is repeated up to three
times. To express the nucleic acid sequences, the latter are inserted behind the promoter via a suitable cleavage site,
for example in the polylinker. Advantageously, each nucleic acid sequence has its own promoter and, if appropriate, its
own terminator. Such advantageous constructs are disclosed, for example, in DE 101 02 337 or DE 101 02 338. However,
it is also possible to insert a plurality of nucleic acid sequences behind a promoter and, if appropriate, in front of a
terminator. Here, the insertion site, or the sequence, of the inserted nucleic acids in the expression cassette is not of
critical importance, that is to say a nucleic acid sequence can be inserted at the first or last position in the cassette
without its expression being substantially influenced thereby. Advantageously, different promoters such as, for example,
EP 2 376 638 B1
12
5
10
15
20
25
30
35
40
45
50
55
the USP, LegB4 or DC3 promoters, and different terminators can be used in the expression cassette. However, it is also
possible to use only one type of promoter in the cassette. This, however, may lead to undesired recombination events.
[0055] The recombinant expression vectors used can be designed for the expression in prokaryotic or eukaryotic cells.
This is advantageous since intermediate steps of the vector construction are frequently carried out in microorganisms
for the sake of simplicity. For example, the Δ12-desaturase, Δ15-desaturase, Δ12- and Δ15-desaturases, ω3-desaturase,
Δ6-desaturase, Δ6-elongase, Δ9-elongase, Δ8-desaturase, Δ5-desaturase, Δ5-elongase and/or Δ4-desaturase genes
can be expressed in bacterial cells, insect cells (using Baculovirus expression vectors), "yeast and other fungal cells
(see Romanos, M.A., et al. (1992) "Foreign gene expression in yeast: a review", Yeast 8:423-488; van den Hondel,
C.A.M.J.J., et al. (1991) "Heterologous gene expression in filamentous fungi"; in: More Gene Manipulations in Fungi,
J.W. Bennet & L.L. Lasure, Eds., pp. 396-428: Academic Press: San Diego; and van den Hondel, C.A.M.J.J., & Punt,
P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of
Fungi, Peberdy, J.F., et al., Eds., pp. 1-28, Cambridge University Press: Cambridge), algae (Falciatore et al., 1999,
Marine Biotechnology.1, 3:239-251), ciliates of the types: Holotrichia, Peritrichia, Spirotrichia, Suctoria, Tetrahymena,
Paramecium, Colpidium, Glaucoma, Platyophrya, Potomacus, Desaturapseudocohnilembus, Euplotes, Engelmaniella
and Stylonychia, in particular of the genus Stylonychia lemnae, using vectors in a transformation method as described
in WO 98/01572 and, preferably, in cells of multicellular plants (see Schmidt, R. and Willmitzer, L. (1988) "High efficiency
Agrobacterium tumefaciens-mediated transformation of Arabidopsis thaliana leaf and cotyledon explants" Plant Cell
Rep.:583-586; Plant Molecular Biology and Biotechnology, C Press, Boca Raton, Florida, Chapter 6/7, pp.71-119 (1993);
F.F. White, B. Jenes et al., Techniques for Gene Transfer, in: Transgenic Plants, Vol. 1, Engineering and Utilization,
Eds.: Kung and R. Wu, Academic Press (1993), 128-43; Potrykus, Annu. Rev. Plant Physiol. Plant Molec. Biol. 42 (1991),
205-225 (and references cited therein)). Suitable host cells are furthermore discussed in Goeddel, Gene Expression
Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). As an alternative, the recombinant
expression vector can be transcribed and translated in vitro, for example using T7-promoter regulatory sequences and
T7-polymerase.
[0056] In most cases, the expression of proteins in prokaryotes involves the use of vectors comprising constitutive or
inducible promoters which govern the expression of fusion or nonfusion proteins. Typical fusion expression vectors are,
inter alia, pGEX (Pharmacia Biotech Inc; Smith, D.B., and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England
Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ), where glutathione S-transferase (GST), maltose-E-
binding protein and protein A, respectively, are fused with the recombinant target protein. Examples of suitable inducible
nonfusion E. coli expression vectors are, inter alia, pTrc (Amann et al. (1988) Gene 69:301-315) and pET 11d (Studier
et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89).
The target gene expression from the vector pTrc is based on the transcription from a hybrid trp-lac fusion promoter by
the host RNA polymerase. The target gene expression from the vector pET 11 d is based on the transcription of a T7-
gn10-lac fusion promoter, which is mediated by a viral RNA polymerase (T7 gn1), which is coexpressed. This viral
polymerase is provided by the host strains BL21 (DE3) or HMS174 (DE3) from a resident λ-prophagene which harbors
a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. Other vectors which are suitable for prokaryotic
organisms are known to the skilled worker, these vectors are, for example in E. coli pLG338, pACYC184, the pBR series
such as pBR322, the pUC series such as pUC18 or pUC19, the M113mp series, pKC30, pRep4, pHS1, pHS2, pPLc236,
pMBL24, pLG200, pUR290, pIN-111113-B1, λgt11 or pBdCl, in Streptomyces pIJ101, pIJ364, pIJ702 or pIJ361, in
Bacillus pUB110, pC194 or pBD214, in Corynebacterium pSA77 or pAJ667.
[0057] In a further embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression
in the yeast S. cerevisiae comprise pYeDesaturasec1 (Baldari et al. (1987) Embo J. 6:229-234), pMFa (Kurjan and
Herskowitz (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123) and pYES2 (Invitrogen Corporation,
San Diego, CA). Vectors and processes for the construction of vectors which are suitable for use in other fungi, such
as the filamentous fungi, comprise those which are described in detail in: van den Hondel, C.A.M.J.J., & Punt, P.J. (1991)
"Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of fungi, J.F.
Peberdy et al., Ed., pp. 1-28, Cambridge University Press: Cambridge, or in: More Gene Manipulations in Fungi [J.W.
Bennet & L.L. Lasure, Eds., pp. 396-428: Academic Press: San Diego]. Further suitable yeast vectors are, for example,
pAG-1, YEp6, YEp13 or pEMBLYe23.
[0058] As an alternative, the polynucleotides of the present invention can also be expressed in insect cells using
Baculovirus expression vectors. Baculovirus vectors which are available for the expression of proteins in cultured insect
cells (for example Sf9 cells) comprise the pAc series (Smith et al. (1983) Mol. Cell Biol.. 3:2156-2165) and the pVL series
(Lucklow and Summers (1989) Virology 170:31-39).
[0059] Preferred plant expression vectors comprise those which are described in detail in: Becker, D., Kemper, E.,
Schell, J., and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left
border", Plant Mol. Biol. 20:1195-1197; and Bevan, M.W. (1984) "Binary Agrobacterium vectors for plant transformation",
Nucl. Acids Res. 12:8711-8721; Vectors for Gene Transfer in Higher Plants; in: Transgenic Plants, Vol. 1, Engineering
and Utilization, Eds.: Kung and R. Wu, Academic Press, 1993, p. 15-38. A plant expression cassette preferably comprises
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expression control sequences which are capable of governing the expression of genes in plant cells and which are linked
operably so that each sequence can fulfill its function, such as transcriptional termination, for example polyadenylation
signals. Preferred polyadenylation signals are those which are derived from Agrobacterium tumefaciens T-DNA, such
as gene 3 of the Ti plasmid pTiACH5 (Gielen et al., EMBO J. 3 (1984) 835 et seq.), which is known as octopine synthase,
or functional equivalents thereof, but all other terminators which are functionally active in plants are also suitable. Since
plant gene expression is very often not limited to transcriptional levels, a plant expression cassette preferably comprises
other sequences which are linked operably, such as translation enhancers, for example the overdrive sequence, which
comprises the tobacco mosaic virus 5’-untranslated leader sequence, which increases the protein/RNA ratio (Gallie et
al., 1987, Nucl. Acids Research 15:8693-8711). As described above, plant gene expression must be linked operably
with a suitable promoter which triggers gene expression with the correct timing or in a cell- or tissue-specific manner.
Utilizable promoters are constitutive promoters (Benfey et al., EMBO J. 8 (1989) 2195-2202), such as those which are
derived from plant viruses, such as 35S CAMV (Franck et al., Cell 21 (1980) 285-294), 19S CaMV (see also US 5352605
and WO 84/02913), or plant promoters, such as the promoter of the small Rubisco subunit, which is described in US
4,962,028. Other preferred sequences for use in operable linkage in plant gene expression cassettes are targeting
sequences, which are required for steering the gene product into its corresponding cell compartment (see a review in
Kermode, Crit. Rev. Plant Sci. 15, 4 (1996) 285-423 and references cited therein), for example into the vacuole, into the
nucleus, all types of plastids, such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondria,
the endoplasmic reticulum, oil bodies, peroxisomes and other compartments of plant cells.
[0060] As described above, plant gene expression can also be facilitated via a chemically inducible promoter (see
review in Gatz 1997, Annu. Rev. Plant Physiol. Plant Mol. Biol., 48:89-108). Chemically inducible promoters are partic-
ularly suitable when it is desired that the gene expression takes place in a time-specific manner. Examples of such
promoters are a salicylic-acid-inducible promoter (WO 95/19443), a tetracyclin-inducible promoter (Gatz et al. (1992)
Plant J. 2, 397-404) and an ethanol-inducible promoter. Promoters which respond to biotic or abiotic stress conditions
are also suitable, for example the pathogen-induced PRP1 gene promoter (Ward et al., Plant. Mol. Biol. 22 (1993)
361-366), the heat-inducible tomato hsp80 promoter (US 5,187,267), the chill-inducible potato alpha-amylase promoter
(WO 96/12814) or the wound-inducible pinll promoter (EP-A-0 375 091).
[0061] Especially preferred are those promoters which bring about the gene expression in tissues and organs in which
the biosynthesis of fatty acids, lipids and oils takes place, in seed cells, such as the cells of the endosperm and of the
developing embryo. Suitable promoters are the oilseed rape napin gene promoter (US 5,608,152), the Vicia faba USP
promoter (Baeumlein et al., Mol Gen Genet, 1991, 225 (3):459-67), the Arabidopsis oleosin promoter (WO 98/45461),
the Phaseolus vulgaris phaseolin promoter (US 5,504,200), the Brassica Bce4 promoter (WO 91/13980) or the legumine
B4 promoter (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2):233-9), and promoters which bring about the seed-
specific expression in monocotyledonous plants such as maize, barley, wheat, rye, rice and the like. Suitable noteworthy
promoters are the barley lpt2 or lpt1 gene promoter (WO 95/15389 and WO 95/23230) or the promoters from the barley
hordein gene, the rice glutelin gene, the rice oryzin gene, the rice prolamine gene, the wheat gliadine gene, the wheat
glutelin gene, the maize zeine gene, the oat glutelin gene, the sorghum kasirin gene or the rye secalin gene, which are
described in WO 99/16890. Especially suitable promoters are likewise those which bring about the plastid-specific
expression, since plastids are the compartment in which the precursors and some of the end products of lipid biosynthesis
are synthesized. Suitable promoters, such as the viral RNA polymerase promoter, are described in WO 95/16783 and
WO 97/06250, and the clpP promoter from Arabidopsis, described in WO 99/46394.
[0062] The abovementioned vectors are only a small overview of possible vectors which are suitable. Further plasmids
are known to the skilled worker and are described for example in: Cloning Vectors (eds. Pouwels, P.H., et al., Elsevier,
Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018). Further suitable expression systems for prokaryotic and
eukaryotic cells, see chapters 16 and 17 of Sambrook, J., Fritsch, E.F., and Maniatis, T., Molecular Cloning: A Laboratory
Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
[0063] As described above, the expression vector can, in addition to the polynucleotides according to the invention,
also comprise further genes which are to be introduced into the organisms. It is possible and preferred to introduce into
the host organisms, and express in them, regulatory genes, such as genes for inductors, repressors or enzymes which,
as a result of their enzymatic activity, engage in the regulation of one or more genes of a biosynthetic pathway. These
genes can be of heterologous or homologous origin. Heterologous genes or polynucleotides are derived from an organism
of origin which differs from the target organism into which the genes or polynucleotides are to be introduced. In the case
of homologous genes or polynucleotides, target organism and organism of origin are identical. The vector therefore
preferably comprises at least one further polynucleotide which codes for a further enzyme which is involved in the
biosynthesis of lipids or fatty acids. The enzyme is preferably selected from the group consisting of: acyl-CoA dehydro-
genase(s), acyl-ACP [= acyl carrier protein] desaturase(s), acyl-ACP thioesterase(s), fatty acid acyltransferase(s), acyl-
CoA:lysophospholipid acyltransferase(s), fatty acid synthase(s), fatty acid hydroxylase(s), acetyl-coenzyme A carbox-
ylase(s), acyl-coenzyme A oxidase(s), fatty acid desaturase(s), fatty acid acetylenase(s), lipoxygenase(s), triacylglycerol
lipase(s), allene oxide synthase(s), hydroperoxide lyase(s), fatty acid elongase(s), Δ4-desaturase(s), Δ5-desaturase(s),
EP 2 376 638 B1
14
5
10
15
20
25
30
35
40
45
50
55
Δ6-desaturase(s), Δ8-desaturase(s), Δ9-desaturase(s), Δ12-desaturase(s), Δ15-desaturase(s), Δ12- and Δ15-desatu-
rase(s), ω3-desaturase, Δ5-elongase(s), Δ6-elongase(s) and Δ9-elongase(s).
Especially preferred gene combinations are listed in tables 5 and 6 in the examples which follow.
[0064] The invention also relates to a host cell which comprises the polynucleotide according to the invention or the
vector according to the invention.
[0065] In principle, host cells for the purposes of the present invention may be all eukaryotic or prokaryotic cells. They
may be primary cells from animals, plants or multi-celled microorganisms, for example from those which are mentioned
in another place in the description. The term furthermore also comprises cell lines which can be obtained from these
organisms.
[0066] However, host cells for the purposes of the invention may also be single-celled microorganisms, for example
bacteria or fungi. Especially preferred microorganisms are fungi selected from the group of the families Chaetomiaceae,
Choanephoraceae, Cryptococcaceae, Cunninghamellaceae, Demetiaceae, Hydnangiaceae (genus Laccaria), Monil-
iaceae, Mortierellaceae, Mucoraceae, Pythiaceae, Sacharomycetaceae, Saprolegniaceae, Schizosacharomycetaceae,
Sodariaceae or Tuberculariaceae. Further preferred microorganisms are selected from the group: Choanephoraceae,
such as the genera Blakeslea, Choanephora, for example the genera and species Blakeslea trispora, Choanephora
cucurbitarum, Choanephora infundibulifera var. cucurbitarum, Hydnangiaceae (for example genus Laccaria, in particular
species Laccaria bicolor), Mortierellaceae, such as the genus Mortierella, for example the genera and species Mortierella
isabellina, Mortierella polycephala, Mortierella ramanniana, Mortierella vinacea, Mortierella zonata, the family Mucorales,
such as the genera and species Rhizopus oryzae, Rhizopus stolonifer, Fusarium graminearium, Pythiaceae, such as
the genera Phytium, Phytophthora, for example the genera and species Pythium debaryanum, Pythium intermedium,
Pythium irregulare, Pythium megalacanthum, Pythium paroecandrum, Pythium sylvaticum, Pythium ultimum, Phytoph-
thora cactorum, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora, Phytophthora cryptogea,
Phytophthora drechsleri, Phytophthora erythroseptica, Phytophthora lateralis, Phytophthora megasperma, Phytophthora
nicotianae, Phytophthora nicotianae var. parasitica, Phytophthora palmivora, Phytophthora parasitica, Phytophthora
syringae, Saccharomycetaceae, such as the genera Hansenula, Pichia, Saccharomyces, Saccharomycodes, Yarrowia,
for example the genera and species Hansenula anomala, Hansenula californica, Hansenula canadensis, Hansenula
capsulata, Hansenula ciferrii, Hansenula glucozyma, Hansenula henricii, Hansenula holstii, Hansenula minuta, Hansenu-
la nonfermentans, Hansenula philodendri, Hansenula polymorpha, Hansonula saturnus, Hansenula subpelliculosa,
Hansenula wickerhamii, Hansenula wingei, Pichia alcoholophila, Pichia angusta, Pichia anomala, Pichia bispora, Pichia
burtonii, Pichia canadensis, Pichia capsulata, Pichia carsonii, Pichia cellobiosa, Pichia ciferrii, Pichia farinosa, Pichia
fermentans, Pichia finlandica, Pichia glucozyma, Pichia guilliermondii, Pichia haplophila, Pichia henricii, Pichia holstii,
Pichia jadinii, Pichia lindnerii, Pichia membranaefaciens, Pichia methanolica, Pichia minuta var. minuta, Pichia minuta
var. nonfermentans, Pichia norvegensis, Pichia ohmeri, Pichia pastoris, Pichia philodendri, Pichia pini, Pichia polymor-
pha, Pichia quercuum, Pichia rhodanensis, Pichia sargentensis, Pichia stipitis, Pichia strasburgensis, Pichia subpellic-
ulosa, Pichia toletana, Pichia trehalophila, Pichia vini, Pichia xylosa, Saccharomyces aceti, Saccharomyces bailii, Sac-
charomyces bayanus, Saccharomyces bisporus, Saccharomyces capensis, Saccharomyces carlsbergensis, Saccha-
romyces cerevisiae, Saccharomyces cerevisiae var. ellipsoideus, Saccharomyces chevalieri, Saccharomyces delbrueck-
ii, Saccharomyces diastaticus, Saccharomyces drosophilarum, Saccharomyces elegans, Saccharomyces ellipsoideus,
Saccharomyces fermentati, Saccharomyces florentinus, Saccharomyces fragilis, Saccharomyces heterogenicus, Sac-
charomyces hienipiensis, Saccharomyces inusitatus, Saccharomyces italicus, Saccharomyces kluyveri, Saccharomyces
krusei, Saccharomyces lactis, Saccharomyces marxianus, Saccharomyces microellipsoides, Saccharomyces montanus,
Saccharomyces norbensis, Saccharomyces oleaceus, Saccharomyces paradoxus, Saccharomyces pastorianus, Sac-
charomyces pretoriensis, Saccharomyces rosei, Saccharomyces rouxii, Saccharomyces uvarum, Saccharomycodes
ludwigii, Yarrowia lipolytica, Schizosaccharomycetaceae such as the genera Schizosaccharomyces e.g. the species
Schizosaccharomyces japonicus var. japonicus, Schizosaccharomyces japonicus var. versatilis, Schizosaccharomyces
malidevorans, Schizosaccharomyces octosporus, Schizosaccharomyces pombe var. malidevorans, Schizosaccharo-
myces pombe var. pombe, Thraustochytriaceae such as the genera Althornia, Aplanochytrium, Japonochytrium,
Schizochytrium, Thraustochytrium e.g. the species Schizochytrium aggregatum, Schizochytrium limacinum, Schizo-
chytrium mangrovei, Schizochytrium minutum, Schizochytrium octosporum, Thraustochytrium aggregatum, Thrausto-
chytrium amoeboideum, Thraustochytrium antacticum, Thraustochytrium arudimentale, Thraustochytrium aureum,
Thraustochytrium benthicola, Thraustochytrium globosum, Thraustochytrium indicum, Thraustochytrium kerguelense,
Thraustochytrium kinnei, Thraustochytrium motivum, Thraustochytrium multirudimentale, Thraustochytrium pachyder-
mum, Thraustochytrium proliferum, Thraustochytrium roseum, Thraustochytrium rossii, Thraustochytrium striatum or
Thraustochytrium visurgense.
[0067] Equally preferred as microorganisms are bacteria selected from the group of the families Bacillaceae, Entero-
bacteriacae or Rhizobiaceae. It is especially preferred to mention the following bacteria selected from the group: Bacil-
laceae, such as the genus Bacillus, for example the genera and species Bacillus acidocaldarius, Bacillus acidoterrestris,
Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus amylolyticus, Bacillus brevis, Bacillus cereus, Bacillus circu-
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lans, Bacillus coagulans, Bacillus sphaericus subsp. fusiformis, Bacillus galactophilus, Bacillus globisporus, Bacillus
globisporus subsp. marinus, Bacillus halophilus, Bacillus lentimorbus, Bacillus lentus, Bacillus licheniformis, Bacillus
megaterium, Bacillus polymyxa, Bacillus psychrosaccharolyticus, Bacillus pumilus, Bacillus sphaericus, Bacillus subtilis
subsp. spizizenii, Bacillus subtilis subsp. subtilis or Bacillus thuringiensis; Enterobacteriacae such as the genera Citro-
bacter, Edwardsiella, Enterobacter, Erwinia, Escherichia, Klebsiella, Salmonella or Serratia, for example the genera and
species Citrobacter amalonaticus, Citrobacter diversus, Citrobacter freundii, Citrobacter genomospecies, Citrobacter
gillenii, Citrobacter intermedium, Citrobacter koseri, Citrobacter murliniae, Citrobacter sp., Edwardsiella hoshinae, Ed-
wardsiella ictaluri, Edwardsiella tarda, Erwinia alni, Erwinia amylovora, Erwinia ananatis, Erwinia aphidicola, Erwinia
billingiae, Erwinia cacticida, Erwinia cancerogena, Erwinia carnegieana, Erwinia carotovora subsp. atroseptica, Erwinia
carotovora subsp. betavasculorum, Erwinia carotovora subsp. odorifera, Erwinia carotovora subsp. wasabiae, Erwinia
chrysanthemi, Erwinia cypripedii, Erwinia dissolvens, Erwinia herbicola, Erwinia mallotivora, Erwinia milletiae, Erwinia
nigrifluens, Erwinia nimipressuralis, Erwinia persicina, Erwinia psidii, Erwinia pyrifoliae, Erwinia quercina, Erwinia rhapon-
tici, Erwinia rubrifaciens, Erwinia salicis, Erwinia stewartii, Erwinia tracheiphila, Erwinia uredovora, Escherichia adecar-
boxylata, Escherichia anindolica, Escherichia aurescens, Escherichia blattae, Escherichia coli, Escherichia coli var.
communior, Escherichia coli-mutabile, Escherichia fergusonii, Escherichia hermannii, Escherichia sp., Escherichia vul-
neris, Klebsiella aerogenes, Klebsiella edwardsii subsp. atlantae, Klebsiella ornithinolytica, Klebsiella oxytoca, Klebsiella
planticola, Klebsiella pneumoniae, Klebsiella pneumoniae subsp. pneumoniae, Klebsiella sp., Klebsiella terrigena, Kleb-
siella trevisanii, Salmonella abony, Salmonella arizonae, Salmonella bongori, Salmonella choleraesuis subsp. arizonae,
Salmonella choleraesuis subsp. bongori, Salmonella choleraesuis subsp. cholereasuis, Salmonella choleraesuis subsp.
diarizonae, Salmonella choleraesuis subsp. houtenae, Salmonella choleraesuis subsp. indica, Salmonella choleraesuis
subsp. salamae, Salmonella daressalaam, Salmonella enterica subsp. houtenae, Salmonella enterica subsp. salamae,
Salmonella enteritidis, Salmonella gallinarum, Salmonella heidelberg, Salmonella panama, Salmonella senftenberg,
Salmonella typhimurium, Serratia entomophila, Serratia ficaria, Serratia fonticola, Serratia grimesii, Serratia liquefaciens,
Serratia marcescens, Serratia marcescens subsp. marcescens, Serratia marinorubra, Serratia odorifera, Serratia ply-
mouthensis, Serratia plymuthica, Serratia proteamaculans, Serratia proteamaculans subsp. quinovora, Serratia quini-
vorans or Serratia rubidaea; Rhizobiaceae, such as the genera Agrobacterium, Carbophilus, Chelatobacter, Ensifer,
Rhizobium, Sinorhizobium, for example the genera and species Agrobacterium atlanticum, Agrobacterium ferrugineum,
Agrobacterium gelatinovorum, Agrobacterium larrymoorei, Agrobacterium meteori, Agrobacterium radiobacter, Agro-
bacterium rhizogenes, Agrobacterium rubi, Agrobacterium stellulatum, Agrobacterium tumefaciens, Agrobacterium vitis,
Carbophilus carboxidus, Chelatobacter heintzii, Ensifer adhaerens, Ensifer arboris, Ensifer fredii, Ensifer kostiensis,
Ensifer kummerowiae, Ensifer medicae, Ensifer meliloti, Ensifer saheli, Ensifer terangae, Ensifer xinjiangensis, Rhizo-
bium ciceri, Rhizobium etli, Rhizobium fredii, Rhizobium galegae, Rhizobium gallicum, Rhizobium giardinii, Rhizobium
hainanense, Rhizobium huakuii, Rhizobium huautlense, Rhizobium indigoferae, Rhizobium japonicum, Rhizobium le-
guminosarum, Rhizobium loessense, Rhizobium loti, Rhizobium lupini, Rhizobium mediterraneum, Rhizobium meliloti,
Rhizobium mongolense, Rhizobium phaseoli, Rhizobium radiobacter, Rhizobium rhizogenes, Rhizobium rubi, Rhizobium
sullae, Rhizobium tianshanense, Rhizobium trifolii, Rhizobium tropici, Rhizobium undicola, Rhizobium vitis, Sinorhizo-
bium adhaerens, Sinorhizobium arboris, Sinorhizobium fredii, Sinorhizobium kostiense, Sinorhizobium kummerowiae,
Sinorhizobium medicae, Sinorhizobium meliloti, Sinorhizobium morelense, Sinorhizobium saheli or Sinorhizobium xin-
jiangense.
[0068] Further utilizable host cells are detailed in: Goeddel, Gene Expression Technology: Methods in Enzymology
185, Academic Press, San Diego, CA (1990). Expression strains which can be used, for example those with a lower
protease activity, are described in: Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic
Press, San Diego, California (1990) 119-128. These include plant cells and certain tissues, organs and parts of plants
in all their phenotypic forms such as anthers, fibers, root hairs, stalks, embryos, calli, cotelydons, petioles, harvested
material, plant tissue, reproductive tissue and cell cultures which are derived from the actual transgenic plant and/or can
be used for bringing about the transgenic plant.
[0069] Polynucleotides or vectors can be introduced into the host cell as described above by means of transformation
or transfection methods which are known in the prior art. Conditions and media for the cultivation of the host cells are
also known to the skilled worker.
[0070] The host cell according to the invention preferably additionally comprises at least one further enzyme which is
involved in the biosynthesis of lipids or fatty acids. Preferred enzymes have already been mentioned in another place
in the description. The enzyme can be present in the host cell in endogenous form, i.e. the host cell already naturally
expresses a gene which codes for a corresponding enzyme. Alternatively, it is also possible to introduce, into the host
cell, a heterologous polynucleotide which codes for the enzyme. Suitable methods and means for the expression of a
heterologous polynucleotide are known in the prior art and are described herein in connection with the polynucleotides,
vectors and host cells according to the invention.
[0071] The invention also relates to a method of generating a polypeptide with desaturase activity, comprising the steps:
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(a) expressing a polynucleotide according to the invention as defined above in a host cell; and
(b) obtaining, from the host cell, the polypeptide which is encoded by the polynucleotide in (a).
[0072] In this context, the polypeptide can be obtained or isolated by all current protein purification methods. The
methods comprise, for example, affinity chromatography, molecular sieve chromatography, high-pressure liquid chro-
matography or else protein precipitation, if appropriate with specific antibodies. Although this is preferred, the process
need not necessarily provide a pure polypeptide preparation.
[0073] The invention therefore also relates to a polypeptide which is encoded by the polynucleotide according to the
invention or which is obtainable by the abovementioned method according to the invention.
[0074] The term "polypeptide" refers both to an essentially pure polypeptide, and also to a polypeptide preparation
which additionally comprises further components or impurities. The term is also used for fusion proteins and protein
aggregates which comprise the polypeptide according to the invention and additionally further components. The term
also refers to chemically modified polypeptides. In this context, chemical modifications comprise artificial modifications
or naturally occurring modifications, for example posttranslational modifications such as phosphorylation, myristylation,
glycosylation and the like. The terms polypeptide, peptide and protein are interchangeable and are used accordingly in
the description and in the prior art. The polypeptides according to the invention have the abovementioned biological
activities, that is to say desaturase activities, and can influence the biosynthesis of polyunsaturated fatty acids (PUFAs),
preferably the long-chain PUFAs (LCPUFAs), as herein described.
[0075] The invention also comprises an antibody which specifically recognizes the polypeptide according to the in-
vention.
[0076] Antibodies against the polypeptide according to the invention can be prepared by means of known methods,
where purified polypeptide or fragments thereof with suitable epitopes are used as the antigen. Suitable epitopes can
be determined by means of known algorithms for the antigenicity determination, based on the amino acid sequences of
the polypeptides according to the invention provided herein. The relevant polypeptides or fragments can then be syn-
thesized or obtained by recombinant techniques. After suitable animals, preferably mammals, for example hares, rats
or mice, have been immunized, the antibodies can then be obtained from the serum, using known methods. Alternatively,
monoclonal antibodies or antibody fragments can be provided with the known methods; see, for example, Harlow and
Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988 or Köhler and Milstein, Nature 256
(1975), 495, and Galfré, Meth. Enzymol. 73 (1981), 3.
[0077] The antibodies preferably take the form of monoclonal or polyclonal antibodies, single-chain antibodies or
chimeric antibodies, and fragments of these such as Fab, Fv or scFv. Further antibodies within the meaning of the
invention are bispecific antibodies, synthetic antibodies or their chemically modified derivatives.
[0078] The antibodies according to the invention specifically recognize the polypeptides according to the invention,
that is to say they do not cross-react significantly with other proteins. For example, an antibody according to the invention
which specifically binds a Δ12-desaturase will not react with a Δ6-desaturase. This can be assayed by means of methods
known in the prior art. For example, the antibodies can be employed for the purposes of detection reactions, immuno-
precipitation, immunhistochemistry or protein purification (for example affinity chromatography).
[0079] The invention furthermore relates to a transgenic, nonhuman organism which comprises the polynucleotide,
the vector or the host cell of the present invention. The transgenic, nonhuman organism preferably takes the form of an
animal, a plant or a multicellular microorganism.
[0080] The term "transgenic" is understood as meaning that a heterologous polynucleotide, that is to say a polynucle-
otide which does not occur naturally in the respective organism, is introduced into the organism. This can be achieved
either by random insertion of the polynucleotide or by homologous recombination. Naturally, it is also possible to introduce
the vector according to the invention instead of the polynucleotide. Methods of introducing polynucleotides or vectors
for the purposes of random insertion or homologous recombination are known in the prior art and also described in
greater detail hereinbelow. Host cells which comprise the polynucleotide or the vector can also be introduced into an
organism and thus generate a transgenic organism. In such a case, such an organism takes the form of a chimeric
organism, where only those cells which are derived from the introduced cells are transgenic, i.e. comprise the heterologous
polynucleotide.
[0081] The transgenic nonhuman organisms are preferably oil-producing organisms, which means organisms which
are used for the production of oils, for example fungi such as Rhizopus or Thraustochytrium, algae such as Euglena,
Nephroselmis, Pseudoscourfielda, Prasinococcus, Scherffelia, Tetraselmis, Mantoniella, Ostreococcus, Crypthecodin-
ium, Phaeodactylum, or diatoms such as Pythium or Phytophthora or plants.
[0082] Transgenic plants which can be used are, in principle, all plants, that is to say both dicotyledonous and mono-
cotyledonous plants. They preferably take the form of oil crop plants which comprise large amounts of lipid compounds,
such as peanut, oilseed rape, canola, sunflower, safflower (Carthamus tinctoria), poppy, mustard, hemp, castor-oil plant,
olive, sesame, Calendula, Punica, evening primrose, verbascum, thistle, wild roses, hazelnut, almond, macadamia,
avocado, bay, pumpkin/squash, linseed, soybean, pistachios, borage, trees (oil palm, coconut or walnut) or arable crops
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such as maize, wheat, rye, oats, triticale, rice, barley, cotton, cassava, pepper, Tagetes, Solanaceae plants such as
potato, tobacco, eggplant and tomato, Vicia species, pea, alfalfa or bushy plants (coffee, cacao, tea), Salix species, and
perennial grasses and fodder crops. Preferred plants according to the invention are oil crop plants such as peanut,
oilseed rape, canola, sunflower, safflower, poppy, mustard, hemp, castor-oil plant, olive, Calendula, Punica, evening
primrose, pumpkin/squash, linseed, soybean, borage, trees (oil palm, coconut). Especially preferred are plants which
are high in C18:2- and/or C18:3-fatty acids, such as sunflower, tobacco, verbascum, sesame, cotton, pumpkin/squash,
poppy, evening primrose, walnut, linseed, hemp, thistle or safflower. Very especially preferred plants are plants such
as safflower, sunflower, poppy, evening primrose, walnut, linseed or hemp. In principle, however, all plants which are
capable of synthesizing fatty acids are suitable, such as all dicotyledonous or monocotyledonous plants, algae or mosses.
Advantageous plants are selected from the group of the plant families Adelotheciaceae, Anacardiaceae, Asteraceae,
Apiaceae, Betulaceae, Boraginaceae, Brassicaceae, Bromeliaceae, Caricaceae, Cannabaceae, Convolvulaceae,
Chenopodiaceae, Crypthecodiniaceae, Cucurbitaceae, Ditrichaceae, Elaeagnaceae, Ericaceae, Euphorbiaceae, Fa-
baceae, Geraniaceae, Gramineae, Juglandaceae, Lauraceae, Leguminosae, Linaceae, Prasinophyceae or vegetable
plants or ornamentals such as Tagetes.
[0083] Examples which may especially preferably be mentioned are the following plants selected from the group
consisting of: Adelotheciaceae such as the genera Physcomitrella, for example the genus and species Physcomitrella
patens, Anacardiaceae such as the genera Pistacia, Mangifera, Anacardium, for example the genus and species Pistacia
vera [pistachio], Mangifer indica [mango] or Anacardium occidentale [cashew], Asteraceae, such as the genera Calen-
dula, Carthamus, Centaurea, Cichorium, Cynara, Helianthus, Lactuca, Locusta, Tagetes, Valeriana, for example the
genus and species Calendula officinalis [common marigold], Carthamus tinctorius [safflower], Centaurea cyanus [corn-
flower], Cichorium intybus [chicory], Cynara scolymus [artichoke], Helianthus annus [sunflower], Lactuca sativa, Lactuca
crispa, Lactuca esculenta, Lactuca scariola L. ssp. sativa, Lactuca scariola L. var. integrata, Lactuca scariola L. var.
integrifolia, Lactuca sativa subsp. romana, Locusta communis, Valeriana locusta [salad vegetables], Tagetes lucida,
Tagetes erecta or Tagetes tenuifolia [African or French marigold], Apiaceae, such as the genus Daucus, for example
the genus and species Daucus carota [carrot], Betulaceae, such as the genus Corylus, for example the genera and
species Corylus avellana or Corylus columa [hazelnut], Boraginaceae, such as the genus Borago, for example the genus
and species Borago officinalis [borage], Brassicaceae, such as the genera Brassica, Camelina, Melanosinapis, Sinapis,
Arabadopsis, for example the genera and species Brassica napus, Brassica rapa ssp. [oilseed rape], Sinapis arvensis
Brassica juncea, Brassica juncea var. juncea, Brassica juncea var. crispifolia, Brassica juncea var. foliosa, Brassica
nigra, Brassica sinapioides, Camelina sativa, Melanosinapis communis [mustard], Brassica oleracea [fodder beet] or
Arabadopsis thaliana, Bromeliaceae, such as the genera Ananas, Bromelia (pineapple), for example the genera and
species Ananas comosus, Ananas ananas or Bromelia comosa [pineapple], Caricaceae, such as the genus Carica,
such as the genus and species Carica papaya [pawpaw], Cannabaceae, such as the genus Cannabis, such as the
genus and species Cannabis sative [hemp], Convolvulaceae, such as the genera Ipomea, Convolvulus, for example the
genera and species Ipomoea batatus, Ipomoea pandurata, Convolvulus batatas, Convolvulus tiliaceus, Ipomoea fas-
tigiata, Ipomoea tiliacea, Ipomoea triloba or Convolvulus panduratus [sweet potato, batate], Chenopodiaceae, such as
the genus Beta, such as the genera and species Beta vulgaris, Beta vulgaris var. altissima, Beta vulgaris var. vulgaris,
Beta maritima, Beta vulgaris var. perennis, Beta vulgaris var. conditiva or Beta vulgaris var. esculenta [sugarbeet],
Crypthecodiniaceae, such as the genus Crypthecodinium, for example the genus and species Cryptecodinium cohnii,
Cucurbitaceae, such as the genus Cucurbita, for example the genera and species Cucurbita maxima, Cucurbita mixta,
Cucurbita pepo or Cucurbifa moschata [pumpkin/squash], Cymbellaceae, such as the genera Amphora, Cymbella,
Okedenia, Phaeodactylum, Reimeria, for example the genus and species Phaeodactylum tricornutum, Ditrichaceae,
such as the genera Ditrichaceae, Astomiopsis, Ceratodon, Chrysoblastella, Ditrichum, Distichium, Eccremidium, Lo-
phidion, Philibertiella, Pleuridium, Saelania, Trichodon, Skottsbergia, for example the genera and species Ceratodon
antarcticus, Ceratodon columbiae, Ceratodon heterophyllus, Ceratodon purpurascens, Ceratodon purpureus, Ceratodon
purpureus ssp. convolutus, Ceratodon purpureus ssp. stenocarpus, Ceratodon purpureus var. rotundifolius, Ceratodon
ratodon, Ceratodon stenocarpus, Chrysoblastella chilensis, Ditrichum ambiguum, Ditrichum brevisetum, Ditrichum
crispatissimum, Ditrichum difficile, Ditrichum falcifolium, Ditrichum flexicaule, Ditrichum giganteum, Ditrichum hetero-
mallum, Ditrichum lineare, Ditrichum montanum, Ditrichum pallidum, Ditrichum punctulatum, Ditrichum pusillum, Ditri-
chum pusillum var. tortile, Ditrichum rhynchostegium, Ditrichum schimperi, Ditrichum tortile, Distichium capillaceum,
Distichium hagenii, Distichium inclinatum, Distichium macounii, Eccremidium floridanum, Eccremidium whiteleggei, Lo-
phidion strictus, Pleuridium acuminatum, Pleuridium altemifolium, Pleuridium holdridgei, Pleuridium mexicanum, Pleu-
ridium ravenelii, Pleuridium subulatum, Saelania glaucescens, Trichodon borealis, Trichodon cylindricus or Trichodon
cylindricus var. oblongus, Elaeagnaceae, such as the genus Elaeagnus, for example the genus and species Olea
europaea [olive], Ericaceae, such as the genus Kalmia, for example the genera and species Kalmia latifolia, Kalmia
angustifolia, Kalmia microphylla, Kalmia polifolia, Kalmia occidentalis, Cistus chamaerhodendros or Kalmia lucida [moun-
tain laurel], Euphorbiaceae, such as the genera Manihot, Janipha, Jatropha, Ricinus, for example the genera and species
Manihot utilissima, Janipha manihot, Jatropha manihot, Manihot aipil, Manihot .dulcis, Manihot manihot, Manihot melano-
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basis, Manihot esculenta [cassava] or Ricinus communis [castor-oil plant], Fabaceae, such as the genera Pisum, Albizia,
Cathormion, Feuillea, Inga, Pithecolobium, Acacia, Mimosa, Medicago, Glycine, Dolichos, Phaseolus, soybean, for
example the genera and species Pisum sativum, Pisum arvense, Pisum humile [pea], Albizia berteriana, Albizia julibrissin,
Albizia lebbeck, Acacia berteriana, Acacia littoralis, Albizia berteriana, Albizzia berteriana, Cathormion berteriana, Feuil-
lea berteriana, Inga fragrans, Pithecellobium berterianum, Pithecellobium fragrans, Pithecolobium berterianum, Pseu-
dalbizzia berteriana, Acacia julibrissin, Acacia nemu, Albizia nemu, Feuilleea julibrissin, Mimosa julibrissin, Mimosa
speciosa, Sericandra julibrissin, Acacia lebbeck, Acacia macrophylla, Albizia lebbeck, Feuilleea lebbeck, Mimosa leb-
beck, Mimosa speciosa [silk tree], Medicago sativa, Medicago falcata, Medicago varia [alfalfa] Glycine max Dolichos
soja, Glycine gracilis, Glycine hispida, Phaseolus max, Soja hispida or Soja max [soybean], Funariaceae, such as the
genera Aphanorrhegma, Entosthodon, Funaria, Physcomitrella, Physcomitrium, for example the genera and species
Aphanorrhegma serratum, Entosthodon attenuatus, Entosthodon bolanderi, Entosthodon bonplandii, Entosthodon cal-
ifornicus, Entosthodon drummondii, Entosthodon jamesonii, Entosthodon leibergii; Entosthodon neoscoticus, Entostho-
don rubrisetus, Entosthodon spathulifolius, Entosthodon tucsoni, Funaria americana, Funaria bolanderi, Funaria calca-
rea, Funaria californica, Funaria calvescens, Funaria convoluta, Funaria flavicans, Funaria groutiana, Funaria hygro-
metrica, Funaria hygrometrica var. arctica, Funaria hygrometrica var. calvescens, Funaria hygrometrica var. convoluta,
Funaria hygrometrica var. muralis, Funaria hygrometrica var. utahensis, Funaria microstoma, Funaria microstoma var.
obtusifolia, Funaria muhlenbergii, Funaria orcuttii, Funaria plano-convexa, Funaria polaris, Funaria ravenelii, Funaria
rubriseta, Funaria serrata, Funaria sonorae, Funaria sublimbatus, Funaria tucsoni, Physcomitrella californica, Phys-
comitrella patens, Physcomitrella readeri, Physcomitrium australe, Physcomitrium californicum, Physcomitrium collen-
chymatum, Physcomitrium coloradense, Physcomitrium cupuliferum, Physcomitrium drummondii, Physcomitrium eurys-
tomum, Physcomitrium flexifolium, Physcomitrium hookeri, Physcomitrium hookeri var. serratum, Physcomitrium immer-
sum, Physcomitrium kellermanii, Physcomitrium megalocarpum, Physcomitrium pyriforme, Physcomitrium pyriforme var
serratum, Physcomitrium rufipes, Physcomitrium sandbergii, Physcomitrium subsphaericum, Physcomitrium washing-
toniense, Geraniaceae, such as the genera Pelargonium, Cocos, Oleum, for example the genera and species Cocos
nucifera, Pelargonium grossularioides or Oleum cocois [coconut], Gramineae, such as the genus Saccharum, for example
the genus and species Saccharum officinarum, Juglandaceae, such as the genera Juglans, Wallia, for example the
genera and species Juglans regia, Juglans ailanthifolia, Juglans sieboldiana, Juglans cinerea, Wallia cinerea, Juglans
bixbyi, Juglans californica, Juglans hindsii, Juglans intermedia, Juglans jamaicensis, Juglans major, Juglans microcarpa,
Juglans nigra or Wallia nigra [walnut], Lauraceae, such as the genera Persea, Laurus, for example the genera and
species Laurus nobilis [bay], Persea americana, Persea gratissima or Persea persea [avocado], Leguminosae, such as
the genus Arachis, for example the genus and species Arachis hypogaea [peanut], Linaceae, such as the genera Linum,
Adenolinum, for example the genera and species Linum usitatissimum, Linum humile, Linum austriacum, Linum bienne,
Linum angustifolium, Linum catharticum, Linum flavum, Linum grandiflorum, Adenolinum grandiflorum, Linum lewisii,
Linum narbonense, Linum perenne, Linum perenne var. lewisii, Linum pratense or Linum trigynum [linseed], Lythrarieae,
such as the genus Punica, for example the genus and species Punica granatum [pomegranate], Malvaceae, such as
the genus Gossypium, for example the genera and species Gossypium hirsutum, Gossypium arboreum, Gossypium
barbadense, Gossypium herbaceum or Gossypium thurberi [cotton], Marchantiaceae, such as the genus Marchantia,
for example the genera and species Marchantia berteroana, Marchantia foliacea, Marchantia macropora, Musaceae,
such as the genus Musa, for example the genera and species Musa nana, Musa acuminata, Musa paradisiaca, Musa
spp. [banana], Onagraceae, such as the genera Camissonia, Oenothera, for example the genera and species Oenothera
biennis or Camissonia brevipes [evening primrose], Palmae, such as the genus Elacis, for example the genus and
species Elaeis guineensis [oil palm], Papaveraceae, such as the genus Papaver, for example the genera and species
Papaver orientale, Papaver rhoeas, Papaver dubium [poppy], Pedaliaceae, such as the genus Sesamum, for example
the genus and species Sesamum indicum [sesame], Piperaceae, such as the genera Piper, Artanthe, Peperomia,
Steffensia, for example the genera and species Piper aduncum, Piper amalago, Piper angustifolium, Piper auritum,
Piper betel, Piper cubeba, Piper longum, Piper nigrum, Piper retrofractum, Artanthe adunca, Artanthe elongata, Peper-
omia elongata, Piper elongatum, Steffensia elongata [cayenne pepper], Poaceae, such as the genera Hordeum, Secale,
Avena, Sorghum, Andropogon, Holcus, Panicum, Oryza, Zea (maize), Triticum, for example the genera and species
Hordeum vulgare, Hordeum jubatum, Hordeum murinum, Hordeum secalinum, Hordeum distichon, Hordeum aegiceras,
Hordeum hexastichon, Hordeum hexastichum, Hordeum irregulare, Hordeum sativum, Hordeum secalinum [barley],
Secale cereale [rye], Avena sativa, Avena fatua, Avena byzantina, Avena fatua var. sativa, Avena hybrida [oats], Sorghum
bicolor, Sorghum halepense, Sorghum saccharatum, Sorghum vulgare, Andropogon drummondii, Holcus bicolor, Holcus
sorghum, Sorghum aethiopicum, Sorghum arundinaceum, Sorghum caffrorum, Sorghum cernuum, Sorghum dochna,
Sorghum drummondii, Sorghum durra, Sorghum guineense, Sorghum lanceolatum, Sorghum nervosum, Sorghum sac-
charatum, Sorghum subglabrescens, Sorghum verticilliflorum, Sorghum vulgare, Holcus halepensis, Sorghum mil-
iaceum, Panicum militaceum [millet], Oryza sativa, Oryza latifolia [rice], Zea mays [maize] Triticum aestivum, Triticum
durum, Triticum turgidum, Triticum hybernum, Triticum macha, Triticum sativum or Triticum vulgare [wheat], Porphyrid-
iaceae, such as the genera Chroothece, Flintiella, Petrovanella, Porphyridium, Rhodella, Rhodosorus, Vanhoeffenia,
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for example the genus and species Porphyridium cruentum, Proteaceae, such as the genus Macadamia, for example
the genus and species Macadamia intergrifolia [macadamia], Prasinophyceae, such as the genera Nephroselmis, Pra-
sinococcus, Scherffelia, Tetraselmis, Mantoniella, Ostreococcus, for example the genera and species Nephroselmis
olivacea, Prasinococcus capsulatus, Scherffelia dubia, Tetraselmis chui, Tetraselmis suecica, Mantoniella squamata,
Ostreococcus tauri, Rubiaceae, such as the genus Coffea, for example the genera and species Coffea spp., Coffea
arabica, Coffea canephora or Coffea liberica [coffee], Scrophulariaceae, such as the genus Verbascum, for example
the genera and species Verbascum blattaria, Verbascum chaixii, Verbascum densiflorum, Verbascum lagurus, Verbas-
cum longifolium, Verbascum lychnitis, Verbascum nigrum, Verbascum olympicum, Verbascum phlomoides, Verbascum
phoenicum, Verbascum pulverulentum or Verbascum thapsus [verbascum], Solanaceae, such as the genera Capsicum,
Nicotiana, Solanum, Lycopersicon, for example the genera and species Capsicum annuum, Capsicum annuum var.
glabriusculum, Capsicum frutescens [pepper], Capsicum annuum [paprika], Nicotiana tabacum, Nicotiana alata, Nico-
tiana attenuata, Nicotiana glauca, Nicotiana langsdorffii, Nicotiana obtusifolia, Nicotiana quadrivalvis, Nicotiana repanda,
Nicotiana rustica, Nicotiana sylvestris [tobacco], Solanum tuberosum [potato], Solanum melongena [eggplant], Lycop-
ersicon esculentum, Lycopersicon lycopersicum, Lycopersicon pyriforme, Solanum integrifolium or Solanum lycopersi-
cum [tomato], Sterculiaceae, such as the genus Theobroma, for example the genus and species Theobroma cacao
[cacao] or Theaceae, such as the genus Camellia, for example the genus and species Camellia sinensis [tea].
[0084] Multicellular microorganisms which can be employed as transgenic nonhuman organisms are preferably protists
or diatoms selected from the group of the families Dinophyceae, Turaniellidae or Oxytrichidae, such as the genera and
species: Crypthecodinium cohnii, Phaeodactylum tricornutum, Stylonychia mytilus, Stylonychia pustulata, Stylonychia
putrina, Stylonychia notophora, Stylonychia sp., Colpidium campylum or Colpidium sp.
[0085] The invention further relates to a process for the production of a substance which has the structure shown in
the general formula I hereinbelow
wherein the variables and substituents are as follows:
R1 = hydroxyl, coenzyme A (thioester), lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylg-
lycerol, lysodiphosphatidylglycerol, lysophosphatidylserine, lysophosphatidylinositol, sphingo base or a radical
of the formula II
R2 = hydrogen, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol or a satu-
rated or unsaturated C2 to C24-alkylcarbonyl,
R3 = hydrogen, a saturated or unsaturated C2 to C24-alkylcarbonyl, or R2 and R3 independently of one another are
a radical of the formula la:
in which
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n = 2, 3, 4, 5, 6, 7 or 9, m = 2, 3, 4, 5 or 6 and p = 0 or 3;
and wherein the process comprises the cultivation of (i) a host cell according to the invention or (ii) of a transgenic,
nonhuman organism according to the invention under conditions which permit the biosynthesis of the substance. Pref-
erably, the abovementioned substance is provided in an amount of at least 1% by weight based on the total lipid content
in the host cell or the transgenic organism.
[0086] Preferred alkyl radicals R2 which may be mentioned are substituted or unsubstituted, saturated or unsaturated
C2-C24-alkylcarbonyl chains such as ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbo-
nyl, n-heptylcarbonyl, n-octylcarbonyl, n-nonylcarbonyl, n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tri-
decylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, n-octadecyl-
carbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n-docosanylcarbonyl or n-tetracosanylcarbonyl, which comprise one
or more double bonds. Saturated or unsaturated C10-C22-alkylcarbonyl radicals such as n-decylcarbonyl, n-undecylcar-
bonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-hep-
tadecylcarbonyl, n-octadecylcarbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n-docosanylcarbonyl or n-tetracosanyl-
carbonyl, which comprise one or more double bonds are preferred. Especially preferred are saturated and/or unsaturated
C10-C22-alkylcarbonyl radicals such as C10-alkylcarbonyl, C11-alkylcarbonyl, C12-alkylcarbonyl, C13-alkylcarbonyl,
C14-alkylcarbonyl, C16-alkylcarbonyl, C18-alkylcarbonyl, C20-alkylcarbonyl or C22-alkylcarbonyl radicals which comprise
one or more double bonds. Very especially preferred are saturated or unsaturated C16-C22-alkylcarbonyl radicals such
as C16-alkylcarbonyl, C18-alkylcarbonyl, C20-alkylcarbonyl or C22-alkylcarbonyl radicals which comprise one or more
double bonds. These preferred radicals can comprise two, three, four, five or six double bonds. The especially preferred
radicals with 20 or 22 carbon atoms in the fatty acid chain comprise up to six double bonds, preferably three, four, five
or six double bonds, especially preferably five or six double bonds. All the abovementioned radicals are derived from
the corresponding fatty acids.
[0087] Preferred alkyl radicals R3 which may be mentioned are substituted or unsubstituted, saturated or unsaturated
C2-C24-alkylcarbonyl chains such as ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbo-
nyl, n-heptylcarbonyl, n-octylcarbonyl, n-nonylcarbonyl, n-decylcarbonyl, n-undecylcarbonyl, n-dodecylcarbonyl, n-tri-
decylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-heptadecylcarbonyl, n-octadecyl-
carbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n-docosanylcarbonyl or n-tetracosanylcarbonyl, which comprise one
or more double bonds. Saturated or unsaturated C10-C22-alkylcarbonyl radicals such as n-decylcarbonyl, n-undecylcar-
bonyl, n-dodecylcarbonyl, n-tridecylcarbonyl, n-tetradecylcarbonyl, n-pentadecylcarbonyl, n-hexadecylcarbonyl, n-hep-
tadecylcarbonyl, n-octadecylcarbonyl, n-nonadecylcarbonyl, n-eicosylcarbonyl, n-docosanylcarbonyl or n-tetracosanyl-
carbonyl, which comprise one or more double bonds are preferred. Especially preferred are saturated and/or unsaturated
C10-C22-alkylcarbonyl radicals such as C10-alkylcarbonyl, C11-alkylcarbonyl, C12-alkylcarbonyl, C13-alkylcarbonyl,
C14-alkylcarbonyl, C16-alkylcarbonyl, C18-alkylcarbonyl, C20-alkylcarbonyl or C22-alkylcarbonyl radicals which comprise
one or more double bonds. Very especially preferred are saturated or unsaturated C16-C22-alkylcarbonyl radicals such
as C16-alkylcarbonyl, C18-alkylcarbonyl, C20-alkylcarbonyl or C22-alkylcarbonyl radicals which comprise one or more
double bonds. These preferred radicals can comprise two, three, four, five or six double bonds. The especially preferred
radicals with 20 or 22 carbon atoms in the fatty acid chain comprise up to six double bonds, preferably three, four, five
or six double bonds, especially preferably five or six double bonds. All the abovementioned radicals are derived from
the corresponding fatty acids.
[0088] The abovementioned radicals of R1, R2 and R3 can be substituted by hydroxyl and/or epoxy groups and/or can
comprise triple bonds.
[0089] The polyunsaturated fatty acids produced in the process according to the invention advantageously comprise
at least two, advantageously three, four, five or six, double bonds. The fatty acids especially advantageously comprise
four, five or six double bonds. Fatty acids produced in the process advantageously have 18, 20 or 22 C atoms in the
fatty acid chain; the fatty acids preferably comprise 20 or 22 carbon atoms in the fatty acid chain. Saturated fatty acids
are advantageously reacted to a minor degree, or not at all, with the nucleic acids used in the process. To a minor degree
is to be understood as meaning that the saturated fatty acids are reacted with less than 5% of the activity, advantageously
less than 3%, especially advantageously with less than 2%, very especially preferably with less than 1, 0.5, 0.25 or
0.125% in comparison with polyunsaturated fatty acids. These fatty acids which have been produced can be produced
in the process as a single product or be present in a fatty acid mixture.
[0090] The radicals R2 or R3 in the general formulae II may be indentical or non-identical, R2 and R3 preferably being
a saturated or unsaturated C18-C22-alkylcarbonyl, especially preferably an unsaturated C18-, C20- or C22-alkylcarbonyl
with at least two double bonds.
[0091] The polyunsaturated fatty acids produced in the process are advantageously bound in membrane lipids and/or
triacylglycerides, but may also occur in the organisms as free fatty acids or else bound in the form of other fatty acid
esters. In this context, they may be present as "pure products" or else advantageously in the form of mixtures of various
fatty acids or mixtures of different glycerides. The various fatty acids which are bound in the triacylglycerides can be
derived from short-chain fatty acids with 4 to 6 C atoms, medium-chain fatty acids with 8 to 12 C atoms or long-chain
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fatty acids with 14 to 24 C atoms; preferred are long-chain fatty acids, more preferably long-chain fatty acids LCPUFAs
of C18-.C20- and/or C22- fatty acids.
[0092] The process according to the invention advantageously yields fatty acid esters with polyunsaturated C18-, C20-
and/or C22-fatty acid molecules with at least two double bonds in the fatty acid ester, advantageously with at least three,
four, five or six double bonds in the fatty acid ester, especially advantageously with at least five or six double bonds in
the fatty acid ester and advantageously leads to the synthesis of linoleic acid (=LA, C18:2Δ9,12), γ-linolenic acid (= GLA,
C18:3Δ6,9,12), stearidonic acid (= SDA, C18:4Δ6,9,12,15), dihomo-γ-linolenic acid (= DGLA, 20:3 Δ8,11,14), ω3-eicosatetrae-
noic acid (= ETA, C20:4 Δ5,8,11,14), arachidonic acid (ARA, C20:4 Δ5,8,11,14), eicosapentaenoic acid (EPA, C20:
5Δ5,8,11,14,17), ω6-docosapentaenoic acid (C22:5Δ4,7,10,13,16), ω6-docosatetraenoic acid (C22:4Δ,7,10,13,16), ω3-docosap-
entaenoic acid (= DPA, C22:5Δ7,10,13,16,19), docosahexaenoic acid (= DHA, C22:6Δ4,7,10,13,16,19) or mixtures of these,
preferably ARA, EPA and/or DHA. ω3-Fatty acids such as EPA and/or DHA are very especially preferably produced.
[0093] The fatty acid esters with polyunsaturated C18-, C20- and/or C22-fatty acid molecules can be isolated in the
form of an oil or lipid, for example in the form of compounds such as sphingolipids, phosphoglycerides, lipids, glycolipids
such as glycosphingolipids, phospholipids such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine,
phosphatidylglycerol, phosphatidylinositol or diphosphatidylglycerol, monoacylglycerides, diacylglycerides, triacylglyc-
erides or other fatty acid esters such as the acyl-coenzyme A esters which comprise the polyunsaturated fatty acids
with at least two, three, four, five or six, preferably five or six double bonds, from the organisms which have been used
for the preparation of the fatty acid esters; advantageously, they are isolated in the form of their diacylglycerides, tria-
cylglycerides and/or in the form of phosphatidylcholine, especially preferably in the form of the triacylglycerides. In
addition to these esters, the polyunsaturated fatty acids are also present in the organisms, advantageously the plants,
as free fatty acids or bound in other compounds. As a rule, the various abovementioned compounds (fatty acid esters
and free fatty acids) are present in the organisms with an approximate distribution of 80 to 90% by weight of triglycerides,
2 to 5% by weight of diglycerides, 5 to 10% by weight of monoglycerides, 1 to 5% by weight of free fatty acids, 2 to 8%
by weight of phospholipids, the total of the various compounds amounting to 100% by weight.
[0094] The process according to the invention yields the LCPUFAs produced in a content of at least 3% by weight,
advantageously at least 5% by weight, preferably at least 8% by weight, especially preferably at least 10% by weight,
most preferably at least 15% by weight, based on the total fatty acids in the transgenic organisms, advantageously in a
transgenic plant. In this context, it is advantageous to convert C18- and/or C20-fatty acids which are present in the host
organisms to at least 10%, advantageously to at least 20%, especially advantageously to at least 30%, most advanta-
geously to at least 40% to give the corresponding products such as DPA or DHA, to mention just two examples. The
fatty acids are advantageously produced in bound form. These unsaturated fatty acids can, with the aid of the nucleic
acids used in the process according to the invention, be positioned at the sn1, sn2 and/or sn3 position of the advanta-
geously produced triglycerides. Since a plurality of reaction steps are performed by the starting compounds linoleic acid
(C18:2) and linolenic acid (C18:3) in the process according to the invention, the end products of the process such as,
for example, arachidonic acid (ARA), eicosapentaenoic acid (EPA), ω6-docosapentaenoic acid or DHA are not obtained
as absolutely pure products; minor traces of the precursors are always present in the end product. If, for example, both
linoleic acid and linolenic acid are present in the starting organism and the starting plant, the end products such as ARA,
EPA or DHA are present as mixtures. The precursors should advantageously not amount to more than 20% by weight,
preferably not to more than 15% by weight, especially preferably not to more than 10% by weight, most preferably not
to more than 5% by weight, based on the amount of the end product in question. Advantageously, only ARA, EPA or
only DHA, bound or as free acids, are produced as end products in a transgenic plant in the process according to the
invention. If the compounds ARA, EPA and DHA are produced simultaneously, they are advantageously produced in a
ratio of at least 3:2:1 (EPA:ARA:DHA).
[0095] Fatty acid esters or fatty acid mixtures produced by the process according to the invention advantageously
comprise 6 to 15% of palmitic acid, 1 to 6% of stearic acid, 7-85% of oleic acid, 0.5 to 8% of vaccenic acid, 0.1 to 1 %
of arachic acid, 7 to 25% of saturated fatty acids, 8 to 85% of monounsaturated fatty acids and 60 to 85% of polyunsaturated
fatty acids, in each case based on 100% and on the total fatty acid content of the organisms. Advantageous polyunsat-
urated fatty acid which is present in the fatty acid esters or fatty acid mixtures is preferably eicosapentaenoic acid.
Moreover, the fatty acid esters or fatty acid mixtures which have been produced by the process of the invention advan-
tageously comprise fatty acids selected from the group of the fatty acids erucic acid (13-docosaenoic acid), sterculic
acid (9,10-methyleneoctadec-9-enoic acid), malvalic acid (8,9-methyleneheptadec-8-enoic acid), chaulmoogric acid (cy-
clopentenedodecanoic acid), furan fatty acid (9,12-epoxyoctadeca-9,11-dienoic acid), vernolic acid (9,10-epoxyoctadec-
12-enoic acid), tarinic acid (6-octadecynoic acid), 6-nonadecynoic acid, santalbic acid (t11-octadecen-9-ynoic acid), 6,9-
octadecenynoic acid, pyrulic acid (t10-heptadecen-8-ynoic acid), crepenynic acid (9-octadecen-12-ynoic acid), 13,14-
dihydrooropheic acid, octadecen-13-ene-9,11-diynoic acid, petroselinic acid (cis-6-octadecenoic acid), 9c,12t-octadec-
adienoic acid, calendulic acid (8t10t12c-octadecatrienoic acid), catalpic acid (9t11t13c-octadecatrienoic acid), eleostearic
acid (9c11t13t-octadecatrienoic acid), jacaric acid (8c10t12c-octadecatrienoic acid), punicic acid (9c11t13c-octadeca-
trienoic acid), parinaric acid (9c11t13t15c-octadecatetraenoic acid), pinolenic acid (all-cis-5,9,12-octadecatrienoic acid),
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laballenic acid (5,6-octadecadienallenic acid), ricinoleic acid (12-hydroxyoleic acid) and/or coriolic acid (13-hydroxy-9c,
11t-octadecadienoic acid). The abovementioned fatty acids are, as a rule, advantageously only found in traces in the
fatty acid esters or fatty acid mixtures produced by the process according to the invention, that is to say that, based on
the total fatty acids, they occur to less than 30%, preferably to less than 25%, 24%, 23%, 22% or 21 %, especially
preferably to less than 20%, 15%, 10%, 9%, 8%, 7%, 6% or 5%, very especially preferably to less than 4%, 3%, 2% or
1 %. The fatty acid esters or fatty acid mixtures produced by the process according to the invention advantageously
comprise less than 0.1 %, based on the total fatty acids, or no butyric acid, no cholesterol, no clupanodonic acid (=
docosapentaenoic acid, C22:5Δ4,8,12,15,21) and no nisinic acid (tetracosahexaenoic acid, C23:6Δ3,8,12,15,18,21).
[0096] Owing to the nucleic acid sequences of the invention, or the nucleic acid sequences used in the process
according to the invention, an increase in the yield of polyunsaturated fatty acids of at least 50%, advantageously of at
least 80%, especially advantageously of at least 100%, very especially advantageously of at least 150%, in comparison
with the nontransgenic starting organism, for example a yeast, an alga, a fungus or a plant such as Arabidopsis or linseed
can be obtained in a comparison by GC analysis.
[0097] Chemically pure polyunsaturated fatty acids or fatty acid compositions can also be prepared by the processes
described above. To this end, the fatty acids or the fatty acid compositions are isolated from the organism, such as the
microorganisms or the plants or the culture medium in or on which the organisms have been grown, or from the organism
and the culture medium, in a known manner, for example via extraction, distillation, crystallization, chromatography or
combinations of these methods. These chemically pure fatty acids or fatty acid compositions are advantageous for
applications in the food industry sector, the cosmetic industry sector and especially the pharmacological industry sector.
[0098] In principle, all genes of the fatty acid or lipid metabolism can be used in the process for the production of
polyunsaturated fatty acids, advantageously in combination with the inventive polynucleotide(s) (for the purposes of the
present application, the plural is understood as encompassing the singular and vice versa). Genes of the fatty acid or
lipid metabolism which are used are advantageously selected from the group consisting of acyl-CoA dehydrogenase(s),
acyl-ACP [= acyl carrier protein] desaturase(s), acyl-ACP thioesterase(s), fatty acid acyltransferase(s), acyl-CoA:lyso-
phospholipid acyltransferases, fatty acid synthase(s), fatty acid hydroxylase(s), acetyl-coenzyme A carboxylase(s), acyl-
coenzyme A oxidase(s), fatty acid desaturase(s), fatty acid acetylenases, lipoxygenases, triacylglycerol lipases, allene
oxide synthases, hydroperoxide lyases or fatty acid elongase(s). Genes selected from the group of the Δ4-desaturases,
Δ5-desaturases, Δ6-desaturases, Δ8-desaturases, Δ9-desaturases, Δ12-desaturases, Δ15-desaturases, Δ12- and Δ15-
desaturases, ω3-desaturases, Δ6-elongases, Δ9-elongases or Δ5-elongases in combination with the polynucleotides
according to the invention are preferably used, it being possible to use individual genes or a plurality of genes in com-
bination. For especially preferred gene combinations, reference is made here to tables 5 and 6, which are shown in the
examples.
[0099] Advantageously, the desaturases used in the process according to the invention convert their respective sub-
strates in the form of the CoA-fatty acid esters: If preceded by an elongation step, this advantageously results in an
increased product yield. The respective desaturation products are thereby synthesized in greater quantities, since the
elongation step is usually carried out with the CoA-fatty acid esters, while the desaturation step is predominantly carried
out with the phospholipids or the triglycerides. Therefore, a substitution reaction between the CoA-fatty acid esters and
the phospholipids or triglycerides, which would require a further, possibly limiting, enzyme reaction, is not necessary.
[0100] Owing to the enzymatic activity of the polypeptides used in the process according to the invention, a wide range
of polyunsaturated fatty acids can be produced in the process according to the invention. Depending on the choice of
the organisms, such as the preferred plants, used for the process according to the invention, mixtures of the various
polyunsaturated fatty acids or individual polyunsaturated fatty acids, such as EPA or ARA, can be produced in free or
bound form. Depending on the prevailing fatty acid composition in the starting plant (C18:2- or C18:3-fatty acids), fatty
acids which are derived from C18:2-fatty acids, such as GLA, DGLA or ARA, or fatty acids which are derived from C18:
3-fatty acids, such as SDA, ETA or EPA, are thus obtained. If only linoleic acid (= LA, C18:2Δ9,12) is present as unsaturated
fatty acid in the plant used for the process, the process can only afford GLA, DGLA and ARA as products, all of which
can be present as free fatty acids or in bound form. If only α-linolenic acid (= ALA, C18:3Δ9,12,15) is present as unsaturated
fatty acid in the plant used for the process, the process can only afford SDA, ETA, EPA and/or DHA as products, all of
which can be present as free fatty acids or in bound form, as described above. Owing to the modification of the activity
of the enzymes Δ5-desaturase, Δ6-desaturase, Δ4-desaturase, Δ12-desaturase, Δ15-desaturase, ω3-desaturase, Δ5-
elongase and/or Δ6-elongase which play a role in the synthesis, it is possible to produce, in a targeted fashion, only
individual products in the abovementioned organisms, advantageously in the abovementioned plants. Owing to the
activity of Δ6-desaturase and Δ6-elongase, for example, GLA and DGLA, or SDA and ETA, are formed, depending on
the starting plant and unsaturated fatty acid. DGLA or ETA or mixtures of these are preferably formed. If Δ5-desaturase,
Δ5-elongase and Δ4-desaturase are additionally introduced into the organisms, advantageously into the plant, ARA,
EPA and/or DHA are additionally formed. Advantageously, only ARA, EPA or DHA or mixtures of these are synthesized,
depending on the fatty acids present in the organism, or in the plant, which acts as starting substance for the synthesis.
Since biosynthetic cascades are involved, the end products in question are not present as pure substances in the
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organisms. Small amounts of the precursor compounds are always additionally present in the end product. These small
amounts amount to less than 20% by weight, advantageously less than 15% by weight, especially advantageously less
than 10% by weight, most advantageously less than 5, 4, 3, 2 or 1% by weight, based on the end product DGLA, ETA
or their mixtures, or ARA, EPA, DHA or their mixtures, advantageously EPA or DHA or their mixtures.
[0101] In addition to the production, directly in the organism, of the starting fatty acids for the polypeptides used in the
process of the invention, the fatty acids can also be fed externally. The production in the organism is preferred for reasons
of economy. Preferred substrates are linoleic acid (C18:2Δ9,12), γ-linolenic acid (C18:3Δ6,9,12), eicosadienoic acid (C20:
2Δ11,14), dihomo-γ-linolenic acid (C20:3Δ8,11,14), arachidonic acid (C20:4Δ5,8,11,14), docosatetraenoic acid (C22:
4Δ7,10,13,16) and docosapentaenoic acid (C22:5Δ4,7,10,13,15).
[0102] To increase the yield in the described process for the production of oils and/or triglycerides with an advanta-
geously elevated content of polyunsaturated fatty acids, it is advantageous to increase the amount of starting product
for the synthesis of fatty acids; this can be achieved for example by introducing, into the organism, a nucleic acid which
codes for a polypeptide with a Δ12-desaturase and/or (15-desaturase activity according to the invention. This is particularly
advantageous in oil-producing organisms such as those from the family of the Brassicaceae, such as the genus Brassica,
for example oilseed rape; the family of the Elaeagnaceae, such as the genus Elaeagnus, for example the genus and
species Olea europaea, or the family Fabaceae, such as the genus Glycine, for example the genus and species Glycine
max, which are high in oleic acid. Since these organisms are only low in linoleic acid (Mikoklajczak et al., Journal of the
American Oil Chemical Society, 38, 1961, 678 - 681), the use of the abovementioned Δ12-desaturases and/or (15-
desaturases according to the invention for producing the starting material linoleic acid is advantageous.
[0103] The process according to the invention advantageously employs the abovementioned nucleic acid sequences
or their derivatives or homologs which code for polypeptides which retain the enzymatic activity of the proteins encoded
by nucleic acid sequences. These sequences, individually or in combination with the polynucleotides according to the
invention, are cloned into expression constructs and used for the introduction into, and expression in, organisms. Owing
to their construction, these expression constructs make possible an advantageous optimal synthesis of the polyunsat-
urated fatty acids produced in the process according to the invention.
[0104] In a preferred embodiment, the process furthermore comprises the step of obtaining a cell or an intact organism
which comprises the nucleic acid sequences used in the process, where the cell and/or the organism is transformed
with a polynucleotide according to the invention, a gene construct or a vector as described below, alone or in combination
with further nucleic acid sequences which code for proteins of the fatty acid or lipid metabolism. In a further preferred
embodiment, this process furthermore comprises the step of obtaining the oils, lipids or free fatty acids from the organism
or from the culture. The culture can, for example, take the form of a fermentation culture, for example in the case of the
cultivation of microorganisms, such as, for example, Mortierella, Thalassiosira, Mantoniella, Ostreococcus, Saccharo-
myces or Thraustochytrium, or a greenhouse- or field-grown culture of a plant. The cell or the organism thus produced
is advantageously a cell of an oil-producing organism, such as an oil crop, such as, for example, peanut, oilseed rape,
canola, linseed, hemp, soybean, safflower, sunflowers or borage.
[0105] In the case of plant cells, plant tissue or plant organs, "growing" is understood as meaning, for example, the
cultivation on or in a nutrient medium, or of the intact plant on or in a substrate, for example in a hydroponic culture,
potting compost or on arable land.
[0106] Suitable organisms or host cells for the process according to the invention are those which are capable of
synthesizing fatty acids, specifically unsaturated fatty acids, and/or which are suitable for the expression of recombinant
genes Examples which may be mentioned are plants such as Arabidopsis, Asteraceae such as Calendula or crop plants
such as soybean, peanut, castor-oil plant, sunflower, maize, cotton, flax, oilseed rape, coconut, oil palm, safflower
(Carthamus tinctorius) or cacao bean, microorganisms, such as fungi, for example the genus Mortierella, Thraustochytri-
um, Saprolegnia, Phytophthora or Pythium, bacteria, such as the genus Escherichia or Shewanella, yeasts, such as the
genus Saccharomyces, cyanobacteria, ciliates, algae such as Mantoniella or Ostreococcus, or protozoans such as
dinoflagellates, such as Thalassiosira or Crypthecodinium. Preferred organisms are those which are naturally capable
of synthesizing substantial amounts of oil, such as fungi, such as Mortierella alpina, Pythium insidiosum, Phytophthora
infestans, or plants such as soybean, oilseed rape, coconut, oil palm, safflower, flax, hemp, castor-oil plant, Calendula,
peanut, cacao bean or sunflower, or yeasts such as Saccharomyces cerevisiae, with soybean, flax, oilseed rape, saf-
flower, sunflower, Calendula, Mortierella or Saccharomyces cerevisiae being especially preferred. In principle, suitable
as host organisms are, in addition to the abovementioned transgenic organisms, also transgenic animals, advantageously
nonhuman animals, for example Caenorhabditis elegans. Further suitable host cells and organisms have already been
described extensively above.
[0107] Transgenic plants which comprise the polyunsaturated fatty acids synthesized in the process according to the
invention can advantageously be marketed directly without there being any need for the oils, lipids or fatty acids syn-
thesized to be isolated. Plants for the process according to the invention are listed as meaning intact plants and all plant
parts, plant organs or plant parts such as leaf, stem, seeds, root, tubers, anthers, fibers, root hairs, stalks, embryos,
calli, cotelydons, petioles, harvested material, plant tissue, reproductive tissue and cell cultures which are derived from
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the transgenic plant and/or can be used for bringing about the transgenic plant. In this context, the seed comprises all
parts of the seed such as the seed coats, epidermal cells, seed cells, endosperm or embryonic tissue. However, the
compounds produced in the process according to the invention can also be isolated from the organisms, advantageously
plants, in the form of their oils, fats, lipids and/or free fatty acids. Polyunsaturated fatty acids produced by this process
can be obtained by harvesting the organisms, either from the crop in which they grow, or from the field. This can be
done via pressing or extraction of the plant parts, preferably of the plant seeds. In this context, the oils, fats, lipids and/or
free fatty acids can be obtained by pressing by what is known as cold-beating or cold-pressing without applying heat.
To allow for greater ease of disruption of the plant parts, specifically the seeds, they are previously comminuted, steamed
or roasted. The seeds which have been pretreated in this manner can subsequently be pressed or extracted with solvent
such as warm hexane. The solvent is subsequently removed. In the case of microorganisms, the latter are, after har-
vesting, for example extracted directly without further processing steps or else, after disruption, extracted via various
methods with which the skilled worker is familiar. In this manner, more than 96% of the compounds produced in the
process can be isolated. Thereafter, the resulting products are processed further, i.e. refined. In this process, for example
the plant mucilages and suspended matter are first removed. What is known as desliming can be effected enzymatically
or, for example, chemico-physically by addition of acid such as phosphoric acid. Thereafter, the free fatty acids are
removed by treatment with a base, for example sodium hydroxide solution. The resulting product is washed thoroughly
with water to remove the alkali remaining in the product and then dried. To remove the pigments remaining in the product,
the products are subjected to bleaching, for example using fuller’s earth or active charcoal. At the end, the product is
deodorized, for example using steam.
[0108] The PUFAs or LCPUFAs produced by this process are preferably C18-, C20- or C22-fatty acid molecules,
advantageously C20- or C22-fatty acid molecules, with at least two double bonds in the fatty acid molecule, preferably
three, four, five or six double bonds. These C18-, C20- or C22-fatty acid molecules can be isolated from the organism in
the form of an oil, a lipid or a free fatty acid. Suitable organisms are, for example, those mentioned above. Preferred
organisms are transgenic plants.
[0109] One embodiment of the invention is therefore oils, lipids or fatty acids or fractions thereof which have been
produced by the abovedescribed process, especially preferably oil, lipid or a fatty acid composition comprising PUFAs
and being derived from transgenic plants.
[0110] These oils, lipids or fatty acid compositions preferably comprise the abovementioned fatty acids, particularly
preferably in the abovementioned concentration. In one embodiment of the invention, the oils, lipids or fatty acid com-
positions obtained by the methods according to the invention are distinguished by the fact that the preparations which
comprise said oils, lipids or fatty acid compositions contain traces of the nucleic acids according to the invention. These
traces can be detected by suitable highly-sensitive detection methods, for example PCR-based technologies.
[0111] A further embodiment according to the invention is the use of the oil, lipid, the fatty acids and/or the fatty acid
composition in feedstuffs, foodstuffs, cosmetics or pharmaceuticals. The oils, lipids, fatty acids or fatty acid mixtures
according to the invention can be used in the manner with which the skilled worker is familiar for mixing with other oils,
lipids, fatty acids or fatty acid mixtures of animal origin, such as, for example, fish oils. These oils, lipids, fatty acids or
fatty acid mixtures, which are composed of vegetable and animal constituents, may also be used for the preparation of
feedstuffs, foodstuffs, cosmetics or pharmaceuticals.
[0112] The term "oil", "lipid" or "fat" is understood as meaning a fatty acid mixture comprising unsaturated, saturated,
preferably esterified, fatty acid(s). The oil, lipid or fat is preferably high in polyunsaturated free or, advantageously,
esterified fatty acid(s), in particular those mentioned above. The amount of unsaturated esterified fatty acids preferably
amounts to approximately 30%, a content of 50% is more preferred, a content of 60%, 70%, 80% or more is even more
preferred. For the analysis, the fatty acid content can, for example, be determined by gas chromatography after converting
the fatty acids into the methyl esters by transesterification. The oil, lipid or fat can comprise various other saturated or
unsaturated fatty acids, for example calendulic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid and the like.
The content of the various fatty acids in the oil or fat can vary, in particular depending on the starting organism.
[0113] The polyunsaturated fatty acids with advantageously at least two double bonds which are produced in the
process are, as described above, for example sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids,
monoacylglycerol, diacylglycerol, triacylglycerol or other fatty acid esters.
[0114] Starting from the polyunsaturated fatty acids with advantageously at least five or six double bonds, which acids
have been prepared in the process according to the invention, the polyunsaturated fatty acids which are present can be
liberated for example via treatment with alkali, for example aqueous KOH or NaOH, or acid hydrolysis, advantageously
in the presence of an alcohol such as methanol or ethanol, or via enzymatic cleavage, and isolated via, for example,
phase separation and subsequent acidification via, for example, H2SO4. The fatty acids can also be liberated directly
without the abovedescribed processing step.
[0115] After their introduction into an organism, advantageously a plant cell or plant, the nucleic acids used in the
process can either be present on a separate plasmid or, advantageously, integrated into the genome of the host cell. In
the case of integration into the genome, integration can be random or else be effected by recombination such that the
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native gene is replaced by the copy introduced, whereby the production of the desired compound by the cell is modulated,
or by the use of a gene in "trans", so that the gene is linked operably with a functional expression unit which comprises
at least one sequence which ensures the expression of a gene and at least one sequence which ensures the polyade-
nylation of a functionally transcribed gene. The nucleic acids are advantageously introduced into the organisms via
multiexpression cassettes or constructs for multiparallel expression, advantageously into the plants for the multiparallel
seed-specific expression of genes.
[0116] Mosses and algae are the only known plant systems which produce substantial amounts of polyunsaturated
fatty acids such as arachidonic acid (ARA) and/or eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA).
Mosses comprise PUFAs in membrane lipids, while algae, organisms which are related to algae and a few fungi also
accumulate substantial amounts of PUFAs in the triacylglycerol fraction. This is why nucleic acid molecules which are
isolated from such strains that also accumulate PUFAs in the triacylglycerol fraction are particularly advantageous for
the process according to the invention and thus for the modification of the lipid and PUFA production system in a host,
in particular plants such as oil crops, for example oilseed rape, canola, linseed, hemp, soybeans, sunflowers and borage.
They can therefore be used advantageously in the process according to the invention.
[0117] Substrates which are suitable for the polypeptides according to the invention of the fatty acid or lipid metabolism
selected from the group acyl-CoA dehydrogenase(s), acyl-ACP [= acyl carrier protein] desaturase(s), acyl-ACP thioeste-
rase(s), fatty acid acyltransferase(s), acyl-CoA:lysophospholipid acyltransferase(s), fatty acid synthase(s), fatty acid
hydroxylase(s), acetyl-coenzyme A carboxylase(s), acyl-coenzymeA oxidase(s), fatty acid desaturase(s), fatty acid acet-
ylenase(s), lipoxygenase(s), triacylglycerol lipase(s), allene oxide synthase(s), hydroperoxide lyase(s) or fatty acid elon-
gase(s) are preferably C16-, C18- or C20-fatty acids. The fatty acids converted as substrates in the process are preferably
converted in the form of their acyl-CoA esters and/or their phospholipid esters.
[0118] To produce the long-chain PUFAs according to the invention, the polyunsaturated C18-fatty acids must first be
desaturated by the enzymatic activity of a desaturase and subsequently be elongated by at least two carbon atoms via
an elongase. After one elongation cycle, this enzyme activity gives C20-fatty acids and after two elongation cycles,
C22-fatty acids. The activity of the desaturases and elongases used in the processes according to the invention preferably
leads to C18-, C20- and/or C22-fatty acids, advantageously with at least two double bonds in the fatty acid molecule,
preferably with three, four, five or six double bonds, especially preferably to C20- and/or C22-fatty acids with at least two
double bonds in the fatty acid molecule, preferably with three, four, five or six double bonds, very especially preferably
with five or six double bonds in the molecule. After a first desaturation and the elongation have taken place, further
desaturation and elongation steps such as, for example, such a desaturation in the Δ5 and Δ4 positions may take place.
Products of the process according to the invention which are especially preferred are dihomo-γ-linolenic acid, arachidonic
acid, eicosapentaenoic acid, docosapentaenoic acid and/or docosahexaenoic acid. The C20-fatty acids with at least two
double bonds in the fatty acid can be desaturated by the enzymatic activity according to the invention in the form of the
free fatty acid or in the form of the esters, such as phospholipids, glycolipids, sphingolipids, phosphoglycerides, monoa-
cylglycerol, diacylglycerol or triacylglycerol.
[0119] The preferred biosynthesis site of fatty acids, oils, lipids or fats in the plants which are advantageously used
is, for example, in general the seed or cell strata of the seed, so that seed-specific expression of the nucleic acids used
in the process is sensible. However, it is obvious that the biosynthesis of fatty acids, oils or lipids need not be limited to
the seed tissue, but can also take place in a tissue-specific manner in all the other parts of the plant - for example in
epidermal cells or in the tubers.
[0120] If microorganism such as yeasts, such as Saccharomyces or Schizosaccharomyces, fungi such as Mortierella,
Aspergillus, Phytophthora, Entomophthora, Mucor or Thraustochytrium, algae such as Isochrysis, Mantoniella, Ostreo-
coccus, Phaeodactylum or Crypthecodinium are used as organisms in the process according to the invention, these
organisms are advantageously grown in fermentation cultures. Owing to the use of the nucleic acids according to the
invention which code for a desaturase, the polyunsaturated fatty acids produced in the process can be increased by at
least 5%, preferably by at least 10%, especially preferably by at least 20%, very especially preferably by at least 50%
in comparison with the wild type of the organisms which do not comprise the nucleic acids recombinantly.
[0121] In principle, the polyunsaturated fatty acids produced by the process according to the invention in the organisms
used in the process can be increased in two different ways. Advantageously, the pool of free polyunsaturated fatty acids
and/or the content of the esterified polyunsaturated fatty acids produced via the process can be enlarged. Advantageously,
the pool of esterified polyunsaturated fatty acids in the transgenic organisms is enlarged by the process according to
the invention.
[0122] If microorganisms are used as organisms in the process according to the invention, they are grown or cultured
in a manner with which the skilled worker is familiar, depending on the host organism. As a rule, microorganisms are
grown in a liquid medium comprising a carbon source, usually in the form of sugars, a nitrogen source, usually in the
form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as salts
of iron, manganese and magnesium and, if appropriate, vitamins, at temperatures of between 0°C and 100°C, preferably
between 10°C and 60°C, while introducing oxygen gas. The pH of the nutrient liquid can either be kept constant, that is
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to say regulated during the culturing period, or not. The cultures can be grown batchwise, semi-batchwise or continuously.
Nutrients can be provided at the beginning of the fermentation or fed in semicontinuously or continuously. The polyun-
saturated fatty acids produced can be isolated from the organisms as described above by processes known to the skilled
worker, for example by extraction, distillation, crystallization, if appropriate precipitation with salt, and/or chromatography.
To this end, the organisms can advantageously be disrupted beforehand.
[0123] If the host organisms are microorganisms, the process according to the invention is advantageously carried
out at a temperature of between 0°C and 95°C, preferably between 10°C and 85°C, especially preferably between 15°C
and 75°C, very especially preferably between 15°C and 45°C.
[0124] In this process, the pH value is advantageously kept between pH 4 and 12, preferably between pH 6 and 9,
especially preferably between pH 7 and 8.
[0125] The process according to the invention can be operated batchwise, semibatchwise or continuously. An overview
of known cultivation methods can be found in the textbook by Chmiel (Bioprozeßtechnik 1. Einführung in die Bioverfah-
renstechnik [Bioprocess technology 1. Introduction to bioprocess technology] (Gustav Fischer Verlag, Stuttgart, 1991))
or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and peripheral equipment] (Vieweg
Verlag, Brunswick/Wiesbaden, 1994)).
[0126] The culture medium to be used must suitably meet the requirements of the strains in question. Descriptions of
culture media for various microorganisms can be found in the textbook "Manual of Methods for General Bacteriology"
of the American Society for Bacteriology (Washington D.C., USA, 1981).
[0127] As described above, these media which can be employed in accordance with the invention usually comprise
one or more carbon sources, nitrogen sources, inorganic salts, vitamins and/or trace elements.
[0128] Preferred carbon sources are sugars, such as mono-, di- or polysaccharides. Examples of very good carbon
sources are glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch
or cellulose. Sugars can also be added to the media via complex compounds such as molasses or other by-products
from sugar raffination. The addition of mixtures of a variety of carbon sources may also be advantageous. Other possible
carbon sources are oils and fats such as, for example, soya oil, sunflower oil, peanut oil and/or coconut fat, fatty acids
such as, for example, palmitic acid, stearic acid and/or linoleic acid, alcohols and/or polyalcohols such as, for example,
glycerol, methanol and/or ethanol, and/or organic acids such as, for example, acetic acid and/or lactic acid.
[0129] Nitrogen sources are usually organic or inorganic nitrogen compounds or materials comprising these com-
pounds. Examples of nitrogen sources comprise ammonia in liquid or gaseous form or ammonium salts such as am-
monium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea,
amino acids or complex nitrogen sources such as cornsteep liquor, soya meal, soya protein, yeast extract, meat extract
and others. The nitrogen sources can be used individually or as a mixture.
[0130] Inorganic salt compounds which may be present in the media comprise the chloride, phosphorus and sulfate
salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
[0131] Inorganic sulfur-containing compounds such as, for example, sulfates, sulfites, dithionites, tetrathionates, thi-
osulfates, sulfides, or else organic sulfur compounds such as mercaptans and thiols may be used as sources of sulfur
for the production of sulfur-containing fine chemicals, in particular of methionine.
[0132] Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding
sodium-containing salts may be used as sources of phosphorus.
[0133] Chelating agents may be added to the medium in order to keep the metal ions in solution. Particularly suitable
chelating agents comprise dihydroxyphenols such as catechol or protocatechuate and organic acids such as citric acid.
[0134] The fermentation media used according to the invention for cultivating microorganisms usually also comprise
other growth factors such as vitamins or growth promoters, which include, for example, biotin, riboflavin, thiamine, folic
acid, nicotinic acid, panthothenate and pyridoxine. Growth factors and salts are frequently derived from complex media
components such as yeast extract, molasses, cornsteep liquor and the like. It is moreover possible to add suitable
precursors to the culture medium. The exact composition of the media compounds depends heavily on the particular
experiment and is decided upon individually for each specific case. Information on the optimization of media can be
found in the textbook "Applied Microbiol. Physiology, A Practical Approach" (Editors P.M. Rhodes, P.F. Stanbury, IRL
Press (1997) pp. 53-73, ISBN 0 19 963577 3). Growth media can also be obtained from commercial suppliers, for
example Standard 1 (Merck) or BHI (brain heart infusion, DIFCO) and the like.
[0135] All media components are sterilized, either by heat (20 min at 1.5 bar and 121°C) or by filter sterilization. The
components may be sterilized either together or, if required, separately. All media components may be present at the
start of the cultivation or added continuously or batchwise, as desired.
[0136] The culture temperature is normally between 15°C and 45°C, preferably at from 25°C to 40°C, and may be
kept constant or altered during the experiment. The pH of the medium should be in the range from 5 to 8.5, preferably
around 7.0. The pH for cultivation can be controlled during cultivation by adding basic compounds such as sodium
hydroxide, potassium hydroxide, ammonia and aqueous ammonia or acidic compounds such as phosphoric acid or
sulfuric acid. Foaming can be controlled by employing antifoams such as, for example, fatty acid polyglycol esters. To
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maintain the stability of plasmids it is possible to add to the medium suitable substances having a selective effect, for
example antibiotics. Aerobic conditions are maintained by introducing oxygen or oxygen-containing gas mixtures such
as, for example, ambient air, into the culture. The temperature of the culture is normally 20°C to 45°C and preferably
25°C to 40°C. The culture is continued until formation of the desired product is at a maximum. This aim is normally
achieved within 10 hours to 160 hours.
[0137] The fermentation broths obtained in this way, in particular those containing polyunsaturated fatty acids, usually
contain a dry mass of from 7.5 to 25% by weight.
[0138] The fermentation broth can then be processed further. The biomass may, according to requirement, be removed
completely or partially from the fermentation broth by separation methods such as, for example, centrifugation, filtration,
decanting or a combination of these methods or be left completely in said broth. It is advantageous to process the
biomass after its separation.
[0139] However, the fermentation broth can also be thickened or concentrated without separating the cells, using
known methods such as, for example, with the aid of a rotary evaporator, thin-film evaporator, falling-film evaporator,
by reverse osmosis or by nanofiltration. Finally, this concentrated fermentation broth can be processed to obtain the
fatty acids present therein.
[0140] The polynucleotides or polypeptides of the present invention which are involved in the metabolism of lipids and
fatty acids, PUFA cofactors and enzymes or in the transport of lipophilic compounds across membranes are used in the
process according to the invention for the modulation of the production of PUFAs in transgenic organisms, advantageously
in plants, such as maize, wheat, rye, oats, triticale, rice, barley, soybean, peanut, cotton, Linum species such as linseed
or flax, Brassica species such as oilseed rape, canola and turnip rape, pepper, sunflower, borage, evening primrose
and Tagetes, Solanaceae plants such as potato, tobacco, eggplant and tomato, Vicia species, pea, cassava, alfalfa,
bushy plants (coffee, cacao, tea), Salix species, trees (oil palm, coconut) and perennial grasses and fodder crops, either
directly (for example when the overexpression or optimization of a fatty acid biosynthesis protein has a direct effect on
the yield, production and/or production efficiency of the fatty acid from modified organisms) and/or can have an indirect
effect which nevertheless leads to an enhanced yield, production and/or production efficiency of the PUFAs or a reduction
of undesired compounds (for example when the modulation of the metabolism of lipids and fatty acids, cofactors and
enzymes leads to modifications of the yield, production and/or production efficiency or the composition of the desired
compounds within the cells, which, in turn, can affect the production of one or more fatty acids).
[0141] The combination of various precursor molecules and biosynthesis enzymes leads to the production of various
fatty acid molecules, which has a decisive effect on lipid composition, since polyunsaturated fatty acids (= PUFAs) are
not only easily incorporated into triacylglycerol but also into membrane lipids.
[0142] Brassicaceae, Boraginaceae, Primulaceae, or Linaceae are particularly suitable for the production of PUFAs,
for example stearidonic acid, eicosapentaenoic acid and docosahexaenoic acid. Linseed (Linum usitatissimum) is es-
pecially advantageously suitable for the production of PUFAs with the nucleic acid sequences according to the invention,
advantageously, as described, in combination with further desaturases and elongases.
[0143] Lipid synthesis can be divided into two sections: the synthesis of fatty acids and their binding to sn-glycerol-3-
phosphate, and the addition or modification of a polar head group. Usual lipids which are used in membranes comprise
phospholipids, glycolipids, sphingolipids and phosphoglycerides. Fatty acid synthesis starts with the conversion of acetyl-
CoA into malonyl-CoA by acetyl-CoA carboxylase or into acetyl-ACP by acetyl transacylase. After a condensation
reaction, these two product molecules together form acetoacetyl-ACP, which is converted via a series of condensation,
reduction and dehydratation reactions so that a saturated fatty acid molecule with the desired chain length is obtained.
The production of the unsaturated fatty acids from these molecules is catalyzed by specific desaturases, either aerobically
by means of molecular oxygen or anaerobically (regarding the fatty acid synthesis in microorganisms, see F.C. Neidhardt
et al. (1996) E. coli and Salmonella. ASM Press: Washington, D.C., pp. 612-636 and references cited therein; Lengeler
et al. (Ed.) (1999) Biology of Procaryotes. Thieme: Stuttgart, New York, and the references therein, and Magnuson, K.,
et al. (1993) Microbiological Reviews 57:522-542 and the references therein). To undergo the further elongation steps,
the resulting phospholipid-bound fatty acids must be returned to the fatty acid CoA ester pool from the phospholipids.
For further desaturation as described above, the fatty acid can be transferred back into the phospholipid pool. If appro-
priate, this reaction sequence can be traversed repeatedly.
[0144] Examples of precursors for the biosynthesis of PUFAs are oleic acid, linoleic acid and linolenic acid. These
C18-carbon fatty acids must be elongated to C20 and C22 in order to obtain fatty acids of the eicosa and docosa chain
type. With the aid of the desaturases used in the process, such as the Δ12-, Δ15-, Δ12- and Δ15-, ω3-, Δ4-, Δ5- and Δ6-
desaturases and/or the Δ5-, Δ6-elongases, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid or docosa-
hexaenoic acid, advantageously eicosapentaenoic acid and/or docosahexaenoic acid, can be produced and subse-
quently employed in various applications regarding foodstuffs, feedstuffs, cosmetics or pharmaceuticals. C20- and/or
C22-fatty acids with at least two, advantageously at least three, four, five or six, double bonds in the fatty acid molecule,
preferably C20- or C22-fatty acids with advantageously four, five or six double bonds in the fatty acid molecule, can be
prepared using the abovementioned enzymes. Desaturation may take place before or after elongation of the fatty acid
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in question. This is why the products of the desaturase activities and of the further desaturation and elongation steps
which are possible result in preferred PUFAs with a higher degree of desaturation, including a further elongation from
C20- to C22-fatty acids, to fatty acids such as γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, stearidonic acid,
eicosatetraenoic acid or eicosapentaenoic acid. Substrates of the desaturases and elongases used in the process
according to the invention are C16-, C18- or C20-fatty acids such as, for example, linoleic acid, γ-linolenic acid, α-linolenic
acid, dihomo-γ-linolenic acid, eicosatetraenoic acid or stearidonic acid. Preferred substrates are linoleic acid, γ-linolenic
acid and/or α-linolenic acid, dihomo-γ-linolenic acid or arachidonic acid, eicosatetraenoic acid or eicosapentaenoic acid.
The synthesized C20-or C22-fatty acids with at least two, three, four, five or six double bonds in the fatty acid are obtained
in the process according to the invention in the form of the free fatty acid or in the form of their esters, for example in
the form of their glycerides.
[0145] The term "glyceride" is understood as meaning a glycerol esterified with one, two or three carboxyl radicals
(mono-, di- or triglyceride). "Glyceride" is also understood as meaning a mixture of various glycerides. The glyceride or
glyceride mixture may comprise further additions, for example free fatty acids, antioxidants, proteins, carbohydrates,
vitamins and/or other substances.
[0146] For the purposes of the process according to invention, a "glyceride" is furthermore understood as meaning
glycerol derivatives. In addition to the abovedescribed fatty acid glycerides, these also include glycerophospholipids and
glyceroglycolipids. Preferred examples which may be mentioned in this context are the glycerophospholipids such as
lecithin (phosphatidylcholine), cardiolipin, phosphatidylglycerol, phosphatidylserine and alkylacylglycerophospholipids.
[0147] Furthermore, fatty acids must subsequently be translocated to various modification sites and incorporated into
the triacylglycerol storage lipid. A further important step in lipid synthesis is the transfer of fatty acids to the polar head
groups, for example by glycerol fatty acid acyltransferase (see Frentzen, 1998, Lipid, 100(4-5):161-166). Publications
on plant fatty acid biosynthesis and on the desaturation, the lipid metabolism and the membrane transport of lipidic
compounds, on beta-oxidation, fatty acid modification and cofactors, triacylglycerol storage and triacylglycerol assembly,
including the references therein, see the following papers: Kinney, 1997, Genetic Engineering, Ed.: JK Setlow, 19:
149-166; Ohlrogge and Browse, 1995, Plant Cell 7:957-970; Shanklin and Cahoon, 1998, Annu. Rev. Plant Physiol.
Plant Mol. Biol. 49:611-641; Voelker, 1996, Genetic Engineering, Ed.: JK Setlow, 18:111-13; Gerhardt, 1992, Prog. Lipid
R. 31:397-417; Gühnemann-Schäfer & Kindl, 1995, Biochim. Biophys Acta 1256:181-186; Kunau et al., 1995, Prog.
Lipid Res. 34:267-342; Stymne et al., 1993, in: Biochemistry and Molecular Biology of Membrane and Storage Lipids of
Plants, Ed.: Murata and Somerville, Rockville, American Society of Plant Physiologists, 150-158, Murphy & Ross 1998,
Plant Journal. 13(1):1-16.
[0148] The PUFAs produced in the process comprise a group of molecules which higher animals are no longer capable
of synthesizing and must therefore take up, or which higher animals are no longer capable of synthesizing themselves
in sufficient quantities and must therefore take up additional quantities, although they can be synthesized readily by
other organisms such as bacteria; for example, cats have lost the ability to synthesize arachidonic acid in the course of
evolution.
[0149] "Phospholipids" for the purposes of the invention are understood as meaning phosphatidylcholine, phosphati-
dylethanolamine, phosphatidylserine, phosphatidylglycerol and/or phosphatidylinositol, advantageously phosphatidyl-
choline. The terms "production or productivity" are known in the art and encompass the concentration of the fermentation
product (compounds of the formula I) which is formed within a specific period of time and in a specific fermentation
volume (for example kg of product per hour per liter). It also comprises the productivity within a plant cell or a plant, that
is to say the content of the desired fatty acids produced in the process relative to the content of all fatty acids in this cell
or plant. The term "production efficiency" comprises the time required for obtaining a specific production quantity (for
example the time required by the cell to establish a certain throughput rate of a fine chemical). The term "yield or product/
carbon yield" is known in the art and comprises the efficiency of the conversion of the carbon source into the product
(i.e. the fine chemical). This is usually expressed for example as kg of product per kg of carbon source. By increasing
the yield or production of the compound, the amount of the molecules obtained of this compound, or of the suitable
molecules of this compound obtained, in a specific culture quantity over a specified period of time is increased. The
terms "biosynthesis or biosynthetic pathway" are known in the art and comprise the synthesis of a compound, preferably
an organic compound, by a cell from intermediates, for example in a multi-step and strongly regulated process. The
terms "catabolism or catabolic pathway" are known in the art and comprise the cleavage of a compound, preferably of
an organic compound, by a cell to give catabolites (in more general terms, smaller or less complex molecules), for
example in a multi-step and strongly regulated process. The term "metabolism" is known in the art and comprises the
totality of the biochemical reactions which take place in an organism. The metabolism of a certain compound (for example
the metabolism of a fatty acid) thus comprises the totality of the biosynthetic pathways, modification pathways and
catabolic pathways of this compound in the cell which relate to this compound.
[0150] By employing, in the process according to the invention, the polynucleotides according to the invention and
optionally further polynucleotides which code for enzymes of the lipid or fatty acid metabolism it is possible to achieve
various advantageous effects. Thus, it is possible to influence the yield, production and/or production efficiency of the
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polyunsaturated fatty acids in a plant, preferably in an oil crop plant, or in a microorganism. The number or activity of
the polypeptides or polynucleotides according to the invention can be increased, so that larger amounts of the gene
products and, ultimately, larger amounts of the compounds of the general formula I are produced. A de novo synthesis
in an organism, which, before the gene(s) in question was/were introduced, had been lacking the activity and ability to
biosynthesize the compounds, is also possible. The same applies analogously to the combination with further desaturases
or elongases or further enzymes of the fatty acid and lipid metabolism. The use of a variety of divergent sequences, i.e.
sequences which differ at the DNA sequence level, may also be advantageous in this context, or else the use of gene
expression promoters which makes possible a different gene expression as far as timing is concerned, for example as
a function of the degree of maturity of a seed or oil-storing tissue.
[0151] By introducing, into an organism, a polynucleotide according to the invention alone or in combination with other
genes in a cell it is possible not only to increase the biosynthetic flow towards the end product, but also to increase, or
to create de novo, the corresponding triacylglycerol composition. Equally, the number or activity of other genes which
are required for the import of nutrients for the biosynthesis of one or more fatty acids, oils, polar and/or neutral lipids can
be increased, so that the concentration of these precursors, cofactors or intermediates within the cells or within the
storage compartment is increased, whereby the ability of the cells to produce PUFAs is further enhanced. By optimizing
the activity, or increasing the number, of one or more polynucleotides or polypeptides according to the invention which
are involved in the biosynthesis of these compounds, or by destroying the activity of one or more genes which are
involved in the degradation of these compounds, it may be possible to increase the yield, production and/or production
efficiency of fatty acid and lipid molecules from organisms, in particular from plants. The fatty acids obtained in the
process are suitable as starting materials for the chemical synthesis of further products of interest. For example, they
can be used for the preparation of pharmaceuticals, foodstuffs, animal feeds or cosmetics, either alone or in combination
with one another.
[0152] It can be seen from what has been said above that the invention also relates to a process for the preparation
of an oil, lipid or fatty acid composition, comprising the steps of the process according to the invention and the further
step of formulating the substance as an oil, lipid or fatty acid composition.
[0153] In a preferred embodiment of this process, the oil, lipid or fatty acid composition is formulated further to give a
drug, a cosmetic product, a foodstuff, a feedstuff, preferably fish food, or a food supplement.
[0154] Finally, the invention relates to the principle of using the polynucleotide, the vector, the host cell, the polypeptide
or the transgenic, nonhuman organism of the present invention for the production of an oil, lipid or fatty acid composition.
The latter should then preferably be employed as drug, cosmetic product, foodstuff, feedstuff, preferably fish food, or
food supplement.
[0155] The content of all the references, patent applications, patents and published patent applications cited in the
present patent application is hereby incorporated by reference to the respective specific disclosure.
Figures
[0156] Figure 1: Biosynthetic pathways for the production of long-chain, polyunsaturated fatty acids such as arachidonic
acid (= ARA, C20:4:Δ5,8,11,14), eicosapentaenoic acid (= EPA, C20:5Δ5,8,11,14,17) or docosahexaenoic acid (= DHA, C22:
6Δ4,7,10,13,16,19).
[0157] Figure 2: Gas-chromatographic determination of the fatty acids from yeasts which have been transformed with
the plasmid pYES (A) or pYES-d15Des(Ch)(B) and pYES-d15Des(Cy) (C), respectively.
Examples
Example 1: General cloning methods
[0158] The cloning methods such as, for example, restriction cleavages, agarose gel electrophoresis, purification of
DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linkage of DNA fragments, transfor-
mation of Escherichia coli cells, bacterial cultures and the sequence analysis of recombinant DNA were carried out as
described by Sambrook et al. (1989) (Cold Spring Harbor Laboratory Press: ISBN 0-87969-309-6).
Example 2: Sequence analysis of recombinant DNA
[0159] Recombinant DNA molecules were sequenced with an ABI laser fluorescence DNA sequencer by the method
of Sanger (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA74, 5463-5467). Fragments obtained by polymerase chain
reaction were sequenced and verified to avoid polymerase errors in constructs to be expressed.
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Example 3: Lipid extraction from yeasts
[0160] The effect of the genetic modification in plants, fungi, algae, ciliates or on the production of a desired compound
(such as a fatty acid) can be determined by growing the modified microorganisms or the modified plant under suitable
conditions (such as those described above) and analyzing the medium and/or the cellular components for the elevated
production of the desired product (i.e. of lipids or a fatty acid). These analytical techniques are known to the skilled
worker and comprise spectroscopy, thin-layer chromatography, various types of staining methods, enzymatic and micro-
biological methods and analytical chromatography such as high-performance liquid chromatography (see, for example,
Ullman, Encyclopedia of Industrial Chemistry, Vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A., et
al., (1987) "Applications of HPLC in Biochemistry" in: Laboratory Techniques in Biochemistry and Molecular Biology,
Vol. 17; Rehm et al. (1993) Biotechnology, Vol. 3, Chapter III: "Product recovery and purification", p. 469-714, VCH:
Weinheim; Belter, P.A., et al. (1988) Bioseparations: downstream processing for Biotechnology, John Wiley, and Sons;
Kennedy, J.F., and Cabral, J.M.S. (1992) Recovery processes for biological Materials, John Wiley and Sons; Shaeiwitz,
J.A., and Henry, J.D. (1988) Biochemical Separations, in: Ullmann’s Encyclopedia of Industrial Chemistry, Vol. B3;
Chapter 11, p. 1-27, VCH: Weinheim; and Dechow, F.J. (1989) Separation and purification techniques in biotechnology,
Noyes Publications).
[0161] In addition to the abovementioned processes, plant lipids are extracted from plant material as described by
Cahoon et al. (1999) Proc. Natl. Acad. Sci. USA 96 (22):12935-12940 and Browse et al. (1986) Analytic Biochemistry
152:141-145. The qualitative and quantitative analysis of lipids or fatty acids is described in Christie, William W., Advances
in Lipid Methodology, Ayr/Scotland: Oily Press (Oily Press Lipid Library; 2); Christie, William W., Gas Chromatography
and Lipids. A Practical Guide - Ayr, Scotland: Oily Press, 1989, Repr. 1992, IX, 307 pp. (Oily Press Lipid Library; 1);
"Progress in Lipid Research", Oxford: Pergamon Press, 1 (1952) - 16 (1977) under the title: Progress in the Chemistry
of Fats and Other Lipids CODEN.
[0162] In addition to measuring the end product of the fermentation, it is also possible to analyze other components
of the metabolic pathways which are used for the production of the desired compound, such as intermediates and by-
products, in order to determine the overall production efficiency of the compound. The analytical methods comprise
measuring the amount of nutrients in the medium (for example sugars, hydrocarbons, nitrogen sources, phosphate and
other ions), measuring the biomass composition and the growth, analyzing the production of conventional metabolites
of biosynthetic pathways and measuring gases which are generated during the fermentation. Standard methods for
these measurements are described in Applied Microbial Physiology; A Practical Approach, P.M. Rhodes and P.F. Stan-
bury, Ed., IRL Press, p. 103-129; 131-163 and 165-192 (ISBN: 0199635773) and references cited therein.
[0163] One example is the analysis of fatty acids (abbreviations: FAME, fatty acid methyl ester; GC-MS, gas liquid
chromatography/mass spectrometry; TAG, triacylglycerol; TLC, thin-layer chromatography).
[0164] Unambiguous proof for the presence of fatty acid products can be obtained by analyzing recombinant organisms
using standard analytical methods: GC, GC-MS or TLC, as described on several occasions by Christie and the references
therein (1997, in: Advances on Lipid Methodology, Fourth Edition: Christie, Oily Press, Dundee, 119-169; 1998, Gas-
chromatographie-Massenspektrometrie-Verfahren [Gas chromatography/mass spectrometry methods], Lipide 33:
343-353).
[0165] The material to be analyzed can be disrupted by sonication, grinding in a glass mill, liquid nitrogen and grinding
or via other applicable methods. After disruption, the material must be centrifuged. The sediment is resuspended in
distilled water, heated for 10 minutes at 100°C, cooled on ice and recentrifuged, followed by extraction for one hour at
90°C in 0.5 M sulfuric acid in methanol with 2% dimethoxypropane, which leads to hydrolyzed oil and lipid compounds,
which give transmethylated lipids. These fatty acid methyl esters are extracted in petroleum ether and finally subjected
to a GC analysis using a capillary column (Chrompack, WCOT Fused Silica, CP-Wax-52 CB, 25 micrometer, 0.32 mm)
at a temperature gradient of between 170°C and 240°C for 20 minutes and 5 minutes at 240°C. The identity of the
resulting fatty acid methyl esters must be defined using standards which are available from commercial sources (i.e.
Sigma).
Example 4: Cloning desaturase genes
[0166] The fungus Mycocentrospora acerina was grown for five days at 25°C in 50 ml of liquid medium (3 g/l yeast
extract, 3 g/l malt extract, 3 g/l peptone, 10 g/l glucose, 0.68 g/l K2HPO4 pH 6.0) on a shaker at 200 rpm. After the cells
were harvested by centrifugation at 2000 x g, 5 min, 4°C, 2 g of cell pellet were obtained. The pellet was washed 3x
with distilled water. Total-RNA was isolated using the RNeasy plant mini Kit (Quiagen, Hilden, Germany) in accordance
with the manufacturer’s instructions. This RNA was employed in order to obtain "5’RACE-ready" and "3’-RACE ready"
cDNA using the SMART RACE cDNA Amplification Kit (Clontech, Heidelberg, Germany), following the manufacturer’s
instructions. To isolate novel desaturase genes, the following degenerate primers were employed in combination with
the "5’-RACE ready" cDNA:
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Deg.1 (SEQ ID No.: 42):
5’-TGGGTI(C/T)T(T/C/G)GCICA(C/T)GA(A/G)TG(C/T)GG(A/T/C)CA-3’
Deg.2 (SEQ ID No.: 43):
5’-TTIGG(A/G)TCIGT(A/G)TG(C/T)TG(A/C/G)A(A/G)(A/G)AAIGT-3’
[0167] The following PCR protocol was employed for the amplification:
a) 2 min at 95°C,
b) 30 sec at 94°C
30 sec at 55-72°C
2 min at 72°C
Number of cycles: 30
c) 10 min at 72°C
[0168] PCR amplificates were sequenced after having been cloned into pCR2.1-TOPO (Invitrogen, Karlsruhe, Ger-
many) following the manufacturer’s instructions. One sequence showed homology to known Δ-12 and Δ-15 desaturases
(Sayanova O et al. J. Biol. Chem., 2006, 281, 36533-36541) in the ClustalW alignment (Thompson JD, et al., Nucleic
Acids Res., 1994, 22: 4673-4680). This known sequence section was extended at both ends (5’ and 3’) by Rapid
Amplification of cDNA Ends (RACE) by means of the SMART RACE cDNA Amplification Kit (Clontech, Heidelberg,
Germany). To this end, the following sequence-specific primers were derived in the known sequence region:
5RACE1 (SEQ ID No.: 44): 5’-ATGAAGACCATGTCGCGCTCCATGT-3’
3RACE1 (SEQ ID No.: 45): 5’-GACGAGCACCTCATCCTGCTTAG-3’
[0169] These primers in combination with the "5’-RACE ready" or "3’-RACE ready" cDNA of the fungus Mycocentro-
spora acerin gave the complete mRNA sequence (SEQ ID No.:15, Table 1).
[0170] For the other candidate sequences listed, complete genomic sequences were identified in a first step, in ac-
cordance with database entries. In a further step, the coding sequence was extracted with the aid of methods of bioin-
formatics. In order to obtain the corresponding coding sequence from the organisms, these can be amplified in a PCR
reaction from cDNA preparations, using the primer sequences defined in Table 1. This may give rise to fragments as
are described in Table 2.
[0171] By searching for conserved regions in the protein sequences, derived from the DNA, of the organisms Coch-
liobolus heterostrophus C5, Cyanothece sp. CCY0110 and Mycocentrospora acerina, it was possible to identify se-
quences with putative Δ12-desaturase activity or Δ15-desaturase activity. In particular when a succession of the desat-
urase motif 1 "GX10HX3HX13GX9PX3WX3H" (SEQ ID No: 46), the desaturase motif 2 "PX14(H/Q)H" (SEQ ID No: 47)
and either the desaturase motif 3 "HX2HHX5PXY" (SEQ ID No: 48) or the desaturase motif 4 "HX2HHX6PXY" (SEQ ID
No: 49) are found in the sequence, this is indicative of Δ12-desaturases or Δ15-desaturases, where X stands for any
amino acid. Whether it is a putative Δ12-, Δ15- or omega3-desaturase can be deduced from the amino acid at the variable
position 16 of the desaturase motif 2 (H or Q): Q = glutamine is indicative of putative Δ12-desaturases, H = histidine is
indicative of putative Δ15- or omega3-desaturases.
Table 1: Primer sequences for cloning the desaturases which have been identified.
Name of gene Organism Primer sequence (5’-3’) SEQ ID No:
D15Des(Ch) Cochliobolus heterostrophus C5 Forward: atgattacgactacgcacc 4
Reverse: ttaagccttggtcttggacc 6
D15Des(Cy) Cyanothece sp. CCY0110 Forward: atgcagcaacctatgactgtg 11
Reverse: ttaaaactttctagattcac 13
D12Des(Mac) Mycocentro spora acerina Forward: atggcctcgaccaccgcccgc 18
Reverse: ttactcgttgtcactctcag 19
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[0172] To characterize the functions of the individual sequences, the open reading frame of the DNA (Table 2) is
cloned downstream of the galactose-inducible GAL1 promoter of pYES2.1/V5-His-TOPO (Invitrogen), giving rise to the
plasmids pYES-D15Des(Ch), pYES-D15Des(Cy) or pYes-D12Des(Mac). Then, following manufacturer’s instructions,
these plasmids can then be transformed into the yeast strain INVSC-1 (Invitrogen) and selected for uracil auxotrophism
on plates with DOB-U agar. Positive colonies are identified by PCR. To this end, PCR is carried out in each case with
1 ml of defrosted cells, 200 mM dNTPs, 2.5 U Taq-polymerase and 100 pmol of each primer in a total volume of 50 ml.
The PCR conditions are as follows: first denaturation at 95°C for 5 minutes, followed by 30 cycles at 94°C for 30 seconds,
55°C for 1 minute and 72°C for 2 minutes, and a last elongation step at 72°C for 10 minutes: In parallel, the empty vector
pYES2.1/V5-His-TOPO is transformed in the above-described manner into competent yeast cells of strain INVSC-1.
Yeast cells with the plasmids pYES-D15Des(Ch), pYES-D15Des(Cy) or pYes-D12Des(Mac) are incubated for 12 h in
liquid DOB-U medium at 28°C and 200 rpm and then grown for a further 12 h in induction medium (DOB-U+2% (w/v)
galactose+2% (w/v) raffinose) and 250 mM of fatty acids which are added into the medium. The specificity and activity
of the gene to be characterized can be determined with reference to the added fatty acids.
[0173] Yeasts transformed with the plasmids pYES2/V5-His-TOPO or pYES-D15Des(Ch), pYES-D15Des(Cy) or pYes-
D12Des(Mac) are analyzed as follows:
The yeast cells from the main cultures are harvested by centrifugation (100 x g, 5 min, 20°C) and washed with 100
mM NaHCO3, pH 8.0 to remove residual medium and fatty acids. Starting with the yeast cell sediments, fatty acid
methyl esters (FAMEs) are prepared by acid methanolysis. To this end, the cell sediments are incubated for one
hour at 80°C together with 2 ml of 1 N methanolic sulfuric acid and 2% (v/v) of dimethoxypropane. The FAMEs are
extracted twice with petroleum ether (PE). To remove nonderivatized fatty acids, the organic phases are washed
in each case once with 2 ml of 100 mM NaHCO3, pH 8.0 and 2 ml of distilled water. Thereafter, the PE phases are
dried with Na2SO4, evaporated under argon and taken up in 100 ml of PE. The samples are separated on a DB-23
capillary column (30 m, 0.25 mm, 0.25 mm, Agilent) in a Hewlett-Packard 6850 gas chromatograph equipped with
flame ionization detector. The conditions for the GLC analysis are as follows: the oven temperature was programmed
from 50°C to 250°C with an increment of 5°C/min and finally 10 min at 250°C (holding).
[0174] The signals are identified by comparing the retention times with corresponding fatty acid standards (Sigma).
(continued)
Name of gene Organism Primer sequence (5’-3’) SEQ ID No:
ω3Des(Hp) Hyaloperonospora parasitica Forward: atggcgaccaagcaatcgg 53
Reverse: ctaagctgctttggcatcac 55
Table 2: Coding polynucleotide or amino acid sequences of the desaturases which have been identified.
Name of gene Organism Nucleotides in bp SEQ ID No: Amino acids SEQ ID
D15Des(Ch) Cochliobolus heterostrophus 
C5
1215 2 404 3
D15Des(Cy) Cyanothece sp. CCY0110 1050 9 349 10
D12Des(Mac) Mycocentrospora acerina 1488 16 495 17
ω3Des(Hp) Hyaloperonospora parasitica 1086 51 361 52
Table 3: Genomic sequences (gDNA) or transcript sequences (mRNA) of the desaturases which have been identified.
Name of gene Organism Type of sequence Nucleotides in bp SEQ ID
D15Des(Ch) Cochliobolus heterostrophus 
C5
gDNA 1870 1
D15Des(Cy) Cyanothece sp. CCY0110 gDNA 1667 4
D12Des(Mac) Mycocentrospora acerina mRNA 1932 7
ω3Des(Hp) Hyaloperonospora parasitica gDNA 1300 50
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The methodology is described for example in Napier and Michaelson, 2001, Lipids. 36(8):761-766; Sayanova et al.,
2001, Journal of Experimental Botany. 52(360):1581-1585, Sperling et al., 2001, Arch. Biochem. Biophys. 388(2):293-298
and Michaelson et al., 1998, FEBS Letters. 439(3):215-218.
Activity and substrate determination of the desaturases which have been identified
[0175] The substrate specificity of D15Des(Ch) or D15Des(Cy) can be determined after expression and after the
feeding of various fatty acids. Departing from the conserved desaturase motif 2 (SEQ ID No. 47), the following activity
was found for the coding sequences (Table 4).
[0176] These activities which have been found were additionally verified by expressing the desaturases in yeast. Table
4A lists the conversion of various fatty acid substrates into the expected fatty acid products. Except for the fatty acid 18:
1 n-9, all substrates were fed in the experiment and are therefore present in excess. Figure 2 shows the chromatograms
of the individual experiments.
Table 4: Activity of the desaturases which have been identified
Name of gene Organism Activity Polynucleotide SEQ ID 
No:
Polypeptide SEQ ID No:
D15Des(Ch) Cochliobolus 
heterostrophus C5
Δ15-desaturase 2 3
D15Des(Cy) Cyanothece sp. 
CCY0110
Δ15-desaturase 5 6
ω3Des(Hp) Hyaloperonospora 
parasitica
ω3-desaturase 51 52
Table 4A: Feeding of yeasts
Sample 
name/
fatty acid 
fed Reaction step observed Conversion rate (%)
Activity 
observed Fig.
Substrate (% of total 
fatty acid content)
Product (% of total fatty 
acid content)
Expected
Observe
d
pYES2 
empty 
vector / 18:
2n-9
18:2n-6 25.3 18:3n-3 0.0 - - - 4a
d15Des
(Ch) / 18:
2n-9
18:2n-6 6.3 18:3n-3 5.7 > 0 47.5 Δ15-des. 4b
d15Des
(Cy) / 18:
2n-9
18:2n-6 13.0 18:3n-3 0.9 > 0 6.4 Δ15-des. 4c
ω3Des
(Hp) / 18:
2n-9
18:2n-6 12.6 18:3n-3 0.0 > 0 0.0 -
ω3Des
(Hp) / 20:
3n-6
20:3n-6 6.3 20:4n-3 0.6 > 0 8.6 ω3-Des
ω3Des
(Hp) / 20:
4n-6
20:4n-6 5.7 20:5n-3 1.8 > 0 24.0 ω3-Des
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[0177] By way of control for the assay for Δ15-desaturase activity, yeasts were transformed with the pYES empty
vector, the fatty acid 18:2n-6 was fed, and the fatty acid profile was analyzed (Figure 2A). In comparison, the additional
fatty acid 18:3n-3 can be observed in yeasts which express the desaturases d15Des(Ch) and d15Des(Cy) (Figure 2B,
2C). These desaturases which have been assayed therefore have Δ15-desaturase activity.
Example 5: Production of transgenic plants for the production of long-chain polyunsaturated fatty acids
[0178] To produce long-chain polyunsaturated fatty acids in plants, various genes of the metabolic pathway are com-
bined on a binary vector. To produce the fatty acid eicosapentaenoic acid (20:5Δ5,8,11,14,17), genes as described in
Table 5 are combined. Analogously, the genes as described in Table 6 are combined for producing the fatty acid
docosahexaenoic acid (22:6Δ4,7,10,13,16,19).
[0179] Further transformation vectors based on pSUN-USP were generated for the transformation of plants. To this
end, Notl cleavage sites were introduced at the 5’ and at the 3’ end of the coding sequence, using the following primer
pairs (see Table 7).
[0180] Composition of the PCR mix (50 ml):
5.00 ml template cDNA
5.00 ml 10x buffer (Advantage polymerase) + 25mM MgCl2
5.00 ml 2mM dNTP
1.25 ml of each primer (10 pmol/mL)
0.50 ml Advantage polymerase
The Advantage polymerase from Clontech is employed.
Table 5: Gene combination for the production of eicosapentaenoic acid
Gene Activity SEQ ID No.
D6Des(Pir) Δ6-desaturase 22
D6Elo(Pp) Δ6-elongase 31
D5Des(Tc) Δ5-desaturase 25
ω3-Des(Pi) ω3-desaturase 28
D15Des(Ch) Δ15-desaturase 2
D15Des(Cy) Δ15-desaturase 9
D12Des(Mac) Δ12-/Δ15-desaturase 16
ω3Des(Hp) ω3-desaturase 51
Table 6: Gene combination for the production of docosahexaenoic acid
Gene Activity SEQ ID No.
D6Des(Pir) Δ6-desaturase 22
D6Elo(Pp) Δ6-elongase 31
D5Des(Tc) Δ5-desaturase 25
ω3Des(Pi) ω3-desaturase 28
D15Des(Ch) Δ15-desaturase 2
D15Des(Cy) (15-desaturase 9
ω3Des(Hp) ω3-desaturase
D12Des(Mac) (12-/(15-desaturase 16
D5Elo(Ot) Δ5-elongase 34
D4Des(Tc) Δ4-desaturase 37
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[0181] PCR reaction conditions:
Annealing temperature: 1 min 55°C
Denaturation temperature: 1 min 94°C
Elongation temperature: 2 min 72°C
Number of cycles: 35
[0182] The PCR products are incubated with the restriction enzyme Notl for 4 h at 37°C. The plant expression vector
pSUN300-USP is incubated in the same manner. Thereafter, the PCR products and the 7624 bp vector are separated
by agarose gel electrophoresis, and the corresponding DNA fragments are excised. The DNA is purified by means of
the Qiagen gel purification kit, following the manufacturer’s instructions. Thereafter, vector and PCR products are ligated.
The Rapid Ligation kit from Roche is used for this purpose. The plasmids generated are verified by sequencing.
[0183] pSUN300 is a derivative of the plasmid pPZP (Hajdukiewicz, P, Svab, Z, Maliga, P., (1994) The small versatile
pPZP family of Agrobacterium binary vectors for plant transformation. Plant Mol Biol 25:989-994). pSUN-USP originated
from pSUN300, by inserting a USP promoter into pSUN300 in the form of an EcoRI fragment. The polyadenylation signal
is the OCS gene from the A. tumefaciens Ti plasmid (ocs-Terminator, Genbank Accession V00088) (De Greve, H.,
Dhaese, P., Seurinck, J., Lemmers, M., Van Montagu, M. and Schell, J. Nucleotide sequence and transcript map of the
Agrobacterium tumefaciens Ti plasmid-encoded octopine synthase gene J. Mol. Appl. Genet. 1 (6), 499-511 (1982).
The USP promoter corresponds to nucleotides 1 to 684 (Genbank Accession X56240), where part of the noncoding
region of the USP gene is present in the promoter. The promoter fragment which is 684 base pairs in size was amplified
by a PCR reaction using standard methods with the aid of a synthesized primer and by means of a commercially available
T7 standard primer (Stratagene)
[0184] (Primer sequence:
Table 7: Primer sequences (for cloning transformation vectors based on pSUN-USP)
Gene Primer SEQ ID No.
D6-Des(Pir) Fwd: gcggccgcgccatggtggacctcaagcctgg 23
Rvs: gcggccgttacatcgctgggaactcgg 24
D5-Des(Tc) Fwd: gcggccgcgccatgggcaagggcagcgaggg 26
Rvs: gcggccgcgcctcagtcctgcttcttggtgtc 27
O3-Des(Pi) Fwd: gcggccgcgccatggcgacgaaggaggcgta 29
Rvs: gcggccgcgttacgtggacttggtcttggcc 30
D6-Elo(Pp) Fwd: gcggccgcgccatggaggtcgtggagagattc 32
Rvs: gcggccgcgtcactcagttttagctccc 33
D15Des(Ch) Fwd: gcggccgcgccatgattacgactacgcacc 5
Rvs: gcggccgcgttaagccttggtcttggacc 7
D15Des(Cy) Fwd: gcggccgcgccatgcagcaacctatgactgtg 12
Rvs: gcggccgcgttaaaactttctagattcac 14
D12Des(Mac) Fwd: gcggccgcgccatggcctcgaccaccgcccgc 20
Rvs: gcggccgcgttactcgttgtcactctcag 21
ω3Des(Hp) Fwd: gcggccgcgccatggcgaccaagcaatcgg 54
Rvs: gcggccgcgctaagctgctttggcatcac 56
D5Elo(Ot) Fwd: gcggccgcgccatgagcgcctccggtgcgctg 35
Rvs: gcggccgcgttagtcaatttttc 36
D4Des(Tc) Fwd: gcggccgcgccatgacggtcggctacgacgag 38
Rvs: gcggccgcgtcaggcagcgcgctgccagg 39
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[0185] The PCR fragment was recut with EcoRI/Sall and inserted into the vector pSUN300 with OCS terminator. This
gave rise to the plasmid named pSUN-USP, which can be employed for transforming plants by means of Agrobacterium
tumefaciens.
a) Generation of transgenic oilseed rape plants (modified method of Moloney et al., 1992, Plant Cell Reports, 8:238-242)
[0186] To generate transgenic oilseed rape plants, binary vectors such as the pSUN plasmids described hereinabove
are transformed into Agrobacterium tumefaciens C58C1:pGV2260 (Deblaere et al, 1984, Nucl. Acids. Res. 13,
4777-4788). A 1:50 dilution of an overnight culture of a positively transformed agrobacterial colony in Murashige-Skoog
medium (Murashige and Skoog 1962 Physiol. Plant. 15, 473) supplemented with 3% sucrose (3MS medium) is used
for transforming oilseed rape plants (cv. Westar). Petioles or hypocotyls of freshly germinated sterile oilseed rape plants
(in each case approx. 1 cm2) are incubated with a 1:50 agrobacterial dilution for 5-10 minutes in a Petri dish. This is
followed by 3 days of coincubation in the dark at 25°C on 3MS medium supplemented with 0.8% Bacto agar. After 3
days, the cultivation is continued with 16 hours light/8 hours dark and is continued, in a 1-week rhythm, on MS medium
supplemented with 500 mg/l Claforan (cefotaxim-sodium), 50 mg/l kanamycin, 20 mM benzylaminopurine (BAP) and 1.6
g/l glucose. Growing shoots are transferred to MS medium supplemented with 2% sucrose, 250 mg/l Claforan and 0.8%
Bacto agar. If no roots have formed after three weeks, the growth hormone 2-indolebutyric acid is added to the medium
to promote rooting.
[0187] Regenerated shoots are obtained on 2MS medium supplemented with kanamycin and Claforan, transferred
into soil once rooted, and after cultivation for two weeks grown in a controlled-environment cabinet or in a greenhouse,
flowering is induced, mature seeds are harvested and analyzed for expression of the desaturase or elongase genes by
means of lipid analyses as described by way of example in Qiu et al. 2001, J. Biol. Chem. 276, 31561-31566.
b) Generation of transgenic linseed plants
[0188] Transgenic linseed plants can be generated for example by the method of Bell et al., 1999, In Vitro Cell. Dev.
Biol.-Plant. 35(6):456-465 by means of particle bombardment. Agrobacterial-mediated transformations can be effected
for example as described by Mlynarova et al. (1994), Plant Cell Report 13: 282-285.
SEQUENCE LISTING
[0189]
<110> BASF Plant Science GmbH
<120> Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms
<130> BPS66115PC
<160> 56
<170> PatentIn version 3.5
<210> 1
<211> 1870
<212> DNA
<213> Cochliobolus heterostrophus C5
<400> 1
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<210> 2
<211> 1215
<212> DNA
<213> Cochliobolus heterostrophus C5
<400> 2
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<210> 3
<211> 404
<212> PRT
<213> Cochliobolus heterostrophus C5
<400> 3
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<210> 4
<211> 19
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<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 4
atgattacga ctacgcacc 19
<210> 5
<211> 30
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 5
gcggccgcgc catgattacg actacgcacc 30
<210> 6
<211> 20
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 6
ttaagccttg gtcttggacc 20
<210> 7
<211> 29
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 7
gcggccgcgt taagccttgg tcttggacc 29
<210> 8
<211> 1667
<212> DNA
<213> Cyanothece sp. CCY0110
<400> 8
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<210> 9
<211> 1050
<212> DNA
<213> Cyanothece sp. CCY0110
<400> 9
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<210> 10
<211> 349
<212> PRT
<213> Cyanothece sp. CCY0110
<400> 10
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<210> 11
<211> 21
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 11
atgcagcaac ctatgactgt g 21
<210> 12
<211> 32
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 12
gcggccgcgc catgcagcaa cctatgactg tg 32
<210> 13
<211> 20
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 13
ttaaaacttt ctagattcac 20
<210> 14
<211> 29
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 14
gcggccgcgt taaaactttc tagattcac 29
<210> 15
<211> 1932
<212> DNA
<213> Mycocentrospora acerina
<400> 15
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<210> 16
<211> 1488
<212> DNA
<213> Mycocentrospora acerina
<400> 16
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<210> 17
<211> 495
<212> PRT
<213> Mycocentrospora acerina
<400> 17
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<210> 18
<211> 21
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 18
atggcctcga ccaccgcccg c 21
<210> 19
<211> 32
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 19
gcggccgcgc catggcctcg accaccgccc gc 32
<210> 20
<211> 20
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 20
ttactcgttg tcactctcag 20
<210> 21
<211> 29
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 21
gcggccgcgt tactcgttgt cactctcag 29
<210> 22
<211> 1380
<212> DNA
<213> Pythium irregulare
<400> 22
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<210> 23
<211> 31
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 23
gcggccgcgc catggtggac ctcaagcctg g 31
<210> 24
<211> 27
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<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 24
gcggccgtta catcgctggg aactcgg 27
<210> 25
<211> 1320
<212> DNA
<213> Thraustochytrium sp.
<400> 25
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<210> 26
<211> 31
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 26
gcggccgcgc catgggcaag ggcagcgagg g 31
<210> 27
<211> 32
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 27
gcggccgcgc ctcagtcctg cttcttggtg tc 32
<210> 28
<211> 1086
<212> DNA
<213> Phytophthora infestans
<400> 28
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<210> 29
<211> 31
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 29
gcggccgcgc catggcgacg aaggaggcgt a 31
<210> 30
<211> 31
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 30
gcggccgcgt tacgtggact tggtcttggc c 31
<210> 31
<211> 873
<212> DNA
<213> Physcomitrella patens
<400> 31
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<210> 32
<211> 32
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 32
gcggccgcgc catggaggtc gtggagagat tc 32
<210> 33
<211> 28
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 33
gcggccgcgt cactcagttt tagctccc 28
<210> 34
<211> 903
<212> DNA
<213> Ostreococcus tauri
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<400> 34
<210> 35
<211> 32
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 35
gcggccgcgc catgagcgcc tccggtgcgc tg 32
<210> 36
<211> 23
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 36
gcggccgcgt tagtcaattt ttc 23
<210> 37
<211> 1560
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<212> DNA
<213> Thraustochytrium sp.
<400> 37
<210> 38
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<211> 32
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 38
gcggccgcgc catgacggtc ggctacgacg ag 32
<210> 39
<211> 29
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 39
gcggccgcgt caggcagcgc gctgccagg 29
<210> 40
<211> 819
<212> DNA
<213> Thalassiosira pseudonana
<400> 40
<210> 41
<211> 1371
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<212> DNA
<213> Ostreococcus tauri
<400> 41
<210> 42
<211> 26
<212> DNA
<213> Artificial
<220>
<223> Degenerate primer
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<220>
<221> modified_base
<222> (6)..(6)
<223> I
<220>
<221> misc feature
<222> (6)..(6)
<223> n is a, c, g, or t
<220>
<221> modified_base
<222> (12)..(12)
<223> I
<220>
<221> misc feature
<222> (12)..(12)
<223> n is a, c, g, or t
<400> 42
tgggtnytbg cncaygartg ygghca 26
<210> 43
<211> 26
<212> DNA
<213> Artificial
<220>
<223> Degenerate primer
<220>
<221> modified_base
<222> (3)..(3)
<223> I
<220>
<221> misc feature
<222> (3)..(3)
<223> n is a, c, g, or t
<220>
<221> modified_base
<222> (9)..(9)
<223> I
<220>
<221> misc feature
<222> (9)..(9)
<223> n is a, c, g, or t
<220>
<221> modified_base
<222> (24)..(24)
<223> I
<220>
<221> misc feature
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<222> (24)..(24)
<223> n is a, c, g, or t
<400> 43
ttnggrtcng trtgytgvar raangt 26
<210> 44
<211> 25
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 44
atgaagacca tgtcgcgctc catgt 25
<210> 45
<211> 23
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 45
gacgagcacc tcatcctgct tag 23
<210> 46
<211> 51
<212> PRT
<213> Artificial
<220>
<223> Desaturase Signature 1
<220>
<221> VARIANT
<222> (1)..(48)
<223> Xaa is any Aminoacid
<220>
<221> VARIANT
<222> (1)..(48)
<223> Xaa is any amino acid
<220>
<221> misc feature
<222> (49)..(50)
<223> Xaa can be any naturally occurring amino acid
<400> 46
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<210> 47
<211> 17
<212> PRT
<213> Artificial
<220>
<223> Desaturase Signature 2
<220>
<221> VARIANT
<222> (1)..(15)
<223> Xaa is any amino acid
<220>
<221> VARIANT
<222> (16)..(16)
<223> Xaa is Gln or His
<400> 47
<210> 48
<211> 13
<212> PRT
<213> Artificial
<220>
<223> Desaturase Signature 3
<220>
<221> VARIANT
<222> (1)..(13)
<223> Xaa is any amino acid
<400> 48
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<210> 49
<211> 14
<212> PRT
<213> Artificial
<220>
<223> Desaturase Signature 4
<220>
<221> VARIANT
<222> (1)..(14)
<223> Xaa is any amino acid
<400> 49
<210> 50
<211> 1300
<212> DNA
<213> Hyaloperonospora parasitica
<400> 50
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<210> 51
<211> 1086
<212> DNA
<213> Hyaloperonospora parasitica
<400> 51
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<210> 52
<211> 361
<212> PRT
<213> Hyaloperonospora parasitica
<400> 52
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<210> 53
<211> 19
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 53
atggcgacca agcaatcgg 19
<210> 54
<211> 30
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 54
gcggccgcgc catggcgacc aagcaatcgg 30
<210> 55
<211> 20
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 55
ctaagctgct ttggcatcac 20
<210> 56
<211> 29
<212> DNA
<213> Artificial
<220>
<223> Primer
<400> 56
gcggccgcgc taagctgctt tggcatcac 29
Claims
1. A polynucleotide comprising a nucleic acid sequence selected from the group consisting of:
(a) nucleic acid sequence as shown in SEQ ID NO. 1 or 2, and;
(b) nucleic acid sequence which codes for a polypeptide which features an amino acid sequence as shown in
SEQ ID NO. 3; and
(c) nucleic acid sequence which has at least 70% identity to the entire length of one of the nucleic acid sequences
of (a) or (b), and which codes for a polypeptide with a ω3-desaturase activity, wherein said nucleic acid sequence
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comprises a sequence encoding the amino acid sequence of SEQ ID NO: 47, wherein at position 16 of SEQ
ID NO: 47 a Histidine residue is present.
2. The polynucleotide according to claim 1, wherein the polynucleotide consists of RNA or DNA.
3. A vector comprising the polynucleotide according to claim 1 or 2.
4. The vector according to claim 3, wherein the vector is an expression vector.
5. The vector according to claim 3 or 4, wherein the vector comprises at least one further polynucleotide which codes
for a further enzyme which is involved in the biosynthesis of lipids or fatty acids.
6. A host cell comprising the polynucleotide according to claim 1 or 2 or the vector according to any of claims 3 to 5.
7. The host cell according to claim 6, wherein the host cell additionally comprises at least one further enzyme which
is involved in the biosynthesis of lipids or fatty acids.
8. The vector according to claim 5 or the host cell according to claim 7, wherein the enzyme is selected from the group
consisting of: acyl-CoA dehydrogenase(s), acyl-ACP [= acyl carrier protein] desaturase(s), acyl-ACP thioesterase
(s), fatty acid acyltransferase(s), acyl-CoA:lysophospholipid acyltransferase(s), fatty acid synthase(s), fatty acid
hydroxylase(s), acetyl-coenzyme A carboxylase(s), acyl-coenzyme A oxidase(s), fatty acid desaturase(s), fatty acid
acetylenase(s), lipoxygenase(s), triacylglycerol lipase(s), allene oxide synthase(s), hydroperoxide lyase(s), fatty
acid elongase(s), Δ4-desaturase(s), Δ5-desaturase(s), Δ6-desaturase(s), Δ8-desaturase(s), Δ9-desaturase(s), Δ12-
desaturase(s), Δ5-elongase(s), Δ6-elongase(s) and Δ9-elongase(s).
9. A method of generating a polypeptide with desaturase activity, comprising the steps:
(a) expressing a polynucleotide according to claim 1 or 2 in a host cell; and
(b) obtaining, from the host cell, the polypeptide which is encoded by the polynucleotide according to (a).
10. A polypeptide which is encoded by the polynucleotide according to claim 1 or 2 or which is obtainable by the method
according to claim 9.
11. An antibody which specifically recognizes the polypeptide according to claim 10.
12. A transgenic, nonhuman organism comprising the polynucleotide according to claim 1 or 2, the vector according to
any of claims 3 to 5 or the host cell according to claim 6 or 7.
13. The transgenic, nonhuman organism according to claim 12, wherein the organism is an animal, a plant or a multi-
cellular microorganism,
14. A process for the production of a substance which has the structure shown in the general formula I hereinbelow
wherein the variables and substituents are as follows:
R1 = hydroxyl, coenzyme A (thioester), lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphati-
dylglycerol, lysodiphosphatidylglycerol, lysophosphatidylserine, lysophosphatidylinositol, sphingo base or a rad-
ical of the formula II
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R2 = hydrogen, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, diphosphatidylglycerol,
phosphatidylserine, phosphatidylinositol or saturated or unsaturated C2 to C24-alkylcarbonyl,
R3 = hydrogen, a saturated or unsaturated C2 to C24-alkylcarbonyl, or R2 and R3 independently of one another
are a radical of the formula Ia:
n = 2,3, 4, 5, 6, 7 or 9, m = 2, 3, 4, 5 or 6 and p = 0 or 3; and wherein the process comprises the cultivation of (i) a
host cell according to any of claims 3 to 5 or (ii) of a transgenic, nonhuman organism according to claim 12 or 13
under conditions which permit the biosynthesis of the substance.
15. A process for the production of an oil, lipid or fatty acid composition, comprising the steps of the process according
to claim 14 and the further step of formulating the substance as an oil, lipid or fatty acid composition.
16. The process according to claim 15, wherein the oil, lipid or fatty acid composition is formulated further to give a drug,
a cosmetic product, a foodstuff, a feedstuff, preferably fish food, or a food supplement.
17. The use of the polynucleotide according to claim 1 or 2, of the vector according to any of claims 3 to 5, of the host
cell according to claim 6 or 7, of the vector or the host cell according to claim 8, of the polypeptide according to
claim 10 or of the transgenic, nonhuman organism according to claim 12 or 13 for the production of an oil, lipid or
fatty acid composition.
18. The use according to claim 17, wherein the oil, lipid or fatty acid composition is to be employed as a drug, cosmetic
product, foodstuff, feedstuff, preferably fish food, or food supplement.
Patentansprüche
1. Polynukleotid, umfassend eine Nukleinsäuresequenz, die aus der Gruppe ausgewählt ist, bestehend aus:
(a) Nukleinsäuresequenz, wie in SEQ ID Nr. 1 oder 2 gezeigt und;
(b) Nukleinsäuresequenz, die ein Polypeptid kodiert, das eine Aminosäuresequenz umfasst, wie in einer der
SEQ ID Nr. 3 dargestellt; und
(c) Nukleinsäuresequenz die mindestens 70% Identität mit der gesamten Länge einer der Nukleinsäuresequen-
zen unter (a) oder (b) aufweist und die ein Polypeptid mit einer ω3-Desaturase-Aktivität kodiert, wobei die
Nukleinsäuresequenz eine die Aminosäuresequenz von SEQ ID Nr. 47 kodierende Sequenz umfasst, wobei
an Position 16 von SEQ ID Nr. 47 ein Histidinrest vorhanden ist.
2. Polynukleotid nach Anspruch 1, wobei das Polynukleotid aus RNA oder DNA besteht.
3. Vektor, der das Polynukleotid nach Anspruch 1 oder 2 umfasst.
4. Vektor nach Anspruch 3, wobei der Vektor ein Expressionsvektor ist.
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5. Vektor nach Anspruch 3 oder 4, wobei der Vektor mindestens ein weiteres Polynukleotid umfasst, das ein weiteres
Enzym kodiert, das an der Biosynthese von Lipiden oder Fettsäuren beteiligt ist.
6. Wirtszelle, die das Polynukleotid nach Anspruch 1 oder 2 oder den Vektor nach einem der Ansprüche 3 bis 5 umfasst.
7. Wirtszelle nach Anspruch 6, wobei die Wirtszelle mindestens ein weiteres Enzym umfasst, das an der Biosynthese
von Lipiden oder Fettsäuren beteiligt ist.
8. Vektor nach Anspruch 5 oder Wirtszelle nach Anspruch 7, wobei das Enzym aus der Gruppe ausgewählt ist, be-
stehend aus: Acyl-CoA-Dehydrogenase(n), Acyl-ACP- [= Acylcarrierprotein-] Desaturase(n), Acyl-ACP-Thioestera-
se(n), Fettsäureacyltransferase(n), Acyl-CoA:Lysophospholipid-Acyltransferase(n), Fettsäuresynthase(n), Fettsäu-
rehydroxylase(n), Acetyl-Coenzym A-Carboxylase(n), Acyl-Coenzym A-Oxidase(n), Fettsäuredesaturase(n), Fett-
säureacetylenase(n), Lipoxygenase(n), Triacylglycerinlipase(n), Allenoxidsynthase(n), Hydroperoxidlyase(n), Fett-
säureelongase(n), Δ4-Desaturase(n), Δ5-Desaturase(n), Δ6-Desaturase(n), Δ8-Desaturase(n), Δ9-Desaturase(n),
Δ12-Desaturase(n), Δ5-Elongase(n), Δ6-Elongase(n) und Δ9-Elongase(n).
9. Verfahren zur Herstellung eines Polypeptids mit Desaturase-Aktivität, das folgende Schritte umfasst:
(a) das Exprimieren eines Polynukleotids nach Anspruch 1 oder 2 in einer Wirtszelle und
(b) Erhalten des Polypeptids, das von dem Polynukleotid unter (a) kodiert wird, aus der Wirtszelle.
10. Polypeptid, das von dem Polynukleotid nach Anspruch 1 oder 2 kodiert wird oder das durch das Verfahren nach
Anspruch 9 erhältlich ist.
11. Antikörper, der spezifisch das Polypeptid nach Anspruch 10 erkennt.
12. Transgener, nicht-menschlicher Organismus, der das Polynukleotid nach Anspruch 1 oder 2, den Vektor nach einem
der Ansprüche 3 bis 5 oder die Wirtszelle nach Anspruch 6 oder 7 umfasst.
13. Transgener, nicht-menschlicher Organismus nach Anspruch 12, wobei der Organismus ein Tier, eine Pflanze oder
ein multizellulärer Mikroorganismus ist.
14. Verfahren zur Herstellung einer Substanz, die die hier nachstehend in der allgemeinen Formel I gezeigte Struktur
aufweist:
wobei die Variablen und Substituenten Folgende sind:
R1 = Hydroxyl, Coenzym A (Thioester), Lysophosphatidylcholin, Lysophosphatidylethanolamin, Lysophospha-
tidylglycerin, Lysodiphosphatidylglycerin, Lysophosphatidylserin, Lysophosphatidylinositol, Sphingobase oder
ein Rest der Formel II
R2 = Wasserstoff, Phosphatidylcholin, Phosphatidylethanolamin, Phosphatidylglycerin, Diphosphatidylglycerin,
Phosphatidylserin, Phosphatidylinositol oder ein gesättigtes oder ungesättigtes C2- bis C24-Alkylcarbonyl,
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R3 = Wasserstoff, ein gesättigtes oder ungesättigtes C2- bis C24-Alkylcarbonyl oder R2 und R3 sind unabhängig
voneinander ein Rest der Formel Ia:
in der n = 2, 3, 4, 5, 6, 7 oder 9, m = 2, 3, 4, 5 oder 6 und p = 0 oder 3;
und
wobei das Verfahren die Züchtung (i) einer Wirtszelle nach einem der Ansprüche 3 bis 5 oder (ii) eines transgenen,
nicht-menschlichen Organismus nach Anspruch 12 oder 13 unter Bedingungen umfasst, die die Biosynthese der
Substanz gestatten.
15. Verfahren zur Herstellung einer Öl-, Lipid- oder Fettsäurezusammensetzung, umfassend die Schritte des Verfahrens
nach Anspruch 14 und den weiteren Schritt der Formulierung der Substanz als eine Öl-, Lipid- oder Fettsäurezu-
sammensetzung.
16. Verfahren nach Anspruch 15, wobei die Öl-, Lipid- oder Fettsäurezusammensetzung weiterhin derart formuliert wird,
dass ein Arzneimittel, ein Kosmetikprodukt, ein Nahrungsmittel, ein Futtermittel, vorzugsweise Fischfutter, oder eine
Nahrungsmittelergänzung erhalten wird.
17. Verwendung des Polynukleotids nach Anspruch 1 oder 2, des Vektors nach einem der Ansprüche 3 bis 5, der
Wirtszelle nach Anspruch 6 oder 7, des Vektors oder der Wirtszelle nach Anspruch 8, des Polypeptids nach Anspruch
10 oder des transgenen, nicht-menschlichen Organismus nach Anspruch 12 oder 13 zur Herstellung einer Öl-, Lipid-
oder Fettsäurezusammensetzung.
18. Verwendung nach Anspruch 17, wobei die Öl-, Lipid- oder Fettsäurezusammensetzung als Arzneimittel, Kosmetik-
produkt, Nahrungsmittel, Futtermittel, vorzugsweise Fischfutter, oder Nahrungsmittelergänzung eingesetzt wird.
Revendications
1. Polynucléotide comprenant une séquence d’acide nucléique choisie dans le groupe constitué de :
(a) une séquence d’acide nucléique telle que décrite dans SEQ ID NO. 1 ou 2, et ;
(b) une séquence d’acide nucléique qui code pour un polypeptide qui comprend une séquence d’acides aminés
telle que décrite dans SEQ ID NO. 3 ; et
(c) une séquence d’acide nucléique qui a au moins 70 % d’identité sur la longueur totale d’une des séquences
d’acide nucléique de (a) ou (b), et qui code pour un polypeptide ayant une activité ω3-désaturase, ladite séquence
d’acide nucléique comprenant une séquence codant pour la séquence d’acides aminés de SEQ ID NO: 47, un
résidu histidine étant présent à la position 16 de SEQ ID NO: 47.
2. Polynucléotide selon la revendication 1, le polynucléotide étant constitué d’ARN ou d’ADN.
3. Vecteur comprenant le polynucléotide selon la revendication 1 ou 2.
4. Vecteur selon la revendication 3, le vecteur étant un vecteur d’expression.
5. Vecteur selon la revendication 3 ou 4, le vecteur comprenant au moins un autre polynucléotide qui code pour une
autre enzyme qui est impliquée dans la biosynthèse de lipides ou d’acides gras.
6. Cellule hôte comprenant le polynucléotide selon la revendication 1 ou 2 ou le vecteur selon l’une quelconque des
revendications 3 à 5.
7. Cellule hôte selon la revendication 6, la cellule hôte comprenant en outre au moins une autre enzyme qui est
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impliquée dans la biosynthèse de lipides ou d’acides gras.
8. Vecteur selon la revendication 5 ou cellule hôte selon la revendication 7, l’enzyme étant choisie dans le groupe
constitué de : acyl-CoA déshydrogénase(s), acyl-ACP [= protéine transporteuse d’acyle] désaturase(s), acyl-ACP
thioestérase(s), acide gras acyltransférase(s), acyl-CoA:lysophospholipide acyltransférase(s), acide gras synthase
(s), acide gras hydroxylase(s), acétyl-coenzyme A carboxylase(s), acyl-coenzyme A oxidase(s), acide gras désa-
turase(s), acide gras acétylénase(s), lipoxygénase(s), triacylglycérol lipase(s), oxyde d’allène synthase(s), hydro-
peroxyde lyase(s), acide gras élongase(s), A4-désaturase(s), A5-désaturase(s), A6-désaturase(s), A8-désaturase
(s), A9-désaturase(s), A12-désaturase(s), A5-élongase(s), A6-élongase(s) et A9-élongase(s).
9. Procédé de génération d’un polypeptide ayant une activité désaturase, comprenant les étapes consistant à :
(a) exprimer un polynucléotide selon la revendication 1 ou 2 dans une cellule hôte ; et
(b) obtenir, à partir de la cellule hôte, le polypeptide qui est codé par le polynucléotide selon (a).
10. Polypeptide qui est codé par le polynucléotide selon la revendication 1 ou 2 ou qui peut être obtenu par le procédé
selon la revendication 9.
11. Anticorps qui reconnaît spécifiquement le polypeptide selon la revendication 10.
12. Organisme transgénique, non humain comprenant le polynucléotide selon la revendication 1 ou 2, le vecteur selon
l’une quelconque des revendications 3 à 5 ou la cellule hôte selon la revendication 6 ou 7.
13. Organisme transgénique, non humain selon la revendication 12, l’organisme étant un animal, une plante ou un
micro-organisme multicellulaire.
14. Procédé pour la production d’une substance qui a la structure décrite dans la formule générale I ci-dessous
les variables et substituants étant comme suit :
R1 = hydroxyle, coenzyme A (thioester), lysophosphatidylcholine, lysophosphatidyléthanolamine, lysophospha-
tidylglycérol, lysodiphosphatidylglycérol, lysophosphatidylsérine, lysophosphatidylinositol, une base sphingoïde
ou un radical de formule II
R2 = hydrogène, phosphatidylcholine, phosphatidyléthanolamine, phosphatidylglycérol, diphosphatidylglycérol,
phosphatidylsérine, phosphatidylinositol ou alkylcarbonyle en C2 à C24 saturé ou insaturé,
R3 = hydrogène, un alkylcarbonyle en C2 à C24 saturé ou insaturé, ou R2 et R3 indépendamment l’un de l’autre
sont un radical de formule Ia :
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n = 2, 3, 4, 5, 6, 7 ou 9, m = 2, 3, 4, 5 ou 6 et p = 0 ou 3 ; et
le procédé comprenant la culture de (i) une cellule hôte selon l’une quelconque des revendications 3 à 5 ou (ii) un
organisme transgénique, non humain selon la revendication 12 ou 13 dans des conditions qui permettent la bio-
synthèse de la substance.
15. Procédé pour la production d’une composition d’huile, de lipide ou d’acide gras, comprenant les étapes du procédé
selon la revendication 14 et l’étape supplémentaire de formulation de la substance sous la forme d’une composition
d’huile, de lipide ou d’acide gras.
16. Procédé selon la revendication 15, la composition d’huile, de lipide ou d’acide gras étant en outre formulée pour
obtenir un médicament, un produit cosmétique, un aliment humain, un aliment pour animaux, de préférence un
aliment pour poisson, ou un supplément alimentaire.
17. Utilisation du polynucléotide selon la revendication 1 ou 2, du vecteur selon l’une quelconque des revendications
3 à 5, de la cellule hôte selon la revendication 6 ou 7, du vecteur ou la cellule hôte selon la revendication 8, du
polypeptide selon la revendication 10 ou de l’organisme transgénique, non humain selon la revendication 12 ou 13
pour la production d’une composition d’huile, de lipide ou d’acide gras.
18. Utilisation selon la revendication 17, la composition d’huile, de lipide ou d’acide gras étant destinée à être utilisée
en tant que médicament, produit cosmétique, aliment humain, aliment pour animaux, de préférence un aliment pour
poisson, ou un supplément alimentaire.
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